ANHANG II VO (EG) 2009/790
| Index-Nr. | Internationale chemische Bezeichnung | EG-Nummer | CAS-Nummer | Einstufung | Kennzeichnung | Spezifische Konzentrationsgrenzen, M-Faktoren | Anmerkungen | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Gefahrenklasse, Gefahrenkategorie und Gefahrenkodierung | Kodierung der Gefahrenhinweise | Piktogramm, Kodierung der Signalworte | Kodierung der Gefahrenhinweise | Kodierung der ergänzenden Gefahrenmerkmale | ||||||
| 003-003-00-5 |
(2-methylpropyl)lithium; isobutyllithium |
440-620-2 | 920-36-5 |
Water-react. 1 Pyr. Liq. 1 Skin Corr. 1A STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 |
H260 H250 H314 H336 H400 H410 |
GHS02 GHS05 GHS07 GHS09 Dgr |
H260 H250 H314 H336 H410 |
EUH014 | ||
| 005-007-00-2 |
boric acid; [1] boric acid, crude natural, containing not more than 85 per cent of H3BO3 calculated on the dry weight [2] |
233-139-2 [1] 234-343-4 [2] |
10043-35-3 [1] 11113-50-1 [2] |
Repr. 1B | H360FD |
GHS08 Dgr |
H360FD | Repr. 1B; H360FD: C ≥ 5,5 % | ||
| 005-008-00-8 |
diboron trioxide; boric oxide |
215-125-8 | 1303-86-2 | Repr. 1B | H360FD |
GHS08 Dgr |
H360FD | Repr. 1B; H360FD: C ≥ 3,1 % | ||
| 005-011-00-4 |
disodium tetraborate, anhydrous; boric acid, disodium salt; [1] tetraboron disodium heptaoxide, hydrate; [2] orthoboric acid, sodium salt [3] |
215-540-4 [1] 235-541-3 [2] 237-560-2 [3] |
1330-43-4 [1] 12267-73-1 [2] 13840-56-7 [3] |
Repr. 1B | H360FD |
GHS08 Dgr |
H360FD | Repr. 1B; H360FD: C ≥ 4,5 % | ||
| 005-011-01-1 |
disodium tetraborate decahydrate; borax decahydrate |
215-540-4 | 1303-96-4 | Repr. 1B | H360FD |
GHS08 Dgr |
H360FD | Repr. 1B; H360FD: C ≥ 8,5 % | ||
| 005-011-02-9 |
disodium tetraborate pentahydrate; borax pentahydrate |
215-540-4 | 12179-04-3 | Repr. 1B | H360FD |
GHS08 Dgr |
H360FD | Repr. 1B; H360FD: C ≥ 6,5 % | ||
| 005-013-00-5 | diethylmethoxyborane | 425-380-9 | 7397-46-8 |
Pyr. Liq. 1 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 4 |
H250 H332 H312 H302 H373** H314 H317 H413 |
GHS02 GHS05 GHS08 GHS07 Dgr |
H250 H332 H312 H302 H373** H314 H317 H413 |
|||
| 005-014-00-0 | 4-formylphenylboronic acid | 438-670-5 | 87199-17-5 | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 005-015-00-6 | 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) | 414-380-4 | 140681-55-6 |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H302 H318 H317 H412 |
GHS05 GHS07 Dgr |
H302 H318 H317 H412 |
|||
| 005-016-00-1 | tetrabutylammonium butyl tris-(4-tert-butylphenyl)borate | 431-370-5 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 005-017-00-7 |
sodium perborate; [1] sodium peroxometaborate; [2] sodium peroxoborate; [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm] |
239-172-9 [1] 231-556-4 [2] |
15120-21-5 [1] 7632-04-4 [2] |
Oxid. Sol. 2 Repr. 1B Acute Tox. 4 * STOT SE 3 Eye Dam. 1 |
H272 H360Df H302 H335 H318 |
GHS03 GHS05 GHS08 GHS07 Dgr |
H272 H360Df H302 H335 H318 |
Repr. 1B; H360Df: C ≥ 9 % Repr. 1B; H360D: 6,5 % ≤ C < 9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % |
||
| 005-017-01-4 |
sodium perborate; [1] sodium peroxometaborate; [2] sodium peroxoborate; [containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm] |
239-172-9 [1] 231-556-4 [2] |
15120-21-5 [1] 7632-04-4 [2] |
Oxid. Sol. 2 Repr. 1B Acute Tox. 3 * Acute Tox. 4 * STOT SE 3 Eye Dam. 1 |
H272 H360Df H331 H302 H335 H318 |
GHS03 GHS06 GHS05 GHS08 Dgr |
H272 H360Df H331 H302 H335 H318 |
Repr. 1B; H360Df: C ≥ 9 % Repr. 1B; H360D: 6,5 % ≤ C < 9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % |
||
| 005-018-00-2 |
perboric acid (H3BO2(O2)), monosodium salt trihydrate; [1] perboric acid, sodium salt, tetrahydrate; [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate; [3] sodium peroxoborate hexahydrate; [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm] |
239-172-9 [1] 234-390-0 [2] 231-556-4 [3] |
13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3] |
Repr. 1B STOT SE 3 Eye Dam. 1 |
H360Df H335 H318 |
GHS05 GHS08 GHS07 Dgr |
H360Df H335 H318 |
Repr. 1B; H360 Df: C ≥ 14 % Repr. 1B; H360D: 10 % ≤ C < 14 % Eye Dam. 1; H318: C ≥ 36 % Eye Irrit. 2; H319: 22 % ≤ C < 36 % |
||
| 005-018-01-X |
perboric acid (H3BO2(O2)), monosodium salt, trihydrate; [1] perboric acid, sodium salt, tetrahydrate; [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate; [3] sodium peroxoborate hexahydrate; [containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm] |
239-172-9 [1] 234-390-0 [2] 231-556-4 [3] |
13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3] |
Repr. 1B Acute Tox. 4 * STOT SE 3 Eye Dam. 1 |
H360Df H332 H335 H318 |
GHS05 GHS08 GHS07 Dgr |
H360Df H332 H335 H318 |
Repr. 1B; H360Df: C ≥ 14 % Repr. 1B; H360D: 10 % ≤ C < 14 % Eye Dam. 1; H318: C ≥ 36 % Eye Irrit. 2; H319: 22 % ≤ C < 36 % |
||
| 005-019-00-8 |
perboric acid, sodium salt; [1] perboric acid, sodium salt, monohydrate; [2] perboric acid (HBO(O2)), sodium salt, monohydrate; [3] sodium peroxoborate; [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm] |
234-390-0 [1] 234-390-0 [2] 231-556-4 [3] |
11138-47-9 [1] 12040-72-1 [2] 10332-33-9 [3] |
Oxid. Sol. 3 Repr. 1B Acute Tox. 4 * STOT SE 3 Eye Dam. 1 |
H272 H360Df H302 H335 H318 |
GHS03 GHS05 GHS08 GHS07 Dgr |
H272 H360Df H302 H335 H318 |
Repr. 1B; H360Df: C ≥ 9 % Repr. 1B; H360D: 6,5 % ≤ C < 9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % |
||
| 005-019-01-5 |
perboric acid, sodium salt; [1] perboric acid, sodium salt, monohydrate; [2] perboric acid (HBO(O2)), sodium salt, monohydrate; [3] sodium peroxoborate; [containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm] |
234-390-0 [1] 234-390-0 [2] 231-556-4 [3] |
11138-47-9 [1] 12040-72-1 [2] 10332-33-9 [3] |
Oxid. Sol. 3 Repr. 1B Acute Tox. 3 * Acute Tox. 4 * STOT SE 3 Eye Dam. 1 |
H272 H360Df H331 H302 H335 H318 |
GHS03 GHS06 GHS05 GHS08 Dgr |
H272 H360Df H331 H302 H335 H318 |
Repr. 1B; H360Df: C ≥ 9 % Repr. 1B; H360D: 6,5 % ≤ C < 9 % Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % |
||
| 006-091-00-3 |
propineb (ISO); polymeric zinc propylenebis(dithiocarbamate) |
— | 9016-72-2 |
Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 |
H332 H373** H317 H400 |
GHS08 GHS07 GHS09 Wng |
H332 H373** H317 H400 |
|||
| 006-092-00-9 | tert-butyl (1S)-N-[1-((2S)-2-oxiranyl)-2-phenylethyl]carbamate | 425-420-5 | 98737-29-2 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 006-093-00-4 | 2,2'-dithio di(ethylammonium)-bis(dibenzyldithiocarbamate) | 427-180-7 | — |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|||
| 006-094-00-X | O-isobutyl-N-ethoxy carbonylthiocarbamate | 434-350-4 | 103122-66-3 |
Flam. Liq. 3 Carc. 1B Muta. 1B Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 |
H226 H350 H340 H302 H373** H317 H411 |
GHS02 GHS08 GHS07 GHS09 Dgr |
H226 H350 H340 H302 H373** H317 H411 |
|||
| 006-095-00-5 |
fosetyl-aluminium (ISO); aluminium triethyl triphosphonate |
254-320-2 | 39148-24-8 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 006-096-00-0 |
chlorpropham (ISO); isopropyl 3-chlorocarbanilate |
202-925-7 | 101-21-3 |
Carc. 2 STOT RE 2 * Aquatic Chronic 2 |
H351 H373** H411 |
GHS08 GHS09 Wng |
H351 H373** H411 |
|||
| 006-097-00-6 | 1-phenyl-3-(p-toluenesulfonyl)urea | 424-620-1 | 13909-63-2 |
Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 3 |
H302 H373** H412 |
GHS08 GHS07 Wng |
H302 H373** H412 |
|||
| 006-098-00-1 | tert-butyl (1R,5S)-3-azabicyclo[3.1.0]hex-6-ylcarbamate | 429-170-8 | 134575-17-0 |
Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 |
H302 H373** H318 H317 |
GHS05 GHS08 GHS07 Dgrg |
H302 H373** H318 H317 |
|||
| 006-099-00-7 |
N-(p-toluenesulfonyl)-N'-(3-(p-toluenesulfonyloxy)phenyl)urea; 3-({[(4-methylphenyl)sulfonyl]carbamoyl}amino)phenyl 4-methylbenzenesulfonate |
432-520-2 | 232938-43-1 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 006-101-00-6 |
reaction mass of: N,N''-(methylenedi-4,1-phenylene)bis[N'-phenylurea]; N-(4-[[4-[[(phenylamino)carbonyl]amino]phenylmethyl]phenyl]-N'-cyclohexylurea; N,N''-(methylenedi-4,1-phenylene)bis[N'-cyclohexylurea] |
423-070-8 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 006-102-00-1 | O-hexyl-N-ethoxycarbonylthiocarbamate | 432-750-3 | — |
Carc. 1B Muta. 1B Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 |
H350 H340 H302 H373** H317 H411 |
GHS08 GHS07 GHS09 Dgr |
H350 H340 H302 H373** H317 H411 |
|||
| 006-103-00-7 | N,N''-(methylenedi-4,1-phenylene)bis[N'-octyl]urea | 445-760-8 | — |
Eye Dam. 1 Resp. Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H334 H400 H410 |
GHS05 GHS08 GHS09 Dgr |
H318 H334 H410 |
M=100 | ||
| 007-028-00-2 | hydroxylammonium nitrate | 236-691-2 | 13465-08-2 |
Expl. 1.1 **** Carc. 2 Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 |
H201 H351 H311 H302 H373** H319 H315 H317 H400 |
GHS01 GHS06 GHS08 GHS09 Dgr |
H201 H351 H311 H302 H373** H319 H315 H317 H400 |
|||
| 007-029-00-8 | diethyldimethylammonium hydroxide | 419-400-5 | 95500-19-9 |
Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A |
H312 H302 H314 |
GHS05 GHS07 Dgr |
H312 H302 H314 |
|||
| 012-004-00-X | aluminium-magnesium-carbonate-hydroxide-perchlorate-hydrate | 422-150-1 | — |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 013-010-00-5 | hydroxy aluminium bis(2,4,8,10-tetra-tert-butyl-6-hydroxy-12H-dibenzo[d,g][1.3.2]dioxaphosphocin-6-oxide) | 430-650-4 | 151841-65-5 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 014-033-00-3 | 2-methyl-3-(trimethoxysilyl)propyl-2-propenoate hydrolysis product with silica | 419-030-4 | 125804-20-8 |
Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 |
H225 H319 H336 |
GHS02 GHS07 Dgr |
H225 H319 H336 |
|||
| 014-034-00-9 | 3-hexylheptamethyltrisiloxane | 428-700-5 | 1873-90-1 |
Acute Tox. 4 * Aquatic Chronic 4 |
H332 H413 |
GHS07 Wng |
H332 H413 |
|||
| 014-035-00-4 | 2-(3,4-epoxycyclohexyl)ethyltriethoxy silane | 425-050-4 | 10217-34-2 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|||
| 014-036-00-X | (4-ethoxyphenyl)(3-(4-fluoro-3-phenoxyphenyl)propyl)dimethylsilane | 405-020-7 | 105024-66-6 |
Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H360F*** H400 H410 |
GHS08 GHS09 Dgr |
H360F*** H410 |
M=1000 | ||
| 014-037-00-5 | 2-butanone-O,O',O''-(phenylsilylidyne)trioxime | 433-360-6 | 34036-80-1 |
STOT RE 2 * Skin Sens. 1 Aquatic Chronic 3 |
H373** H317 H412 |
GHS08 GHS07 Wng |
H373** H317 H412 |
|||
| 014-038-00-0 | S-(3-(triethoxysilyl)propyl) octanethioate | 436-690-9 | 220727-26-4 | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 014-039-00-6 | (2,3-dimethylbut-2-yl)-trimethoxysilane | 439-360-2 | 142877-45-0 |
Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 |
H315 H318 H412 |
GHS05 Dgr |
H315 H318 H412 |
|||
| 014-041-00-7 | N,N-bis(trimethylsilyl)aminopropylmethyldiethoxysilane | 445-890-5 | 201290-01-9 |
Acute Tox. 4 * Skin Sens. 1 |
H302 H317 |
GHS07 Wng |
H302 H317 |
|||
| 014-042-00-2 | reaction mass of: O,O',O'',O'''-silanetetrayl tetrakis(4-methyl-2-pentanone oxime) (3 stereoisomers) | 423-010-0 | — | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 014-043-00-8 | reaction product of amorphous silica (50-85 %), butyl (1-methylpropyl) magnesium (3-15 %), tetraethyl orthosilicate (5-15 %) and titanium tetrachloride (5-20 %) | 432-200-2 | — | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 014-044-00-3 | 3-[(4'-acetoxy-3'-methoxyphenyl) propyl]trimethoxysilane | 433-050-0 | — | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 014-045-00-9 | magnesium sodium fluoride silicate | 442-650-1 | — | STOT RE 2 * | H373** |
GHS08 Wng |
H373** | |||
| 015-113-00-0 |
tolclofos-methyl (ISO); O-(2,6-dichloro-p-tolyl)-O,O-dimethyl thiophosphate |
260-515-3 | 57018-04-9 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|||
| 015-182-00-7 | tetraisopropyldichloromethylenebisphosphonate | 430-630-5 | 10596-22-2 |
Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 |
H302 H319 H317 |
GHS06 Wng |
H302 H319 H317 |
|||
| 015-183-00-2 | (1-hydroxydodecylidene)diphosphonic acid | 425-230-2 | 16610-63-2 |
Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H314 H400 H410 |
GHS05 GHS09 Dgr |
H314 H410 |
|||
| 015-188-00-X | (1-methylethylidene)di-4,1-phenylenetetraphenyl diphosphate | 425-220-8 | 5945-33-5 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 015-190-00-0 |
bis(2,4-dicumylphenyl) neopentyl diphosphite; 3,9-bis[2,4-bis(1-methyl-1-phenylethyl)phenoxy]-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane |
421-920-2 | 154862-43-8 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 015-191-00-6 | dodecyldiphenyl phosphate | 431-760-5 | 27460-02-2 |
Skin Irrit. 2 Aquatic Chronic 3 |
H315 H412 |
GHS07 Wng |
H315 H412 |
|||
| 015-192-00-1 | tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate | 432-770-2 | 139189-30-3 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 015-193-00-7 | triphenyl(phenylmethyl)phosphonium 1,1,2,2,3,3,4,4,4-nonafluoro-N-methyl-1-butanesulfonamide (1:1) | 442-960-7 | 332350-93-3 |
Acute Tox. 3 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H318 H400 H410 |
GHS05 GHS06 GHS09 Dgr |
H301 H318 H410 |
|||
| 015-194-00-2 | tetrabutyl-phosphonium nonafluoro-butane-1-sulfonate | 444-440-5 | 220689-12-3 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|||
| 015-195-00-8 |
reaction mass of: potassium o-toluenephosphonate; potassium m-toluenephosphonate; potassium p-toluenephosphonate |
433-860-4 | — |
Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 |
H319 H317 H412 |
GHS07 Wng |
H319 H317 H412 |
|||
| 015-196-00-3 |
reaction mass of: dimethyl (2-(hydroxymethylcarbamoyl)ethyl)phosphonate; diethyl (2-(hydroxymethylcarbamoyl)ethyl)phosphonate; methyl ethyl (2-(hydroxymethylcarbamoyl)ethyl)phosphonate |
435-960-3 | — |
Carc. 1B Muta. 1B Skin Sens. 1 |
H350 H340 H317 |
GHS08 GHS07 Dgr |
H350 H340 H317 |
|||
| 015-197-00-9 | bis(2,4,4-trimethylpentyl)dithiophosphonic acid | 420-160-9 | 107667-02-7 |
Flam. Liq. 3 Acute Tox. 3 * Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 |
H226 H331 H302 H314 H411 |
GHS02 GHS06 GHS05 GHS09 Dgr |
H226 H331 H302 H314 H411 |
|||
| 015-198-00-4 | (4-phenylbutyl)phosphinic acid | 420-450-5 | 86552-32-1 |
Carc. 2 Eye Dam. 1 |
H351 H318 |
GHS05 GHS08 Dgr |
H351 H318 |
|||
| 016-092-00-0 |
reaction mass of: 4,7-bis(mercaptomethyl)-3,6,9-trithia-1,11-undecanedithiol; 4,8-bis(mercaptomethyl)-3,6,9-trithia-1,11-undecanedithiol; 5,7-bis(mercaptomethyl)-3,6,9-trithia-1,11-undecanedithiol |
427-050-1 | — |
Repr. 1A Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361f H315 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H361f H315 H317 H410 |
|||
| 016-094-00-1 | sulfur | 231-722-6 | 7704-34-9 | Skin Irrit. 2 | H315 |
GHS07 Wng |
H315 | |||
| 016-097-00-8 | 1-amino-2-methyl-2-propanethiol hydrochloride | 434-480-1 | 32047-53-3 |
Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 3 |
H302 H314 H317 H412 |
GHS05 GHS07 Dgr |
H302 H314 H317 H412 |
|||
| 017-023-00-7 | [phosphinyldynetris(oxy)] tris[3-aminopropyl-2-hydroxy-N,N-dimethyl-N-(C6-18)-alkyl] trichlorides | 425-520-9 | 197179-61-6 |
Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H400 H410 |
GHS05 GHS09 Dgr |
H318 H410 |
|||
| 022-004-00-1 | potassium titanium oxide (K2Ti6O13) | 432-240-0 | 12056-51-8 | Carc. 2 | H351 |
GHS08 Dgr |
H351 | |||
| 022-005-00-7 | [N-(1,1-dimethylethyl)-1,1-dimethyl-1-[(1,2,3,4,5-η)-2,3,4,5-tetramethyl-2,4-cyclopentadien-1-yl]silanaminato(2-)-κN][(1,2,3,4-η)-1,3-pentadiene]-titanium | 419-840-8 | 169104-71-6 |
Flam. Sol. 1**** Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 4 |
H228 H314 H317 H413 |
GHS02 GHS05 GHS07 Dgr |
H228 H314 H317 H413 |
|||
| 024-021-00-X | potassium tetrasodium bis[(N,N'-n)-1'-(phenylcarbamoyl)-3,5-disulfonatobenzeneazo-1'-prop-1'-ene-2,2'-diolato]chromate(III) | 425-830-4 | — | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 026-003-00-7 | iron(II) sulfate | 231-753-5 | 7720-78-7 |
Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 |
H302 H319 H315 |
GHS07 Wng |
H302 H319 H315 |
|||
| 026-003-01-4 |
iron (II) sulfate (1:1) heptahydrate; sulfuric acid, iron(II) salt (1:1), heptahydrate; ferrous sulfate heptahydrate |
231-753-5 | 7782-63-0 |
Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 |
H302 H319 H315 |
GHS07 Wng |
H302 H319 H315 |
Skin Irrit. 2; H315: C ≥ 25 % | ||
| 026-004-00-2 | potassium ferrite | 430-010-4 | 12160-44-0 |
Skin Corr. 1B Skin Sens. 1 |
H314 H317 |
GHS05 GHS07 Dgr |
H314 H317 |
|||
| 027-006-00-6 | cobalt acetate | 200-755-8 | 71-48-7 |
Carc. 1B Muta. 2 Repr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360F*** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360F*** H334 H317 H410 |
Carc. 1B; H350i: C ≥ 0,01 % M=10 |
1 | |
| 027-007-00-1 | zinc hexacyanocobaltate(III), tertiary butyl alcohol/polypropylene glycol complex | 425-240-7 | — |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|||
| 027-008-00-7 | complex of cobalt(III)-bis(N-phenyl-4-(5-ethylsulfonyl-2-hydroxyphenylazo)-3-hydroxynaphthylamide), hydrated (n H2O, 2 < n < 3) | 427-390-9 | — | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 027-009-00-2 | cobalt nitrate | 233-402-1 | 10141-05-6 |
Carc. 1B Muta. 2 Repr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360F*** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360F*** H334 H317 H410 |
Carc. 1B; H350i: C ≥ 0,01 % M=10 |
1 | |
| 027-010-00-8 | cobalt carbonate | 208-169-4 | 513-79-1 |
Carc. 1B Muta. 2 Repr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360F*** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360F*** H334 H317 H410 |
Carc. 1B; H350i: C ≥ 0,01 % M=10 |
1 | |
| 028-002-01-4 |
nickel powder; [particle diameter < 1 mm] |
231-111-4 | 7440-02-0 |
Carc. 2 STOT RE 1 Skin Sens. 1 Aquatic Chronic 3 |
H351 H372** H317 H412 |
GHS08 GHS07 Dgr |
H351 H372** H317 H412 |
|||
| 028-011-00-6 | nickel dichloride | 231-743-0 | 7718-54-9 |
Carc. 1A Muta. 2 Repr. 1B Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H331 H301 H372** H315 H334 H317 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H350i H341 H360D*** H331 H301 H372** H315 H334 H317 H410 |
STOT RE. 1; H373: C ≥ 1 % STOT RE. 2; H373: 0,1 % < C < 1 % Skin Irrit. 2; H315: C ≥ 20 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
||
| 028-012-00-1 |
nickel dinitrate; [1] nitric acid, nickel salt [2] |
236-068-5 [1] 238-076-4 [2] |
13138-45-9 [1] 14216-75-2 [2] |
Ox. Sol. 2 Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H272 H350i H341 H360D*** H372** H332 H302 H318 H315 H317 H400 H410 |
GHS03 GHS05 GHS08 GHS07 GHS09 Dgr |
H272 H350i H341 H360D*** H372** H332 H302 H318 H315 H317 H410 |
STOT RE. 1; H373: C ≥ 1 % STOT RE. 2; H373: 0,1 % < C < 1 % Skin Irrit. 2; H315: C ≥ 20 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
||
| 028-013-00-7 | nickel matte | 273-749-6 | 69012-50-6 |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
H | ||
| 028-014-00-2 | slimes and sludges, copper electrolytic refining, decopperised, nickel sulfate | 295-859-3 | 92129-57-2 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H332 H302 H315 H334 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H341 H360D*** H372** H332 H302 H315 H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
||
| 028-015-00-8 | slimes and sludges, copper electrolyte refining, decopperised | 305-433-1 | 94551-87-8 |
Carc. 1A Muta. 2 Repr. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
H | ||
| 028-016-00-3 |
nickel diperchlorate; perchloric acid, nickel(II) salt |
237-124-1 | 13637-71-3 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H314 H334 H317 H400 H410 |
GHS05 GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H314 H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
H | |
| 028-017-00-9 |
nickel dipotassium bis(sulfate); [1] diammonium nickel bis(sulfate) [2] |
237-563-9 [1] 239-793-2 [2] |
13842-46-1 [1] 15699-18-0 [2] |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H332 H302 H334 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H341 H360D*** H372** H332 H302 H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
H | |
| 028-018-00-4 |
nickel bis(sulfamidate); nickel sulfamate |
237-396-1 | 13770-89-3 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
H | |
| 028-019-00-X | nickel bis(tetrafluoroborate) | 238-753-4 | 14708-14-6 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
H | |
| 028-021-00-0 |
nickel diformate; [1] formic acid, nickel salt; [2] formic acid, copper nickel salt [3] |
222-101-0 [1] 239-946-6 [2] 268-755-0 [3] |
3349-06-2 [1] 15843-02-4 [2] 68134-59-8 [3] |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
H | |
| 028-022-00-6 |
nickel di(acetate); [1] nickel acetate [2] |
206-761-7 [1] 239-086-1 [2] |
373-02-4 [1] 14998-37-9 [2] |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H332 H302 H334 H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H341 H360D*** H372** H332 H302 H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
E H | |
| 028-024-00-7 | nickel dibenzoate | 209-046-8 | 553-71-9 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
H | |
| 028-025-00-2 | nickel bis(4-cyclohexylbutyrate) | 223-463-2 | 3906-55-6 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
||
| 028-026-00-8 |
nickel(II) stearate; nickel(II) octadecanoate |
218-744-1 | 2223-95-2 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
H | |
| 028-027-00-3 | nickel dilactate | — | 16039-61-5 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
H | |
| 028-028-00-9 | nickel(II) octanoate | 225-656-7 | 4995-91-9 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Skin Corr. 1A Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H314 H334 H317 H400 H410 |
GHS05 GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H314 H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
H | |
| 028-029-00-4 |
nickel difluoride; [1] nickel dibromide; [2] nickel diiodide; [3] nickel potassium fluoride [4] |
233-071-3 [1] 236-665-0 [2] 236-666-6 [3] - [4] |
10028-18-9 [1] 13462-88-9 [2] 13462-90-3 [3] 11132-10-8 [4] |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
H | |
| 028-030-00-X | nickel hexafluorosilicate | 247-430-7 | 26043-11-8 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
H | |
| 028-031-00-5 | nickel selenate | 239-125-2 | 15060-62-5 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
H | |
| 028-032-00-0 |
nickel hydrogen phosphate; [1] nickel bis(dihydrogen phosphate); [2] trinickel bis(orthophosphate); [3] dinickel diphosphate; [4] nickel bis(phosphinate); [5] nickel phosphinate; [6] phosphoric acid, calcium nickel salt; [7] diphosphoric acid, nickel(II) salt [8] |
238-278-2 [1] 242-522-3 [2] 233-844-5 [3] 238-426-6 [4] 238-511-8 [5] 252-840-4 [6] - [7] - [8] |
14332-34-4 [1] 18718-11-1 [2] 10381-36-9 [3] 14448-18-1 [4] 14507-36-9 [5] 36026-88-7 [6] 17169-61-8 [7] 19372-20-4 [8] |
Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H372** H334 H317 H410 |
H | ||
| 028-033-00-6 | diammonium nickel hexacyanoferrate | — | 74195-78-1 |
Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H372** H334 H317 H410 |
H | ||
| 028-034-00-1 | nickel dicyanide | 209-160-8 | 557-19-7 |
Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H372** H334 H317 H410 |
EUH032 | H | |
| 028-035-00-7 | nickel chromate | 238-766-5 | 14721-18-7 |
Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H372** H334 H317 H410 |
H | ||
| 028-036-00-2 |
nickel(II) silicate; [1] dinickel orthosilicate; [2] nickel silicate (3:4); [3] silicic acid, nickel salt; [4] trihydrogen hydroxybis[orthosilicato(4-)]trinickelate(3-) [5] |
244-578-4 [1] 237-411-1 [2] 250-788-7 [3] 253-461-7 [4] 235-688-3 [5] |
21784-78-1 [1] 13775-54-7 [2] 31748-25-1 [3] 37321-15-6 [4] 12519-85-6 [5] |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
H | ||
| 028-037-00-8 | dinickel hexacyanoferrate | 238-946-3 | 14874-78-3 |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
H | ||
| 028-038-00-3 |
trinickel bis(arsenate); nickel(II) arsenate |
236-771-7 | 13477-70-8 |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350 H372** H317 H410 |
H | ||
| 028-039-00-9 |
nickel oxalate; [1] oxalic acid, nickel salt [2] |
208-933-7 [1] 243-867-2 [2] |
547-67-1 [1] 20543-06-0 [2] |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
H | ||
| 028-040-00-4 | nickel telluride | 235-260-6 | 12142-88-0 |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
H | ||
| 028-041-00-X | trinickel tetrasulfide | — | 12137-12-1 |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
H | ||
| 028-042-00-5 | trinickel bis(arsenite) | — | 74646-29-0 |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
H | ||
| 028-043-00-0 |
cobalt nickel gray periclase; C.I. Pigment Black 25; C.I. 77332; [1] cobalt nickel dioxide; [2] cobalt nickel oxide [3] |
269-051-6 [1] 261-346-8 [2] - [3] |
68186-89-0 [1] 58591-45-0 [2] 12737-30-3 [3] |
Carc. 1A STOT RE 1 Skin Sens. 1 |
H350i H372** H317 |
GHS08 GHS07 Dgr |
H350i H372** H317 |
H | ||
| 028-044-00-6 |
nickel tin trioxide; nickel stannate |
234-824-9 | 12035-38-0 |
Carc. 1A STOT RE 1 Skin Sens. 1 |
H350i H372** H317 |
GHS08 GHS07 Dgr |
H350i H372** H317 |
H | ||
| 028-045-00-1 | nickel triuranium decaoxide | 239-876-6 | 15780-33-3 |
Carc. 1A STOT RE 1 Skin Sens. 1 |
H350i H372** H317 |
GHS08 GHS07 Dgr |
H350i H372** H317 |
H | ||
| 028-046-00-7 | nickel dithiocyanate | 237-205-1 | 13689-92-4 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
EUH032 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
H |
| 028-047-00-2 | nickel dichromate | 239-646-5 | 15586-38-6 |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
H | |
| 028-048-00-8 | nickel(II) selenite | 233-263-7 | 10101-96-9 |
Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H372** H334 H317 H410 |
H | ||
| 028-049-00-3 | nickel selenide | 215-216-2 | 1314-05-2 |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
H | ||
| 028-050-00-9 | silicic acid, lead nickel salt | — | 68130-19-8 |
Carc. 1A Repr. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H360Df H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H360Df H372** H317 H410 |
H | ||
| 028-051-00-4 |
nickel diarsenide; [1] nickel arsenide [2] |
235-103-1 [1] 248-169-1 [2] |
12068-61-0 [1] 27016-75-7 [2] |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
H | ||
| 028-052-00-X |
nickel barium titanium primrose priderite; C.I. Pigment Yellow 157; C.I. 77900 |
271-853-6 | 68610-24-2 |
Carc. 1A STOT RE 1 Skin Sens. 1 |
H350i H372** H317 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 |
H | ||
| 028-053-00-5 |
nickel dichlorate; [1] nickel dibromate; [2] ethyl hydrogen sulfate, nickel(II) salt [3] |
267-897-0 [1] 238-596-1 [2] 275-897-7 [3] |
67952-43-6 [1] 14550-87-9 [2] 71720-48-4 [3] |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
H | |
| 028-054-00-0 |
nickel(II) trifluoroacetate; [1] nickel(II) propionate; [2] nickel bis(benzenesulfonate); [3] nickel(II) hydrogen citrate; [4] citric acid, ammonium nickel salt; [5] citric acid, nickel salt; [6] nickel bis(2-ethylhexanoate); [7] 2-ethylhexanoic acid, nickel salt; [8] dimethylhexanoic acid nickel salt; [9] nickel(II) isooctanoate; [10] nickel isooctanoate; [11] nickel bis(isononanoate); [12] nickel(II) neononanoate; [13] nickel(II) isodecanoate; [14] nickel(II) neodecanoate; [15] neodecanoic acid, nickel salt; [16] nickel(II) neoundecanoate; [17] bis(d-gluconato-O1,O2)nickel; [18] nickel 3,5-bis(tert-butyl)-4-hydroxybenzoate (1:2); [19] nickel(II) palmitate; [20] (2-ethylhexanoato-O)(isononanoato-O)nickel; [21] (isononanoato-O)(isooctanoato-O)nickel; [22] (isooctanoato-O)(neodecanoato-O)nickel; [23] (2-ethylhexanoato-O)(isodecanoato-O)nickel; [24] (2-ethylhexanoato-O)(neodecanoato-O)nickel; [25] (isodecanoato-O)(isooctanoato-O)nickel; [26] (isodecanoato-O)(isononanoato-O)nickel; [27] (isononanoato-O)(neodecanoato-O)nickel; [28] fatty acids, C6-19-branched, nickel salts; [29] fatty acids, C8-18 and C18-unsaturated, nickel salts; [30] 2,7-naphthalenedisulfonic acid, nickel(II) salt; [31] |
240-235-8 [1] 222-102-6 [2] 254-642-3 [3] 242-533-3 [4] 242-161-1 [5] 245-119-0 [6] 224-699-9 [7] 231-480-1 [8] 301-323-2 [9] 249-555-2 [10] 248-585-3 [11] 284-349-6 [12] 300-094-6 [13] 287-468-1 [14] 287-469-7 [15] 257-447-1 [16] 300-093-0 [17] 276-205-6 [18] 258-051-1 [19] 237-138-8 [20] 287-470-2 [21] 287-471-8 [22] 284-347-5 [23] 284-351-7 [24] 285-698-7 [25] 285-909-2 [26] 284-348-0 [27] 287-592-6 [28] 294-302-1 [29] 283-972-0 [30] - [31] |
16083-14-0 [1] 3349-08-4 [2] 39819-65-3 [3] 18721-51-2 [4] 18283-82-4 [5] 22605-92-1 [6] 4454-16-4 [7] 7580-31-6 [8] 93983-68-7 [9] 29317-63-3 [10] 27637-46-3 [11] 84852-37-9 [12] 93920-10-6 [13] 85508-43-6 [14] 85508-44-7 [15] 51818-56-5 [16] 93920-09-3 [17] 71957-07-8 [18] 52625-25-9 [19] 13654-40-5 [20] 85508-45-8 [21] 85508-46-9 [22] 84852-35-7 [23] 84852-39-1 [24] 85135-77-9 [25] 85166-19-4 [26] 84852-36-8 [27] 85551-28-6 [28] 91697-41-5 [29] 84776-45-4 [30] 72319-19-8 [31] |
Carc. 1A Muta. 2 Repr. 1B STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H341 H360D*** H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H341 H360D*** H372** H334 H317 H410 |
STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,1 % ≤ C < 1 % Skin Sens. 1; H317: C ≥ 0,01 % M=1 |
H | |
| 028-055-00-6 |
nickel(II) sulfite; [1] nickel tellurium trioxide; [2] nickel tellurium tetraoxide; [3] molybdenum nickel hydroxide oxide phosphate [4] |
231-827-7 [1] 239-967-0 [2] 239-974-9 [3] 268-585-7 [4] |
7757-95-1 [1] 15851-52-2 [2] 15852-21-8 [3] 68130-36-9 [4] |
Carc. 1A STOT RE 1 Resp. Sens. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H334 H317 H400 H410 |
GHS08 GHS09 Dgr |
H350i H372** H334 H317 H410 |
H | ||
| 028-056-00-1 |
nickel boride (NiB); [1] dinickel boride; [2] trinickel boride; [3] nickel boride; [4] dinickel silicide; [5] nickel disilicide; [6] dinickel phosphide; [7] nickel boron phosphide [8] |
234-493-0 [1] 234-494-6 [2] 234-495-1 [3] 235-723-2 [4] 235-033-1 [5] 235-379-3 [6] 234-828-0 [7] - [8] |
12007-00-0 [1] 12007-01-1 [2] 12007-02-2 [3] 12619-90-8 [4] 12059-14-2 [5] 12201-89-7 [6] 12035-64-2 [7] 65229-23-4 [8] |
Carc. 1A STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H372** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350i H372** H317 H410 |
H | ||
| 028-057-00-7 |
dialuminium nickel tetraoxide; [1] nickel titanium trioxide; [2] nickel titanium oxide; [3] nickel divanadium hexaoxide; [4] cobalt dimolybdenum nickel octaoxide; [5] nickel zirkonium trioxide; [6] molybdenum nickel tetraoxide; [7] nickel tungsten tetraoxide; [8] olivine, nickel green; [9] lithium nickel dioxide; [10] molybdenum nickel oxide; [11] |
234-454-8 [1] 234-825-4 [2] 235-752-0 [3] 257-970-5 [4] 268-169-5 [5] 274-755-1 [6] 238-034-5 [7] 238-032-4 [8] 271-112-7 [9] - [10] - [11] |
12004-35-2 [1] 12035-39-1 [2] 12653-76-8 [3] 52502-12-2 [4] 68016-03-5 [5] 70692-93-2 [6] 14177-55-0 [7] 14177-51-6 [8] 68515-84-4 [9] 12031-65-1 [10] 12673-58-4 [11] |
Carc. 1A STOT RE 1 Skin Sens. 1 |
H350i H372** H317 |
GHS08 GHS07 Dgr |
H350i H372** H317 |
H | ||
| 028-058-00-2 | cobalt lithium nickel oxide | 442-750-5 | — |
Carc. 1A Acute Tox. 2 * STOT RE 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350i H330 H372** H317 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H350i H330 H372** H317 H410 |
|||
| 029-014-00-5 |
reaction mass of: 2,2'-[[cis-1,2-cyclohexanediylbis(nitrilomethylidene)]bis[phenolate]](2-)N,N',O,O'-copper complex; 2,2'-[[trans-1,2-cyclohexanediylbis(nitrilomethylidyne)]bis[phenolate]](2-)N,N',O,O'-copper complex |
419-610-7 | 171866-24-3 |
STOT RE 2 * Aquatic Chronic 2 |
H373** H411 |
GHS08 GHS09 Wng |
H373** H411 |
|||
| 030-009-00-5 | zinc-bis(4-(n-octyloxycarbonylamino)salicylate) dihydrate | 417-130-2 | — |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|||
| 030-010-00-0 | 2-dodec-1-enylbutanedioic acid, 4-methyl ester zinc salt | 430-740-3 | — | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 030-012-00-1 | aluminium-magnesium-zinc-carbonate-hydroxide | 423-570-6 | 169314-88-9 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 030-015-00-8 | tetrazinc(2+)bis(hexacyanocobalt(3+))diacetate | 440-060-9 | — | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 040-003-00-4 | reaction product of 3,5-di-tert-butylsalicylic acid and zirconium oxychloride, dehydrated, basic Zr: DTBS = 1,0: 1,0 to 1,0: 1,5 | 430-610-6 | 226996-19-6 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 042-005-00-0 |
reaction mass of: mono- and di-glycerols of canola oil; canola oil acid amide of branched 1,3-propanediamine,N-[3-(tridecyloxy)-propyl]; N,N-diorgano dithiocarbamate molybdenum complex |
434-240-6 | — |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|||
| 046-001-00-X | tetraammine palladium(II) hydrogen carbonate | 425-270-0 | 134620-00-1 |
Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373** H318 H317 H400 H410 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H302 H373** H318 H317 H410 |
|||
| 047-002-00-8 | polyphosphoric acid, copper, sodium, magnesium, calcium, silver and zinc salt | 416-850-4 | — |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 050-021-00-4 | dichlorodioctyl stannane | 222-583-2 | 3542-36-7 |
Acute Tox. 3 * STOT RE 1 Aquatic Chronic 3 |
H331 H372** H412 |
GHS06 GHS08 Dgr |
H331 H372** H412 |
|||
| 050-022-00-X |
dibutyltin dichloride; (DBTC) |
211-670-0 | 683-18-1 |
Muta. 2 Repr. 1B Acute Tox. 2 * Acute Tox. 3 * Acute Tox. 4 * STOT RE 1 Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H341 H360FD H330 H301 H312 H372** H314 H400 H410 |
GHS06 GHS05 GHS08 GHS09 Dgr |
H341 H360FD H330 H301 H312 H372** H314 H410 |
Skin Corr. 1B; H314: C ≥ 5 % Skin Irrit. 2; H315: 0,01 % ≤ C < 5 % Eye Dam. 1; H318: 3 % ≤ C < 5 % Eye Irrit. 2; H319: 0,01 % ≤ C < 3 % M=10 |
||
| 050-023-00-5 |
reaction mass of: bis[(2-ethyl-1-oxohexyl)oxy]dioctyl stannane; bis[((2-ethyl-1-oxohexyl)oxy)dioctylstannyl]oxide; bis(1-phenyl-1,3-decanedionyl)dioctyl stannane; ((2-ethyl-1-oxohexyl)oxy)-(1-phenyl-1,3-decanedionyl)dioctyl stannane |
422-920-5 | — |
STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H373** H400 H410 |
GHS08 GHS09 Wng |
H373** H410 |
M=10 | ||
| 050-024-00-0 |
reaction mass of: tri-p-tolyltin hydroxide; hexa-p-tolyl-distannoxane |
432-230-6 | — |
STOT RE 1 Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H372** H302 H315 H318 H317 H400 H410 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H372** H302 H315 H318 H317 H410 |
|||
| 064-001-00-8 | gadolinium(III)sulfite trihydrate | 456-900-2 | 51285-81-5 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 078-010-00-X | tetraammine platinum(II) hydrogen carbonate | 426-730-3 | 123439-82-7 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H302 H318 H412 |
GHS05 GHS07 Dgr |
H302 H318 H412 |
|||
| 078-011-00-5 | hydroxydisulfito platinum(II) acid | 423-310-1 | 61420-92-6 |
Acute Tox. 4 * STOT RE 2 * Skin Corr. 1A Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 3 |
H302 H373 H314 H334 H317 H412 |
GHS05 GHS08 GHS07 Dgr |
H302 H373 H314 H334 H317 H412 |
|||
| 078-012-00-0 | platinum(IV) nitrate/nitric acid solution | 432-400-1 | — |
Skin Corr. 1A Aquatic Acute 1 Aquatic Chronic 1 |
H314 H400 H410 |
GHS05 GHS09 Dgr |
H314 H410 |
|||
| 082-012-00-6 | barium calcium cesium lead samarium strontium bromide chloride fluoride iodide europium doped | 431-780-4 | 199876-46-5 |
Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 2 |
H302 H373** H411 |
GHS08 GHS07 GHS09 Wng |
H302 H373** H411 |
|||
| 601-070-00-0 |
reaction mass of: branched icosane; branched docosane; branched tetracosane |
417-050-8 | 151006-58-5 |
Acute Tox. 4 * Aquatic Chronic 4 |
H332 H413 |
GHS07 Wng |
H332 H413 |
|||
| 601-072-00-1 |
reaction mass of: 1-(4-isopropylphenyl)-1-phenylethane; 1-(3-isopropylphenyl)-1-phenylethane; 1-(2-isopropylphenyl)-1-phenylethane |
430-690-2 | 52783-21-8 |
Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H400 H410 |
GHS07 GHS09 Wng |
H315 H410 |
|||
| 601-075-00-8 | 4,4'-bis(N-carbamoyl-4-methylbenzenesulfonamide)diphenylmethane | 418-770-5 | 151882-81-4 | Carc. 2 | H351 |
GHS08 Wng |
H351 | |||
| 601-076-00-3 | ethynyl cyclopropane | 425-430-1 | 6746-94-7 |
Flam. Liq. 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 |
H225 H315 H318 H412 |
GHS02 GHS05 Dgr |
H225 H315 H318 H412 |
|||
| 601-077-00-9 |
reaction mass of: 1-heptyl-4-ethyl-2,6,7-trioxabicyclo[2.2.2]octane; 1-nonyl-4-ethyl-2,6,7-trioxabicyclo[2.2.2]octane |
426-510-7 | 196965-91-0 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 601-078-00-4 |
reaction mass of: 1,7-dimethyl-2-[(3-methylbicyclo[2.2.1]hept-2-yl)methyl]bicyclo[2.2.1]heptane; 2,3-dimethyl-2-[(3-methylbicyclo[2.2.1]hept-2-yl)methyl]bicyclo[2.2.1]heptane |
427-040-5 | — |
Skin Corr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H314 H400 H410 |
GHS05 GHS09 Dgr |
H314 H410 |
|||
| 601-079-00-X |
reaction mass of: trans-trans-cyclohexadeca-1,9-diene; cis-trans-cyclohexadeca-1,9-diene |
429-620-3 | — |
Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 |
H315 H317 H413 |
GHS07 Wng |
H315 H317 H413 |
|||
| 601-080-00-5 |
reaction mass of: sec-butylphenyl(phenyl)methane, mixed isomers; 1-(sec-butylphenyl(phenyl)-2-phenylethane, mixed isomers; 1-(sec-butylphenyl-1-phenylethane, mixed isomers |
431-100-6 | — |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 601-081-00-0 | cyclohexadeca-1,9-diene | 431-730-1 | 4277-06-9 |
Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 |
H315 H317 H413 |
GHS07 Wng |
H315 H317 H413 |
|||
| 601-082-00-6 |
reaction mass of: endo-2-methyl-exo-3-methyl-exo-2-[(exo-3-methylbicyclo[2.2.1]hept-exo-2-yl)methyl]bicyclo[2.2.1]heptane; exo-2-methyl-exo-3-methyl-endo-2-[(endo-3-methylbicyclo[2.2.1]hept-exo-2-yl)methyl]bicyclo[2.2.1]heptane |
434-420-4 | — |
Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H400 H410 |
GHS05 GHS09 Dgr |
H315 H318 H410 |
|||
| 601-083-00-1 | 5-endo-hexyl-bicyclo[2.2.1]hept-2-ene | 435-000-3 | 22094-83-3 |
Asp. Tox. 1 Skin Irrit. 2 Aquatic Chronic 4 |
H304 H315 H413 |
GHS08 GHS07 Dgr |
H304 H315 H413 |
|||
| 601-084-00-7 |
reaction mass of: 5-endo-butyl-bicyclo[2.2.1]hept-2-ene; 5-exo-butyl-bicyclo[2.2.1]hept-2-ene (80:20) |
435-180-3 | — |
Asp. Tox. 1 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H304 H315 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H304 H315 H410 |
|||
| 602-095-00-X |
alkanes, C14-17, chloro; chlorinated paraffins, C14-17 |
287-477-0 | 85535-85-9 |
Lact. Aquatic Acute 1 Aquatic Chronic 1 |
H362 H400 H410 |
GHS09 Wng |
H362 H410 |
EUH066 | ||
| 602-098-00-6 | 2-(3-bromophenoxy)tetrahydro-2H-pyran | 429-030-6 | 57999-49-2 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|||
| 602-099-00-1 | 3-(4-fluorophenyl)-2-methylpropionylchloride | 426-370-7 | — |
Skin Corr. 1A Acute Tox. 4 * Aquatic Chronic 3 |
H314 H302 H412 |
GHS05 GHS07 Dgr |
H314 H302 H412 |
EUH014 EUH029 |
||
| 602-100-00-5 |
reaction mass of: (R,R)-1,1,1,2,2,3,4,5,5,5-decafluoropentane; (S,S)-1,1,1,2,2,3,4,5,5,5-decafluoropentane |
420-640-8 | — | Aquatic Chronic 3 | H412 | — | H412 | |||
| 602-101-00-0 | 2-chloro-4-fluoro-5-nitrophenyl (isobutyl)carbonate | 427-020-6 | 141772-37-4 |
STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H373** H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H373** H317 H410 |
|||
| 602-102-00-6 | 1,1,1,3,3-pentafluorobutane | 430-250-1 | 406-58-6 | Flam. Liq. 2 | H225 |
GHS02 Dgr |
H225 | |||
| 602-103-00-1 | 1-(chlorophenylmethyl)-2-methylbenzene | 431-450-1 | 41870-52-4 |
Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H400 H410 |
GHS07 GHS09 Wng |
H315 H410 |
|||
| 602-104-00-7 | 1,1,2,2,3,3,4-heptafluorocyclopentane | 430-710-1 | 15290-77-4 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 602-105-00-2 | sodium 1,1,2,2,3,3,4,4,4-nonafluoro-1-butanesulfinate | 422-100-7 | 102061-82-5 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|||
| 602-106-00-8 | 2-bromo-4,6-difluoroaniline | 429-430-0 | 444-14-4 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|||
| 602-107-00-3 | 3,3,4,4-tetrafluoro-4-iodo-1-butene | 439-500-2 | 33831-83-3 |
Acute Tox. 4 * Skin Irrit. 2 Aquatic Chronic 2 |
H302 H315 H411 |
GHS07 GHS09 Wng |
H302 H315 H411 |
|||
| 602-108-00-9 | (2,3,5,6-tetrafluorophenyl)methanol | 443-840-7 | 4084-38-2 |
Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 |
H302 H319 H317 |
GHS07 Wng |
H302 H319 H317 |
|||
| 603-109-00-7 |
reaction mass of: 1-ethoxy-1,1,2,3,3,3-hexafluoro-2-(trifluoromethyl)propane; 1-ethoxy-1,1,2,2,3,3,4,4,4-nonafluorobutane |
425-340-0 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 603-110-00-2 |
reaction mass of: cis-2-isobutyl-5-methyl 1,3-dioxane; trans-2-isobutyl-5-methyl 1,3-dioxane |
426-130-1 | 166301-21-9 |
Skin Irrit. 2 Aquatic Chronic 3 |
H315 H412 |
GHS07 Wng |
H315 H412 |
|||
| 603-111-00-8 |
reaction mass of: 1-(1,1-dimethylpropyl)-4-ethoxy-cis-cyclohexane; 1-(1,1-dimethylpropyl)-4-ethoxy-trans-cyclohexane |
426-530-6 | — |
Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H400 H410 |
GHS07 GHS09 Wng |
H315 H410 |
|||
| 603-112-00-3 | cyclopentyl 2-phenylethyl ether | 428-340-9 | — |
Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H400 H410 |
GHS07 GHS09 Wng |
H315 H410 |
|||
| 603-113-00-9 | 6-glycidyloxynapht-1-yl oxymethyloxirane | 429-960-2 | 27610-48-6 |
Muta. 2 Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 |
H341 H312 H315 H317 H412 |
GHS08 GHS07 Wng |
H341 H312 H315 H317 H412 |
|||
| 603-114-00-4 | 9-(2-propenyloxy)tricyclo[5.2.1.0(2,6)]dec-3(or-4-)-ene | 430-830-2 | 26912-64-1 |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|||
| 603-115-00-X | reaction mass of: O,O',O''-(methylsilanetriyl)tris(4-methyl-2-pentanone oxime) (3 stereoisomers) | 423-580-0 | — |
STOT RE 2 * Aquatic Chronic 4 |
H373** H413 |
GHS08 Wng |
H373** H413 |
|||
| 603-116-00-5 | (Z)-(2,4-difluorophenyl)piperidin-4-ylmethanone oxime monohydrochloride | 424-740-2 | 138271-16-6 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H302 H318 H412 |
GHS05 GHS07 Dgr |
H302 H318 H412 |
|||
| 603-182-00-5 | reaction product of: saturated, monounsaturated and multiple unsaturated long-chained partly estrified alcohols of vegetable origin (Brassica napus L., Brassica rapa L., Helianthus annuus L., Glycine hispida, Gossypium hirsutum L., Cocos nucifera L., Elaeis guineensis) with O,O-diisobutyldithiophosphate and 2-ethylhexylamine and hydrogen peroxide | 428-630-5 | — | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 603-188-00-8 |
reaction mass of: 6,7-epoxy-1,2,3,4,5,6,7,8-octahydro-1,1,2,4,4,7-hexamethylnaphthalene; 7,8-epoxy-1,2,3,4,6,7,8,8a-octahydro-1,1,2,4,4,7-hexamethylnaphthalene |
426-970-9 | — |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 603-190-00-9 | 8,8-dimethyl-7-isopropyl-6,10-dioxaspiro[4.5]decane | 424-030-2 | 62406-73-9 |
Skin Irrit. 2 Aquatic Chronic 3 |
H315 H412 |
GHS07 Wng |
H315 H412 |
|||
| 603-192-00-X | (E,E)-3,7,11-trimethyldodeca-1,4,6,10-tetraen-3-ol | 423-240-1 | 125474-34-2 |
Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H315 H318 H317 H410 |
|||
| 603-193-00-5 | disodium 9,10-anthracenedioxide | 426-030-8 | 46492-07-3 | Skin Corr. 1A | H314 |
GHS05 Dgr |
H314 | |||
| 603-194-00-0 |
2-(2-aminoethylamino)ethanol; (AEEA) |
203-867-5 | 111-41-1 |
Repr. 1B Skin Corr. 1B Skin Sens. 1 |
H360Fd H361 H314 H317 |
GHS05 GHS08 GHS07 Dgr |
H360Fd H361 H314 H317 |
STOT SE 3; H335: C ≥ 5 % | ||
| 603-200-00-1 |
1-pentanol; [1] 3-pentanol [2] |
200-752-1 [1] 209-526-7 [2] |
71-41-0 [1] 584-02-1 [2] |
Flam. Liq. 3 Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 |
H226 H332 H335 H315 |
GHS02 GHS07 Wng |
H226 H332 H335 H315 |
|||
| 603-201-00-7 | (E)-(7R,11R)-3,7,11,15-tetramethylhexadec-2-ene-1-ol | 416-120-5 | — |
Skin Irrit. 2 Aquatic Chronic 4 |
H315 H413 |
GHS07 Wng |
H315 H413 |
|||
| 603-202-00-2 | 4,4,5,5,5-pentafluoropentan-1-ol | 421-360-9 | 148043-73-6 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|||
| 603-203-00-8 | (1R,3S,7R,8R,10R,13R)-5,5,7,9,9,13-hexamethyl-4,6-dioxatetracyclo[6.5.1.01,10.03,7]tetradecane | 427-580-1 | — | Skin Irrit. 2 | H315 |
GHS07 Wng |
H315 | |||
| 603-204-00-3 |
reaction mass of: 2,2'-(heptane-1,7-diyl)bis-1,3-dioxolane; 2,2'-(heptane-1,6-diyl)bis-1,3-dioxolane |
428-110-8 | — | Aquatic Chronic 3 | H412 | — | H412 | |||
| 603-205-00-9 | (1S-cis)-4-(2-amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1-methanol hydrochloride | 426-200-1 | 172015-79-1 |
STOT RE 1 Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H372** H302 H318 H317 H412 |
GHS05 GHS08 GHS07 Dgr |
H372** H302 H318 H317 H412 |
|||
| 603-206-00-4 | 2,2-dichloro-1,3-benzodioxol | 426-850-6 | 2032-75-9 |
Flam. Liq. 3 Skin Corr. 1A Acute Tox. 4 * Skin Sens. 1 |
H226 H314 H302 H317 |
GHS02 GHS05 GHS07 Dgr |
H226 H314 H302 H317 |
EUH014 | ||
| 603-207-00-X | 2-isobutyl-2-isopropyl-1,3-dimethoxypropane | 430-800-9 | 129228-21-3 |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|||
| 603-208-00-5 | 1,2-diethoxyethane | 211-076-1 | 629-14-1 |
Flam. Liq. 2 Repr. 1A Eye Irrit. 2 |
H225 H360Df H319 |
GHS02 GHS08 GHS07 Dgr |
H225 H360Df H319 |
EUH019 | ||
| 603-209-00-0 |
spinosad (ISO) (reaction mass of spinosyn A and spinosyn D in ratios between 95:5 to 50:50); reaction mass of 50-95 % of (2R,3aS,5aR,5bS,9S,13S,14R,16aS,16bR)-2-(6-deoxy-2,3,4-tri-O-methyl-α-l-mannopyranosyloxy)-13-(4-dimethylamino-2,3,4,6-tetradeoxy-β-d-erythropyranosyloxy)-9-ethyl-2,3,3a,5a,5b,6,7,9,10,11,12,13,14,15,16a,16b-hexadecahydro-14-methyl-1H-8-oxacyclododeca[b]as-indacene-7,15-dione and 50-5 % (2S,3aR,5aS,5bS,9S,13S,14R,16aS,16bS)-2-(6-deoxy-2,3,4-tri-O-methyl-α-l-mannopyranosyloxy)-13-(4-dimethylamino-2,3,4,6-tetradeoxy-β-d-erythropyranosyloxy)-9-ethyl-2,3,3a,5a,5b,6,7,9,10,11,12,13,14,15,16a,16b-hexadecahydro-4,14-dimethyl-1H-8-oxacyclododeca[b]as-indacene-7,15-dione; [1] spinosyn A; [2] spinosyn D [3] |
- [1] - [2] - [3] |
- [1] 131929-60-7 [2] 131929-63-0 [3] |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | M=10 | ||
| 603-210-00-6 | 2,4-diethyl-1,5-pentanediol | 429-310-8 | 57987-55-0 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 603-211-00-1 |
2,3-epoxypropyltrimethylammonium chloride … %; glycidyl trimethylammonium chloride … % |
221-221-0 | 3033-77-0 |
Carc. 1B Muta. 2 Repr. 2 Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H350 H341 H361f*** H312 H302 H373** H318 H317 H412 |
GHS05 GHS08 GHS07 Dgr |
H350 H341 H361f*** H312 H302 H373** H318 H317 H412 |
B | ||
| 603-212-00-7 |
1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethylindeno[5,6-c]pyran; galaxolide; (HHCB) |
214-946-9 | 1222-05-5 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 603-213-00-2 |
2-methoxy-2-methylbutane; tert-amyl methyl ether |
213-611-4 | 994-05-8 |
Flam. Liq. 2 Acute Tox. 4 * STOT SE 3 |
H225 H302 H336 |
GHS02 GHS07 Dgr |
H225 H302 H336 |
|||
| 603-214-00-8 | 1,1-diisopropoxycyclohexane | 413-740-8 | 1132-95-2 | Skin Corr. 1B | H314 |
GHS05 Dgr |
H314 | |||
| 603-215-00-3 | 1-hydroxy-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) | 418-330-2 | 162241-33-0 |
Expl. 1.1**** Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H201 H302 H373** H318 H317 H400 H410 |
GHS01 GHS05 GHS08 GHS07 GHS09 Dgr |
H201 H302 H373** H318 H317 H410 |
|||
| 603-216-00-9 | cis-1-amino-2,3-dihydro-1H-inden-2-ol | 422-660-2 | 7480-35-5 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|||
| 603-217-00-4 | 2,4,6-tri-tert-butylphenyl 2-butyl-2-ethyl-1,3-propanediolphosphite | 423-560-1 | 161717-32-4 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 603-220-00-0 | 1-{benzyl[2-(2-methoxyphenoxy)ethyl]amino}-3-(9H-carbazol-4-yloxy)propan-2-ol | 432-890-5 | 72955-94-3 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 603-221-00-6 |
1-(2-amino-5-chlorophenyl)-2,2,2-trifluoro-1,1-ethanediol, hydrochloride; [containing < 0,1 % 4-chloroaniline (EC No 203-401-0)] |
433-580-2 | 214353-17-0 |
Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 |
H302 H314 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H314 H411 |
|||
| 603-221-01-3 |
1-(2-amino-5-chlorophenyl)-2,2,2-trifluoro-1,1-ethanediol, hydrochloride; [containing ≥ 0,1 % 4-chloroaniline (EC No 203-401-0)] |
433-580-2 | 214353-17-0 |
Carc. 1B Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 2 |
H350 H302 H314 H411 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H350 H302 H314 H411 |
|||
| 603-222-00-1 | (2R,3S,4R,5R,7R,9R,10R,11S,12S,13R)-10-[(4-dimethylamino-3-hydroxy-6-methyltetrahydropyran-2-yl)oxy]-2-ethyl-3,4,12-trihydroxy-9-methoxy-3,5,7,9,11,13-hexamethyl-6,14-dioxo-1-oxacyclotetradecane | 433-820-6 | 118058-74-5 | Eye Irrit. 2 | H319 |
GHS07 Wng |
H319 | |||
| 603-223-00-7 |
2-cyclopentylidene cyclopentanol; 1,1'-bi(cyclopentyliden)-2-ol |
434-270-1 | 6261-30-9 |
Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 |
H315 H318 H412 |
GHS05 Dgr |
H315 H318 H412 |
|||
| 603-224-00-2 | 3-ethoxy-1,1,1,2,3,4,4,5,5,6,6,6-dodecafluoro-2-(trifluoromethyl)-hexane | 435-790-1 | 297730-93-9 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 603-225-00-8 |
erythromycin A9-oxime (E); (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-((2,6-didesoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopiranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-tridesoxy-3-dimethylamino-β-d-xylohexapiranosyl)oxy)oxacyclotetradecan-2-ona-10-oxime (E) |
437-070-0 | 13127-18-9 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 603-226-00-3 | 4,4'(4-(4-methoxyphenyl)-1,3,5-triazin-2,4-diyl)bisbenzene-1,3-diol | 444-500-0 | 1440-00-2 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 603-227-00-9 |
α-hydro-ω-[[[(1,1-dimethylethyl)dioxy]carbonyl]oxy]-poly[oxy(methyl-1,2-ethanediyl)] ether with 2,2-bis(hydroxymethyl)-1,3-propanediol (4:1); reaction product of: α-hydro-ω-((chlorocarbonyl)oxy)-poly(oxy(methyl-1,2-ethanediyl)) ether with 2,2-bis(hydroxymethyl)-1,3-propanediol with potassium 1,1-dimethylethylperoxalate |
445-060-2 | 203574-04-3 |
**** Aquatic Acute 1 Aquatic Chronic 1 |
**** H400 H410 |
**** GHS09 Wng |
**** H410 |
|||
| 603-228-00-4 |
(+/–)-(R*,R*)-6-fluoro-3,4-dihydro-2-oxiranyl-2H-1-benzopyran; 6-fluoro-2-(2-oxiranyl)chromane |
419-620-1 | — |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|||
| 603-229-00-X | sodium (Z)-3-chloro-3-(4-chlorophenyl)-1-hydroxy-2-propene-1-sulfonate | 420-800-7 | — |
Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H315 H318 H317 H410 |
|||
| 603-230-00-5 | 2,6,6,7,8,8-hexamethyldecahydro-2H-indeno[4,5-b]furan | 440-030-5 | — |
Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 4 |
H315 H318 H413 |
GHS05 Dgr |
H315 H318 H413 |
|||
| 603-231-00-0 | (S)-1,1-diphenyl-1,2-propanediol | 443-220-6 | — | Aquatic Chronic 3 | H412 | — | H412 | |||
| 603-232-00-6 | 3,3,8,8,10,10-hexamethyl-9-[1-(4-oxiranylmethoxy-phenyl)-ethoxy]-1,5-dioxa-9-aza-spiro[5.5]undecane | 444-420-6 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 603-233-00-1 |
reaction mass of: 4-(1,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)-3-methylbutan-2-ol; 4-(3,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)-3-methylbutan-2-ol; 1-(1,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)pentan-3-ol; 1-(3,3a,4,6,7,7a-hexahydro-4,7-methanoinden-5-ylidene)pentan-3-ol; (E)-4-(3a,4,5,6,7,7a-hexahydro-1H-4,7-methanoinden-5-yl)-3-methylbut-3-en-2-ol; (E)-4-(3a,4,5,6,7,7a-hexahydro-3H-4,7-methanoinden-5-yl)-3-methylbut-3-en-2-ol |
444-430-0 | — | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 603-234-00-7 | (1R,4R)-4-methoxy-2,2,7,7-tetramethyltricyclo(6.2.1.0(1,6))undec-5-ene | 444-480-3 | — |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|||
| 604-071-00-4 | 4,4'-(1-{4-[1-(4-hydroxyphenyl)-1-methylethyl]phenyl}ethylidene)diphenol | 425-600-3 | 110726-28-8 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 604-072-00-X | 1,2-bis(phenoxymethyl)benzene | 428-620-0 | 10403-74-4 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 604-073-00-5 | (E)-3-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol | 428-010-4 | 82413-20-5 |
Carc. 2 Repr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H360F*** H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H351 H360F*** H317 H410 |
|||
| 604-074-00-0 |
tetrabromobisphenol-A; 2,2',6,6'-tetrabromo-4,4'-isopropylidenediphenol |
201-236-9 | 79-94-7 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 604-075-00-6 |
4-(1,1,3,3-tetramethylbutyl)phenol; 4-tert-octylphenol |
205-426-2 | 140-66-9 |
Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H400 H410 |
GHS05 GHS09 Dgr |
H315 H318 H410 |
M=10 | ||
| 604-076-00-1 | phenolphthalein | 201-004-7 | 77-09-8 |
Carc. 1B Muta. 2 Repr. 2 |
H350 H341 H361f*** |
GHS08 Dgr |
H350 H341 H361f*** |
Carc. 1A; H350: C ≥ 1 % | ||
| 604-077-00-7 | 2-benzotriazol-2-yl-4-methyl-6-(2-methylallyl)phenol | 419-750-9 | 98809-58-6 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 604-079-00-8 | 4,4'-(1,3-phenylene-bis(1-methylethylidene))bis-phenol | 428-970-4 | 13595-25-0 |
Repr. 2 Skin Sens. 1 Aquatic Chronic 2 |
H361f*** H317 H411 |
GHS08 GHS09 Wng |
H361f*** H317 H411 |
|||
| 604-080-00-3 | 4-fluoro-3-trifluoromethylphenol | 432-560-0 | 61721-07-1 |
Acute Tox. 4 * Skin Corr. 1A Skin Sens. 1 Aquatic Chronic 2 |
H332 H314 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H332 H314 H317 H411 |
|||
| 604-081-00-9 | 1,1-bis(4-hydroxyphenyl)-1-phenylethane | 433-130-5 | 1571-75-1 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 604-082-00-4 | 2-chloro-6-fluoro-phenol | 433-890-8 | 2040-90-6 |
Muta. 1B Repr. 2 Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 |
H340 H361f*** H302 H314 H317 H411 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H340 H361f*** H302 H314 H317 H411 |
|||
| 604-083-00-X | 4,4'-sulfonylbisphenol, polymer with ammonium chloride (NH4Cl), pentachlorophosphorane and phenol | 439-270-3 | 260408-02-4 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 604-084-00-5 | 1-ethoxy-2,3-difluorobenzene | 441-000-4 | 121219-07-6 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|||
| 604-087-00-1 |
reaction mass of: 1,2-naphthoquinonediazide-5-sulfonylchloride (or sulfonic acid)monoester with 4,4'-(1-(4-(1-(4-hydroxyphenyl)-1-methylethyl)phenyl)ethylidene)bisphenol; 1,2-naphthoquinonediazide-5-sulfonylchloride (or sulfonic acid)diester with 4,4'-(1-(4-(1-(4-hydroxyphenyl)-1-methylethyl)phenyl)ethylidene)bisphenol; 1,2-naphthoquinonediazide-5-sulfonylchloride (or sulfonic acid)triester with 4,4'-(1-(4-(1-(4-hydroxyphenyl)-1-methylethyl)phenyl)ethylidene)bisphenol |
433-640-8 | — |
Pyr. Sol. 1 Aquatic Chronic 4 |
H250 H413 |
GHS02 Dgr |
H250 H413 |
EUH044 | ||
| 604-089-00-2 | 2-methyl-5-tert-butylthiophenol | 444-970-7 | — |
Flam. Liq. 3 Repr. 2 STOT RE 2 * Asp. Tox. 1 Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 |
H226 H361d*** H373** H304 H319 H315 H317 H336 H400 H410 |
GHS02 GHS08 GHS07 GHS09 Dgr |
H226 H361d*** H373** H304 H319 H315 H317 H336 H410 |
|||
| 605-023-00-5 | 5-chloro-2-(4-chlorophenoxy)phenol | 429-290-0 | 3380-30-1 |
Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H400 H410 |
GHS05 GHS09 Dgr |
H318 H410 |
|||
| 605-024-00-0 | 2-bromo-5-hydroxy-4-methoxybenzaldehyde | 426-540-0 | 2973-59-3 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|||
| 605-032-00-4 | 3-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-(E)-2-propenal | 425-370-4 | 93957-50-7 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|||
| 605-033-00-X |
reaction mass of: 3,7,11-trimethyl-cis-6,10-dodecadienal; 3,7,11-trimethyl-trans-6,10-dodecadienal |
425-910-9 | 32480-08-3 |
Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H400 H410 |
GHS07 GHS09 Wng |
H315 H410 |
|||
| 605-034-00-5 |
reaction mass of: (1RS,2RS,3SR,6RS,9SR)-9-methoxytricyclo[5.2.1.0(2,6)]decane-3-carbaldehyde; (1RS,2RS,3RS,6RS,8SR)-8-methoxytricyclo[5.2.1.0(2,6)]decane-3-carbaldehyde; (1RS,2RS,4SR,6RS,8SR)-8-methoxytricyclo[5.2.1.0(2,6)]decane-4-carbaldehyde |
429-860-9 | — |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|||
| 605-035-00-0 | (E)-3-(4-(4-fluorophenyl)-5-methoxymethyl-2,6-bis(1-methoxymethyl)pyridin-3-yl)prop-2-enal | 426-330-9 | 177964-68-0 |
Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 |
H319 H317 H413 |
GHS07 Wng |
H319 H317 H413 |
|||
| 605-036-00-6 | 2-bromomalonaldehyde | 430-470-6 | 2065-75-0 |
Acute Tox. 4 * Eye Dam. 1 |
H302 H318 |
GHS05 GHS07 Dgr |
H302 H318 |
|||
| 605-037-00-1 |
trans-3-[2-(7-chloro-2-quinolinyl)vinyl]benzaldehyde; 3-[(E)-2-(7-chloro-2-quinolinyl)vinyl]benzaldehyde |
421-800-1 | 120578-03-2 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 605-038-00-7 | 3-methyl-5-phenylpentan-1-al | 433-900-0 | 55066-49-4 |
Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H302 H315 H317 H411 |
GHS07 GHS09 Wng |
H302 H315 H317 H411 |
|||
| 605-039-00-2 | 3,4-dihydroxy-5-nitrobenzaldehyde | 441-810-8 | 116313-85-0 |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 |
H302 H318 H317 |
GHS05 GHS07 Dgr |
H302 H318 H317 |
|||
| 606-074-00-6 |
reaction mass of: (1R*,2S*)-2-acetyl-1,2,3,4,5,6,7,8-octahydro-1,2,8,8-tetramethylnaphthalene; (2R*,3S*)-2-acetyl-1,2,3,4,5,6,7,8-octahydro-2,3,8,8-tetramethylnaphthalene |
425-570-1 | — |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 606-090-00-3 | 1-[3-[(dimethylamino)methyl]-4-hydroxyphenyl]ethanone | 430-920-1 | 73096-98-7 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H302 H318 H412 |
GHS05 GHS07 Dgr |
H302 H318 H412 |
|||
| 606-093-00-X | 5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one | 414-470-3 | 95885-13-5 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|||
| 606-094-00-5 | N-[ethyl(3-methylbutyl)amino]-3-methyl-1-phenyl-spiro[[1]benzo-pyrano[2,3-c]pyrazole-4(1H),1'(3'H)-isobenzofuran]-3'-one | 417-460-7 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 606-095-00-0 | (R,S)-2-azabicyclo[2.2.1]hept-5-en-3-one | 421-830-3 | 49805-30-3 |
Acute Tox. 4 * Skin Sens. 1 |
H302 H317 |
GHS07 Wng |
H302 H317 |
|||
| 606-096-00-6 | 3-(6-O-(6-desoxy-α-l-mannopyranosyl-O-(α-d-glucopyranosyl)-(β-d-glucopyranosyl)oxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one | 424-170-4 | 130603-71-3 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|||
| 606-097-00-1 | 2,2''-dihydroxy-4,4''-(2-hydroxy-propane-1,3-diyldioxy)dibenzophenone | 424-210-0 | 23911-85-5 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 606-098-00-7 | 1-benzyl-5-(hexadecyloxy)-2,4-imidazolidinedione | 431-220-9 | 158574-65-3 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 606-099-00-2 | 5-methoxy-4'-(trifluoromethyl)valerophenone | 425-000-1 | 61718-80-7 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 606-100-00-6 | 2-butyryl-3-hydroxy-5-thiocyclohexan-3-yl-cyclohex-2-en-1-one | 425-150-8 | 94723-86-1 |
Repr. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 |
H360F*** H302 H317 H412 |
GHS08 GHS07 Dgr |
H360F*** H302 H317 H412 |
|||
| 606-101-00-1 |
reaction mass of: 1,5-bis[(2-ethylhexyl)amino]-9,10-anthracenedione; 1-[(2-ethylhexyl)amino]-5-[3-[(2-ethylhexyl)oxy]propyl]amino-9,10-anthracenedione; 1,5-bis[3-[(2-ethylhexyl)oxy]propyl]amino-9,10-anthracenedione; 1-[(2-ethylhexyl)amino]-5-[(3-methoxypropyl)amino]-9,10-anthracene dione; 1-[3-[(2-ethylhexyl)oxy]propyl]amino-5-[(3-methoxypropyl)amino]-9,10-anthracenedione; 1,5-bis[(3-methyloxypropyl)amino]-9,10-anthracenedione |
426-050-7 | 165038-51-7 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 606-102-00-7 | 4-(3-triethoxysilylpropoxy)-2-hydroxybenzophenone | 431-490-8 | 79876-59-8 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 606-103-00-2 | 1-(4-(trans-4-ethylcyclohexyl)phenyl)ethanone | 426-460-6 | — | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 606-104-00-8 | 1-(4-(trans-4-pentylcyclohexyl)phenyl)ethanone | 426-830-7 | 78531-59-6 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 606-105-00-3 | 3,4,3',4'-tetraphenyl-1,1'-ethandiylbispyrol-2,5-dione | 431-500-0 | 226065-73-2 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 606-106-00-9 | 1-(4-(trans-4-butylcyclohexyl)phenyl)ethanone | 427-320-7 | 83626-30-6 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 606-107-00-4 | 8-azaspiro[4.5]decane-7,9-dione | 427-770-4 | 1075-89-4 |
Acute Tox. 3 * Aquatic Chronic 2 |
H301 H411 |
GHS06 GHS09 Dgr |
H301 H411 |
|||
| 606-108-00-X | 1,1,1,2,2,4,5,5,5-nonafluoro-4-(trifluoromethyl)-3-pentanone | 436-710-6 | 756-13-8 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 606-109-00-5 | 2-(4-methyl-3-pentenyl)anthraquinone | 428-320-1 | 71308-16-2 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 4 |
H302 H317 H314 |
GHS07 Wng |
H302 H317 H314 |
|||
| 606-110-00-0 | 5-ethoxy-5H-furan-2-one | 428-330-4 | 2833-30-9 |
Skin Corr. 1B Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 |
H314 H312 H302 H373** H317 |
GHS05 GHS08 GHS07 Dgr |
H314 H312 H302 H373** H317 |
|||
| 606-111-00-6 | 5-amino-6-methyl-1,3-dihydrobenzoimidazol-2-one | 428-410-9 | 67014-36-2 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H317 H411 |
GHS07 GHS09 Wng |
H302 H317 H411 |
|||
| 606-112-00-1 | (4aR*,8aR*)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-one | 428-690-2 | 1668-86-6 |
Acute Tox. 4 * Eye Irrit. 2 Aquatic Chronic 3 |
H302 H319 H412 |
GHS07 Wng |
H302 H319 H412 |
|||
| 606-113-00-7 | 1-[4-(4-benzoylphenylsulfanyl)phenyl]-2-methyl-2-(4-methylphenylsulfonyl)propan-1-one | 429-040-0 | 272460-97-6 |
Eye Dam. 1 Aquatic Chronic 4 |
H318 H314 |
GHS05 Dgr |
H318 H314 |
|||
| 606-114-00-2 | 4,4',5,5',6,6',7,7'-octachloro-(2,2')biisoindolyl-1,1',3,3'-tetraone | 429-150-9 | 67887-47-2 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 606-115-00-8 |
profoxydim (ISO); 2-{(EZ)-1-[(2RS)-2-(4-chlorophenoxy)propoxyimino]butyl}-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one |
— | 139001-49-3 |
Carc. 2 Repr. 2 Skin Sens. 1 |
H351 H361d H317 |
GHS08 GHS07 Wng |
H351 H361d H317 |
|||
| 606-116-00-3 |
tepraloxydim (ISO); (RS)-(EZ)-2-{1-[(2E)-3-chloroallyloxyimino]propyl}-3-hydroxy-5-perhydropyran-4-ylcyclohex-2-en-1-one |
— | 149979-41-9 |
Carc. 2 Repr. 2 |
H351 H361fd |
GHS08 Wng |
H351 H361fd |
|||
| 606-117-00-9 | 2,6-bis(1,1-dimethylethyl)-4-(phenylenemethylene)cyclohexa-2,5-dien-1-one | 429-460-4 | 7078-98-0 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 606-118-00-4 | N-(1,3-dimethylbutyl)-N'-(phenyl)-1,4-benzoquinonediimine | 429-640-2 | 52870-46-9 |
Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H400 H410 |
GHS07 GHS09 Wng |
H319 H410 |
|||
| 606-119-00-X | (E)-3-methyl-5-cyclopentadecen-1-one | 429-900-5 | — |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|||
| 606-120-00-5 | 2,5-dihydroxy-5-methyl-3-(morpholin-4-yl)-2-cyclopenten-1-one | 430-170-5 | 114625-74-0 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|||
| 606-121-00-0 | (+)-(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptane-3-spiro-1'-(cyclohex-2'-en-4'-one) | 430-460-1 | 133636-82-5 |
Skin Corr. 1B Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H314 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H314 H317 H410 |
|||
| 606-122-00-6 | 3-(2-bromopropionoyl)-4,4-dimethyl-1,3-oxazolan-2-one | 430-820-8 | 114341-88-7 |
Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373** H315 H318 H317 H400 H410 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H302 H373** H315 H318 H317 H410 |
|||
| 606-123-00-1 | 4-hexadecyl-1-phenylpyrazolidin-3-one | 430-840-7 | — |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 606-124-00-7 | 1-cyclopropyl-3-(2-methylthio-4-trifluoromethylphenyl)-1,3-propanedione | 421-080-7 | 161462-35-7 |
STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H373** H400 H410 |
GHS08 GHS09 Wng |
H373** H410 |
|||
| 606-125-00-2 | 1-benzylimidazolidine-2,4-dione | 421-340-1 | 6777-05-5 | Acute Tox. 4 * | H302 |
GHS07 Wng |
H302 | |||
| 606-126-00-8 | 1,4-bis(2,3-dihydroxypropylamino)anthraquinone | 421-470-7 | 99788-75-7 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 606-128-00-9 | 2,2'-(1,3-phenylene)bis[5-chloro-1H-isoindole]-1,3(2H)-dione | 422-650-8 | 148935-94-8 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 606-129-00-4 |
5-amino-[2S-di(methylphenyl)amino]-1,6-diphenyl-4Z-hexen-3-one; (2S,4Z)-5-amino-2-(dibenzylamino)-1,6-diphenylhex-4-en-3-one |
423-090-7 | 156732-13-7 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 606-130-00-X | 4-(1,4-dioxa-spiro[4.5]dec-8-yl)-cyclohexanone | 423-860-2 | 56309-94-5 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|||
| 606-131-00-5 | cyclic 3-(1,2-ethanediylacetale)-estra-5(10),9(11)-diene-3,17-dione | 427-230-8 | 5571-36-8 |
Repr. 1B STOT RE 2 * Aquatic Chronic 2 |
H360F*** H373** H411 |
GHS08 GHS09 Dgr |
H360F*** H373** H411 |
|||
| 606-132-00-0 | (6β)-6,19-epoxyandrost-4-ene-3,17-dione | 433-490-3 | 6563-83-3 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|||
| 606-134-00-1 | androsta-1,4,9(11)-triene-3,17-dione | 433-560-3 | 15375-21-0 | Repr. 2 | H361f*** |
GHS08 Wng |
H361f*** | |||
| 606-135-00-7 | cyclohexadecanone | 438-930-8 | 2550-52-9 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 606-136-00-2 | (3S,6R,9S,12R,15S,18R,21S,24R)-6,18-dibenzyl-3,9,15,21-tetraisobutyl-4,10,12,16,22,24-hexamethyl-1,7,13,19-tetraoxa-4,10,16,22-tetraazacyclo-tetracosane-2,5,8,11,14,17,20,23-octaone | 444-350-6 | 133413-70-4 |
Eye Irrit. 2 Aquatic Chronic 4 |
H319 H413 |
GHS07 Wng |
H319 H413 |
|||
| 606-137-00-8 | trans-7,7'-dimethyl-(4H,4H')-(2,2')bi[benzo[1,4]thiazinylidene]-3,3'-dione | 444-750-0 | 211387-26-7 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 606-138-00-3 | (2-butyl-5-nitrobenzofuran-3-yl)[4-(3-dibutylaminopropoxy)phenyl]methanone | 444-800-1 | 141645-23-0 |
Flam. Liq. 3 Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H226 H302 H373** H315 H318 H317 H400 H410 |
GHS02 GHS05 GHS08 GHS07 GHS09 Dgr |
H226 H302 H373** H315 H318 H317 H410 |
M=10 | ||
| 606-139-00-9 | (S)-4-(3,4-dichlorophenyl)-3,4-dihydro-2H-naphthalen-1-one | 444-830-5 | 124379-29-9 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 606-140-00-4 | 2-hydroxy-1-(4-(4-(2-hydroxy-2-methylpropionyl)benzyl)phenyl)-2-methylpropan-1-one | 444-860-9 | 474510-57-1 |
STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H373** H400 H410 |
GHS08 GHS09 Wng |
H373** H410 |
|||
| 606-141-00-X | sodium 3-(methoxycarbonyl)-4-oxo-3,4,5,6-tetrahydro-2-pyridinolate | 418-410-7 | — | Eye Irrit. 2 | H319 |
GHS07 Wng |
H319 | |||
| 606-142-00-5 |
reaction mass of: (1RS,2SR,7SR,8SR,E) 9 and 10-ethylidene-3-oxatricyclo[6.2.1.0(2,7)]undecan-4-one; (1RS,2SR,7SR,8SR,Z)-10-ethylidene-3-oxatricyclo[6.2.1.0(2,7)]undecan-4-one; (1RS,2SR,7SR,8SR,Z)-9-ethylidene-3-oxatricyclo[6.2.1.0(2,7)]undecan-4-one |
434-290-9 | — |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|||
| 607-417-00-2 | 3-chloropropyl chloroformiate | 425-770-9 | 628-11-5 |
Acute Tox. 3 * Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 |
H331 H302 H373** H315 H318 H317 |
GHS06 GHS05 GHS08 Dgr |
H331 H302 H373** H315 H318 H317 |
|||
| 607-428-00-2 | tetrasodium ethylene diamine tetraacetate | 200-573-9 | 64-02-8 |
Acute Tox. 4 * Eye Dam. 1 |
H302 H318 |
GHS05 GHS07 Dgr |
H302 H318 |
|||
| 607-429-00-8 |
edetic acid; (EDTA) |
200-449-4 | 60-00-4 | Eye Irrit. 2 | H319 |
GHS07 Wng |
H319 | |||
| 607-471-00-7 | 1,6-bis((dibenzylthiocarbamoyl)disulfanyl)hexane | 429-280-6 | 151900-44-6 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-473-00-8 | pentaerythritol, dipentaerythritol, fatty acids, C6-10, mixed esters with adipic acid, heptanoic acid and isostearic acid | 426-590-3 | 187412-41-5 | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 607-477-00-X | (1α5α6α)-6-nitro-3-benzyl-3-azabicyclo[3.1.0]hexane methanesulfonate salt | 426-740-8 | — |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|||
| 607-481-00-1 |
reaction mass of: trihexyl citrate; dihexyloctyl citrate; dioctylhexyl citrate; dihexyldecyl citrate |
430-290-8 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-482-00-7 | N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-l-alanyl-N-carboxyanhydride | 430-360-8 | 84793-24-8 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|||
| 607-483-00-2 |
1,2-benzenedicarboxylic acid; di-C6-8-branched alkylesters, C7-rich |
276-158-1 | 71888-89-6 | Repr. 1B | H360D*** |
GHS08 Dgr |
H360D*** | |||
| 607-484-00-8 | ethyl 2-{[3-acetylamino-4-(6-bromo-2-methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylazo)phenyl]ethylamino}propionate | 430-480-0 | 221452-67-1 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-485-00-3 | (3S-trans)-phenyl-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinecarboxylate | 430-510-2 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-486-00-9 | potassium sodium 5'-(6-chloro-4-(2-(2-vinylsulfonylethoxy)ethylamino)-1,3,5-triazin-2-ylamino)-4'-hydroxy-2,3'-azodinaphthalene-1,2',5,7'-disulfonate | 402-110-8 | 110081-40-8 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 607-491-00-6 |
reaction mass of: diester of 4,4'-methylenebis[2-(2-hydroxy-5-methylbenzyl)-3,6-dimethylphenol] and 6-diazo-5,6-dihydro-5-oxonaphthalene-1-sulfonic acid (1:2); triester of 4,4'-methylenebis[2-(2-hydroxy-5-methylbenzyl)-3,6-dimethylphenol] and 6-diazo-5,6-dihydro-5-oxonaphthalene-1-sulfonic acid (1:3) |
427-140-9 | — | Carc. 2 | H351 |
GHS08 Wng |
H351 | |||
| 607-504-00-5 | diammonium 1-hydroxy-2-(4-(4-carboxyphenylazo)-2,5-dimethoxyphenylazo)-7-amino-3-naphthalenesulfonate | 422-670-7 | — |
Repr. 1A Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H361f H301 H373** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H361f H301 H373** H410 |
|||
| 607-509-00-2 | 2-phenoxyethyl 4-aminobenzoate | 430-880-5 | 88938-23-2 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 607-510-00-8 | (2S,5R)-6,6-dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide | 427-200-4 | 76646-91-8 |
Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 |
H302 H315 H318 H317 |
GHS05 GHS07 Dgr |
H302 H315 H318 H317 |
|||
| 607-511-00-3 |
reaction mass of: 4-[(3-decyloxypropyl)(3-isobutoxy-1-isobutoxycarbonyl-3-oxopropyl)amino]-4-oxobutyric acid; 4-[(3-isobutoxy-1-isobutoxycarbonyl-3-oxopropyl)(3-octyloxypropyl)amino]-4-oxobutyric acid |
423-750-4 | — |
Eye Irrit. 2 Aquatic Chronic 2 |
H319 H411 |
GHS07 GHS09 Wng |
H319 H411 |
|||
| 607-514-00-X | potassium N-(1-methoxy-1-oxobut-2-en-3-yl)valinate | 427-240-2 | 134841-35-3 | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 607-518-00-1 | 3-oxoandrost-4-ene-17-β-carboxylic acid | 414-990-0 | 302-97-6 |
Repr. 1A Aquatic Chronic 4 |
H361f H413 |
GHS08 Dgr |
H361f H413 |
|||
| 607-519-00-7 | poly-[((4-((4-ethyl-ethylene)amino)phenyl)-((4-(ethyl-(2-oxyethylene)amino)phenyl)methinyl)cyclohexa-2,5-dienylidene)-N-ethyl-N-(2-hydroxyethyl)ammonium acetate] | 427-280-0 | 176429-27-9 |
STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H335 H315 H318 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H335 H315 H318 H410 |
|||
| 607-520-00-2 |
reaction mass of: sodium 4,5-dihydro-2-[(propionato)(C6-18)alkyl]-3H-imidazolium-N-ethylphosphate; disodium 4,5-dihydro-2-[(dipropionato)(C6-18)alkyl]-3H-imidazolium-N-ethylphosphate |
427-740-0 | — |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|||
| 607-521-00-8 | tetraethyl N,N'-(methylenedicyclohexane-4,1-diyl)bis-dl-aspartate | 429-270-1 | 136210-30-5 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|||
| 607-522-00-3 | sodium salt of the polymer of: sodium 2-methyl-buta-1,3-diene-1-sulfonate with acrylic acid and 2-hydroxyethyl-2-methylacrylate | 429-720-7 | 184246-86-4 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 607-523-00-9 | reaction mass of mono to tetra(lithium and/or sodium)3-amino-10-[4-(4-amino-3-sulfonatoanilino)-6-[methyl-(2-sulfonatoethyl)amino]-1,3,5-triazin-2-ylamino]-6-13-dichlorobenzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate; mono to tetra(lithium and/or sodium)3-amino-10-[4,6-bis(4-amino-3-sulfonatoanilino)-1,3,5-triazin-2-ylamino]-6-13-dichlorobenzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate; mono to penta(lithium and/or sodium)10,10’-diamino-6,6',13,13’-tetrachloro-3,3'-[6-[methyl-(2-sulfonatoethyl)amino]-1,3,5-triazin-2,4-diyldiimino]bis[benzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate; mono to hepta(lithium and/or sodium)10-amino-6,6',13,13'-tetrachloro-10’[4-(4-amino-3-sulfonatoanilino)-[6-methyl-(2-sulfonatoethyl)amino]-1,3,5-triazin-2,4-diimino]bis[benzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate; mono to hepta(lithium and/or sodium)10,10'-diamino-6,6',3,3'[(2-sulfonato)-1,4-phenylenediiminobis[6-methyl-(2-sulfonatoethyl)amino]-1,3,5-triazin-2,4-diyldiimino]bis[benzo[1,2-B:4,5-B']di[1,4]benzoxazine-4,11-disulfonate | 430-200-7 | — |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|||
| 607-524-00-4 | tall oil 2-[(tetrahydro-2H-pyran-2-yl) thio]ethyl esters | 430-310-5 | — | Aquatic Chronic 4 | H413 | H413 | ||||
| 607-525-00-X | (Z)-2-methoxymino-2-[2-(tritylamino)thiazol-4-yl]acetic acid | 431-520-1 | 64485-90-1 |
Flam. Sol. 1**** Carc. 2 Aquatic Chronic 3 |
H228 H351 H412 |
GHS02 GHS08 Dgr |
H228 H351 H412 |
|||
| 607-528-00-6 | (S)-3-methyl-2-(2-oxotetrahydropyrimidine-1-yl)butyric acid | 430-900-2 | 192725-50-1 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-529-00-1 | benzyl cis-4-ammonium-4'-toluenesulfonato-1-cyclohexanecarboxylate | 426-070-6 | 67299-45-0 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 607-530-00-7 | reaction mass of isomers of: C7-9-alkyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate | 406-040-9 | 125643-61-0 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-531-00-2 | methyl 3-amino-4,6-dibromo-2-methyl-benzoate | 425-190-6 | 119916-05-1 |
STOT RE 2 * Aquatic Chronic 2 |
H373** H411 |
GHS08 GHS09 Wng |
H373** H411 |
|||
| 607-532-00-8 | (S)-1-[2-tert-butoxycarbonyl-3-(2-methoxyethoxy)propyl]-1-cyclopentanecarboxylic acid, cyclohexylamine salt | 425-510-4 | 167944-94-7 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 607-533-00-3 | pentasodium monohydrogen 6-chloro-3,10-bis[2-[4-chloro-6-(2,4-disulfophenylamino)-1,3,5-triazin-2-yl-amino]ethylamino]-13-ethylbenzo[5.6][1.4]oxazino[2,3-b]phenoxazine-4,11-disulfonate | 414-910-4 | — |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|||
| 607-534-00-9 | ethyl 2-(3-benzoylphenyl)propanoate | 414-920-9 | 60658-04-0 |
Acute Tox. 3 * STOT RE 1 Skin Sens. 1 Aquatic Chronic 2 |
H301 H372** H317 H411 |
GHS06 GHS08 GHS09 Dgr |
H301 H372** H317 H411 |
|||
| 607-535-00-4 | potassium 4-iodo-2-sulfonato-benzoic acid | 426-620-5 | — |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|||
| 607-536-00-X | (2,6-xylyloxy) acetic acid | 430-910-7 | 13335-71-2 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H302 H318 H412 |
GHS05 GHS07 Dgr |
H302 H318 H412 |
|||
| 607-537-00-5 | isopropylammonium 2-(3-benzoylphenyl)propionate | 417-970-1 | — |
Acute Tox. 3 * Acute Tox. 4 * STOT RE 1 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H312 H372** H318 H400 H410 |
GHS06 GHS05 GHS08 GHS09 Dgr |
H301 H312 H372** H318 H410 |
|||
| 607-539-00-6 | propyl((4-(5-oxo-3-propylisoxazolidin-4-ylidenmethin)phenyl)propoxycarbonylmethyleneamino)acetate | 431-000-2 | 198705-81-6 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-540-00-1 | 1-(mercaptomethyl)cyclopropylacetic acid | 420-240-3 | 162515-68-6 |
Skin Corr. 1B Acute Tox. 4 * Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H314 H312 H302 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H314 H312 H302 H317 H411 |
|||
| 607-541-00-7 | [(1-methyl-1,2-ethanediyl)bis[nitrilobis(methylene)]]tetrakis(phosphonic acid) | 421-940-1 | 28698-31-9 |
Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H400 H410 |
GHS05 GHS09 Dgr |
H318 H410 |
|||
| 607-542-00-2 | methyl 2-(4-butanesulfonamidophenoxy)tetradecanoate | 422-110-1 | — |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 607-543-00-8 | poly-[((4-((4-(ethyl-ethylene)amino)phenyl)-(4-(ethyl-(2-oxyethylene)amino)phenyl)methinyl)-3-methylcyclohexa-2,5-dienylidene)-N-ethyl-N-(2-hydroxyethyl)ammonium acetate] | 427-480-8 | 176429-22-4 |
STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H335 H315 H318 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H335 H315 H318 H410 |
|||
| 607-544-00-3 | ethyl 6,8-difluoro-1-(formylmethylamino)-1,4-dihydro-7-(4-methyl)piperazin-1-yl)-4-oxo-quinoline-3-carboxylate | 427-490-2 | 158585-86-5 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 607-545-00-9 | 1,2-dimethyl-3-(1-methylethenyl)cyclopentyl acetate | 424-070-0 | 94346-09-5 |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|||
| 607-546-00-4 |
reaction mass of: methyl {[5-acetylamino-4-(2-chloro-4-nitrophenylazo)phenyl]methoxycarbonylmethylamino}acetate; methyl {[5-acetylamino-4-(2-chloro-4-nitrophenylazo)phenyl]ethoxycarbonylmethylamino}acetate |
424-290-7 | 188070-47-5 | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 607-547-00-X | 18-methylnonadecyl 2,2 -dimethylpropanoate | 424-370-1 | 125496-22-2 |
Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic |
H315 H317 H413 |
GHS07 Wng |
H315 H317 H413 |
|||
| 607-548-00-5 | 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethanone methanesulfonate | 431-010-7 | 154486-26-7 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|||
| 607-549-00-0 | methyl (E)-2((3-(1,3-benzodioxol-5-yl)-2-methyl-1-propenyl)amino)benzoate | 424-430-7 | 125778-19-0 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 607-550-00-6 | 2-amino-4-bromo-5-chlorobenzoic acid | 424-700-4 | — |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H410 |
GHS05 Dgr |
H318 H410 |
|||
| 607-551-00-1 | tetrabutylammonium 2-amino-6-iodopurinate | 424-710-9 | 156126-48-6 |
Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H312 H302 H373** H315 H318 H317 H411 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H312 H302 H373** H315 H318 H317 H411 |
|||
| 607-552-00-7 | hexadecyl 3-amino-4-isopropoxybenzoate | 424-830-1 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-553-00-2 | 7-amino-4-hydroxy-2-naphthalenesulfonic acid, coupled with 5 (or 8) -amino-8 (or 5)-[[4-[[4-[[4-amino-6 (or 7)-sulfo-1-naphthyl]azo]phenyl]amino]-3-sulfophenyl]azo]-2-naphthalenesulfonic acid and 4-hydroxy-7-(phenylamino)-2-naphthalenesulfonic acid, sodium salt | 424-850-0 | — | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-554-00-8 | 2,4-diamino-5-[4-[(2-sulfoxyl ethyl)sulfonyl]phenylazo]benzenesulfonic acid | 424-870-1 | 27624-67-5 |
Expl. 1.1 Eye Dam. 1 Aquatic Chronic 3 |
H201 H318 H412 |
GHS01 GHS05 Dgr |
H201 H318 H412 |
|||
| 607-555-00-3 | 1,1,3,3-tetramethylbutylperoxypivalate | 424-980-8 | 22288-41-1 |
Flam. Liq. 2 Org. Perox. D Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H225 H242 H315 H317 H411 |
GHS02 GHS07 GHS09 Dgr |
H225 H242 H315 H317 H411 |
|||
| 607-556-00-9 | 2-acetoxymethylene-4-acetylphenylacetate | 425-160-2 | 24085-06-1 |
Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373** H318 H317 H400 H410 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H302 H373** H318 H317 H410 |
|||
| 607-557-00-4 | salt of: (1S-cis)-1-amino-2,3-dihydro-1H-inden-2-ol and [R-[R*R*]]-2,3-dihydroxybutanedioic acid | 425-210-3 | 169939-84-8 | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 607-558-00-X | 2S-isopropyl-5R-methyl-1R-cyclohexyl (2R,5S)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-[1,3]-oxathiolane-2-carboxylate | 425-250-1 | 147027-10-9 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 607-559-00-5 | coconut oil, reaction products with glycerol esters of 3,5-bis(1,1-dimethylethyl)-4-hydroxybenzenepropanoic acid | 425-400-6 | 179986-09-5 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-560-00-0 | (R,S)-2-butyloctanedioic acid | 431-210-4 | 50905-10-7 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-561-00-6 | sodium 4-hydroxy-3-(N'-(2-(2-hydroxyethylenesulfonyl)ethylene)ureido)-5-nitrobenzenesulfonate | 425-460-3 | — |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|||
| 607-562-00-1 |
reaction mass of: (2R,3R)-3-(2-ethoxyphenoxy)-2-hydroxy-3-phenylpropylammonium methanesulfonate; (2S,3S)-3-(2-ethoxyphenoxy)-2-hydroxy-3-phenylpropylammonium methanesulfonate |
425-530-3 | 98769-75-6 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|||
| 607-563-00-7 | 5,7-dichloro-4-hydroxyquinoline-3-carboxylic acid | 431-250-2 | 171850-30-9 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 607-564-00-2 | 1,6-hexanediammonium, sodium 5-sulfato-1,3-benzenedicarboxylate | 425-730-0 | 51178-75-7 | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 607-565-00-8 | 3-ethyl 5-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate | 425-820-1 | 88150-42-9 |
Acute Tox. 3 * STOT RE 2 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H373** H318 H400 H410 |
GHS06 GHS05 GHS08 GHS09 Dgr |
H301 H373** H318 H410 |
|||
| 607-566-00-3 |
reaction mass of: dodecylphenyl dodecylhydroxybenzenecarboxylate; bis(dodecylphenyl)dodecyl hydroxybenzenedicarboxylate |
426-140-6 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-567-00-9 | potassium 3-iodo-6-methylbenzenesulfonate | 426-300-5 | — | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-568-00-4 | potassium 2-chloro-3-(benzyloxy)propionate | 426-350-8 | 138666-92-9 |
Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 |
H302 H373** H318 H317 |
GHS05 GHS08 GHS07 Dgr |
H302 H373** H318 H317 |
|||
| 607-569-00-X |
reaction mass of: sodium 2-amino-4-(2,6-difluoropyrimidin-4-ylamino)benzenesulfonate; sodium 2-amino-4-(4,6-difluoropyrimidin-4-ylamino)benzenesulfonate |
426-470-0 | — | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 607-570-00-5 | sodium (6R-trans)-7-amino-8-oxo-3-[[[1-(sulfomethyl)-1H-tetrazol-5-yl]thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate monohydrate | 426-520-1 | 71420-85-4 | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 607-571-00-0 | 2-cyclopentene-1-acetic acid, 3-hydroxy-2-pentyl-, methyl ester acetate | 431-400-7 | 57374-49-9 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|||
| 607-572-00-6 | diethyl thiophosphoryl (Z)-(2-aminothiazol-4-yl)methoxyimino acetate | 426-790-0 | 162208-27-7 |
Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H373** H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H312 H302 H373** H317 H410 |
|||
| 607-573-00-1 |
reaction mass of: disodium 7-(2,4-difluoropyrimidin-6-ylamino)-4-hydroxy-3-(4-methoxy-2-sulfonatophenylazo)naphthalene-2-sulfonate; disodium 7-(4,6-difluoropyrimidin-2-ylamino)-4-hydroxy-3-(4-methoxy-2-sulfonatophenylazo)naphthalene-2-sulfonate |
426-840-1 | — | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-574-00-7 | [1R-(1-α,2β,5α)]-mono[5-methyl-2-(1-methylethyl)cyclohexyl]butanedioate | 426-890-4 | 77341-67-4 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-575-00-2 | 4-(5-(5-[1-(4-carboxyphenyl)hexahydro-2,4,6-trioxopyrimidin-5-ylidene]penta-1,3-dienyl)-1,2,3,4-tetrahydro-6-hydroxy-2,4-dioxopyrimidin-1-yl)benzoic acid-triethylamine salt | 426-900-7 | — |
STOT SE 3 Aquatic Chronic 3 |
H335 H412 |
GHS07 Wng |
H335 H412 |
|||
| 607-576-00-8 | branched, octyl 3-[3,5-di(tert-butyl)-4-hydroxyphenyl]propanoate | 427-030-0 | — |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 607-577-00-3 | (2R*,3S*)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol (1R)-10-camphorsulfonate | 427-100-0 | — |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H302 H318 H317 H412 |
GHS05 GHS07 Dgr |
H302 H318 H317 H412 |
|||
| 607-578-00-9 | ethyl 4-((4-diethylamino-2-methylphenyl)imino)-4,5-dihydro-1-isopropyl-5-oxo-1H-pyrazole-3-carboxylate | 427-110-5 | — |
Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 4 |
H302 H373** H413 |
GHS08 GHS07 Wng |
H302 H373** H413 |
|||
| 607-579-00-4 | diethyl[(p-ethoxyanilino)methylene]malonate | 431-430-0 | 103976-28-9 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|||
| 607-580-00-X | ethyl 7-chloro-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate | 422-360-1 | 100491-29-0 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|||
| 607-581-00-5 | ethyl 2-ethoxy-4-carboxymethylbenzoate | 427-630-2 | 99469-99-5 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-582-00-0 |
reaction mass of: tetrasodium 7-(4-(4-fluoro-6-(4-(2-sulfonatoethylsulfonyl)phenylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalene-1,3,6-trisulfonate; tetrasodium 7-(4-(4-hydroxy-6-(4-(2-sulfonatoethylsulfonyl)phenylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalene-1,3,6-trisulfonate |
427-650-1 | — | Aquatic Chronic 3 | H412 | — | H412 | |||
| 607-583-00-6 | 4-amino-3-[[4-[[2-(sulfooxy)ethyl]sulfonyl]phenyl]azo]-1-naphthalene sulfonic acid | 427-680-5 | 188907-52-0 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|||
| 607-584-00-1 | trisodium 3-[2-acetylamino-4-[4-chloro-6-[4-(2-sulfonatoxyethylsulfonyl)phenylamino]-1,3,5-triazine-2-ylamino]phenylazo]naphthalene-1,5-disulfonate | 427-710-7 | 215612-56-9 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|||
| 607-585-00-7 | strontium 2-[(2-hydroxy-6-sulfonato-1-naphthyl)azo]naphthalene-1-sulfonate | 427-930-3 | — | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 607-586-00-2 | dodecyl 3-amino-4-chlorobenzoate | 428-020-9 | 6195-20-6 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 607-587-00-8 | ethyl cis-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine-1-carboxylate | 428-030-3 | 67914-69-6 |
Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373** H400 H410 |
GHS08 GHS07 GHS09 Wng |
H302 H373** H410 |
|||
| 607-588-00-3 |
reaction mass of: 2-ethylhexyl 2,3,4,5-tetrabromobenzoate; bis(2-ethylhexyl) 3,4,5,6-tetrabromophthalate |
428-050-2 | — |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|||
| 607-589-00-9 | tetrakis(1,2,2,6,6-pentamethyl-4-piperidyl)-1,2,3,4-butanetetracarboxylate | 428-070-1 | 91788-83-9 |
STOT RE 1 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H372** H302 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H372** H302 H410 |
|||
| 607-590-00-4 | hexadecyl 3-[2-(5,5-dimethyl-2,4-dioxo-1,3-oxazolidin-3-yl)-4,4-dimethyl-3-oxovaleramido]-4-isopropoxybenzoate | 428-140-1 | 210706-50-6 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-591-00-X |
reaction mass of: trisodium 5-(4-fluoro-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxy-3-(4-(2-sulfooxyethanesulfonyl)phenylazo)naphthalene-2,7-disulfonate; disodium 3-(4-ethenesulfonylphenylazo)-5-(4-fluoro-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxynaphthalene-2,7-disulfonate |
428-400-4 | — | Eye Dam. | H318 |
GHS05 Dgr |
H318 | |||
| 607-592-00-5 | di(C9-11-alkyl) cyclohexane-1,4-dicarboxylate | 428-870-0 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-593-00-0 | 4-(2-methylacryloyloxy)phenyl 4-allyloxybenzoate | 429-000-2 | 159235-16-2 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|||
| 607-594-00-6 | ethyl (1S,5R,6S)-5-(1-ethylpropoxy)-7-oxabicyclo[4.1.0]hept-3-ene-3-carboxylate | 429-020-1 | 204254-96-6 |
STOT RE 2 * Skin Sens. 1 |
H373** H317 |
GHS08 GHS07 Wng |
H373** H317 |
|||
| 607-595-00-1 | N-amidino-N-methylglycine-2-oxopropionate | 429-120-5 | 208535-04-0 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-596-00-7 | ethyl 2-(4-phenoxyphenyl)lactate | 429-220-9 | 132584-17-9 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|||
| 607-597-00-2 | tetrasodium 4,4'-bis{4-[4-(2-hydroxyethylamino)-6-(4-sulfonatoanilino)-1,3,5-triazin-2-ylamino]phenylazo}stilbene-2,2'-disulfonate | 429-230-3 | — | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-598-00-8 | trisodium 3-amino-4-[4-[4-(2-(2-ethenylsulfonylethoxy)ethylamino)-6-fluoro-1,3,5-triazine-2-ylamino]-2-sulfophenylazo]-5-hydroxynaphthalene-2,7-disulfonate | 429-240-8 | 212652-59-0 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-599-00-3 | 1,1-dimethylpropyl 3,5,5-trimethylperoxyhexanoate | 431-610-9 | 68860-54-8 |
Org. Perox. D Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H242 H317 H400 H410 |
GHS02 GHS07 GHS09 Dgr |
H242 H317 H410 |
|||
| 607-600-00-7 | (1S,1'R)-[1-(3',3'-dimethyl-1'-cyclohexyl)ethoxycarbonyl]methyl propanoate | 431-700-8 | — | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 607-601-00-2 | 1,4-dihydroxy-2,2,6,6-tetramethyl piperidinium-2-hydroxy-1,2,3-propanetricarboxylate | 429-370-5 | 220410-74-2 | Acute Tox. 4 * | H302 |
GHS07 Wng |
H302 | |||
| 607-602-00-8 | ethyl (3-cyanomethyl-3,4-dihydro-4-oxophthalazin-1-yl)acetate | 429-680-0 | 122665-86-5 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|||
| 607-603-00-3 | lithium sodium 4,4',4''-(nitrilotris(ethane-2,1-diylimino(6-chloro-1,3,5-triazine-4,2-diyl)imino))tris(5-hydroxy-6-(1-sulfonaphthalene-2-ylazo)-2,7-naphthalene)disulfonate | 429-730-1 | 193562-37-7 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|||
| 607-604-00-9 | guanidinium benzoate | 429-820-0 | 26739-54-8 | Acute Tox. 4 * | H302 |
GHS07 Wng |
H302 | |||
| 607-605-00-4 | methyl 4-iodo-2-(3-(4-methoxy-6-methyl-1,3,5-triazine-2-yl)ureidosulfonyl)benzoate | 429-890-2 | 144550-06-1 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 607-606-00-X | (Z)-2-(2-t-butoxycarbonylamino-4-thiazolyl)pent-2-enoic acid | 430-100-3 | 86978-24-7 | Acute Tox. 4 * | H302 |
GHS07 Wng |
H302 | |||
| 607-607-00-5 |
reaction mass of: calcium bis(C10-14 branched alkyl salicylate); calcium bis(C18-30-alkyl salicylate); calcium C10-14 branched alkylsalicylato-C18-30-alkyl salicylate; calcium bis (C10-14 branched alkyl phenolate); calcium bis (C18-30-alkyl phenolate); calcium C10-14 branched alkylphenolato-C18-30-alkyl phenolate; C10-14 branched alkyl phenol; C18-30-alkyl phenol |
430-180-1 | — |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|||
| 607-608-00-0 | pentapotassium 2-(4-{5-[1-(2,5-disulfophenyl)-4,5-dihydro-3-methylcarbamoyl-5-oxopyrazol-4-ylidene]-3-(2-pyrrolidinone-1-yl)-1,3-pentadienyl}-3-methylcarbamoyl-5-oxopyrazol-1-yl)benzene-1,4-disulfonate | 430-210-1 | — |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 607-609-00-6 | ethyl (3R)-4-cyano-3-hydroxybutanoate | 430-220-6 | 141942-85-0 | Eye Irrit. 2 | H319 |
GHS07 Wng |
H319 | |||
| 607-610-00-1 | trisodium 4-hydroxy-6-(sulfonatomethylamino)-5-(2-(2-sulfatoethylsulfonyl)phenylazo)naphthalene-2-sulfonate | 430-280-3 | — | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 607-611-00-7 | methyl 3-amino-2,2,3-trimethylbutyrate | 431-720-7 | 90886-53-6 |
Skin Corr. 1B Acute Tox. 4 * Aquatic Chronic 3 |
H314 H302 H412 |
GHS05 GHS07 Dgr |
H314 H302 H412 |
|||
| 607-612-00-2 |
reaction mass of: 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-1-octanesulfonic acid; ammonium 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluoro-1-octanesulfonate |
432-190-1 | 182176-52-9 |
Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 |
H302 H373** H318 |
GHS05 GHS08 GHS07 Dgr |
H302 H373** H318 |
|||
| 607-613-00-8 |
reaction mass of: succinic acid; monopersuccinic acid; dipersuccinic acid; monomethyl ester of succinic acid; monomethyl ester of persuccinic acid; dimethyl succinate; glutaric acid; monoperglutaric acid; diperglutaric acid; monomethyl ester of glutaric acid; monomethyl ester of perglutaric acid; dimethyl glutarate; adipic acid; monoperadipic acid; diperadipic acid; monomethyl ester of adipic acid; monomethyl ester of peradipic acid; dimethyl adipate; hydrogen peroxide; methanol; water |
432-790-1 | — |
Muta. 2 Skin Corr. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * |
H341 H314 H332 H312 H302 |
GHS05 GHS08 GHS07 Dgr |
H341 H314 H332 H312 H302 |
|||
| 607-614-00-3 | 2-(10-oxo-10H-9-oxa-10-phosphaphenanthren-10-ylmethyl)succinic acid | 426-480-5 | 63562-33-4 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|||
| 607-615-00-9 | reaction product of thioglycerol and mercaptoacetic acid consisting mainly of 3-mercapto-1,2-bismercaptoacetoxypropane and oligomers of this substance | 431-120-5 | — |
Acute Tox. 3 * Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 |
H331 H302 H319 H317 |
GHS06 Dgr |
H331 H302 H319 H317 |
|||
| 607-616-00-4 | 2,4-dichloro-5-fluorobenzoylchloride | 428-390-1 | 86393-34-2 |
STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H335 H315 H318 H317 H412 |
GHS05 GHS07 Dgr |
H335 H315 H318 H317 H412 |
|||
| 607-617-00-X | bis(2-ethylhexyl)-4,5-epoxycyclohexane-1,2-dicarboxylate | 430-700-5 | 10138-36-0 | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 607-618-00-5 |
menadione sodium bisulfite; 2-naphthalenesulfonic acid, 1,2,3,4-tetrahydro-2-methyl-1,4-dioxo-, sodium salt |
204-987-0 | 130-37-0 |
Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H315 H400 H410 |
GHS07 GHS09 Wng |
H319 H315 H410 |
|||
| 607-619-00-0 |
menadione nicotinamide bisulfite; 1,2,3,4-tetrahydro-2-methyl-1,4-dioxonaphthalene-2-sulfonic acid, compound with nicotin-3-amide (1:1) |
277-543-7 | 73581-79-0 |
Eye Irrit. 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H319 H315 H400 H410 |
GHS07 GHS09 Wng |
H319 H315 H410 |
|||
| 607-620-00-6 | trisodium nitrilotriacetate | 225-768-6 | 5064-31-3 |
Carc. 2 Acute Tox. 4 * Eye Irrit. 2 |
H351 H302 H319 |
GHS08 GHS07 Wng |
H351 H302 H319 |
Carc. 2; H351: C ≥ 5 % | ||
| 607-621-00-1 |
milbemectin (ISO); [reaction mass of milbemycin A3 (CAS No 51596-10-2) and milbemycin A4 (CAS No 51596-11-3) (30:70)] |
— | — |
Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H332 H302 H400 H410 |
GHS07 GHS09 Wng |
H332 H302 H410 |
M=100 | ||
| 607-622-00-7 | 2-ethylhexyl-2-ethylhexanoate | 231-057-1 | 7425-14-1 | Repr. 2 | H361d*** |
GHS08 Wng |
H361d*** | |||
| 607-623-00-2 | diisobutyl phthalate | 201-553-2 | 84-69-5 | Repr. 1B | H360Df |
GHS08 Dgr |
H360Df |
Repr. 1B; H360Df: C ≥ 25 % Repr. 2; H361f: 5 % ≤ C < 25 % |
||
| 607-624-00-8 |
perfluorooctane sulfonic acid; heptadecafluorooctane-1-sulfonic acid; [1] potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate; [2] diethanolamine perfluorooctane sulfonate; [3] ammonium perfluorooctane sulfonate; ammonium heptadecafluorooctanesulfonate; [4] lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate [5] |
217-179-8 [1] 220-527-1 [2] 274-460-8 [3] 249-415-0 [4] 249-644-6 [5] |
1763-23-1 [1] 2795-39-3 [2] 70225-14-8 [3] 29081-56-9 [4] 29457-72-5 [5] |
Carc. 2 Repr. 1B STOT RE 1 Acute Tox. 4 * Acute Tox. 4 * Lact. Aquatic Chronic 2 |
H351 H360D*** H372** H332 H302 H362 H411 |
GHS08 GHS07 GHS09 Dgr |
H351 H360D*** H372** H332 H302 H362 H411 |
|||
| 607-625-00-3 | clodinafop-propargyl (ISO) | — | 105512-06-9 |
Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373** H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H302 H373** H317 H410 |
Skin Sens. 1; H317: C ≥ 0,001 % M=1 |
||
| 607-626-00-9 | ethyl 1-(2,4-dichlorophenyl)-5-(trichloromethyl)-1H-1,2,4-triazole-3-carboxylate | 401-290-5 | 103112-35-2 |
Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H350 H400 H410 |
GHS08 GHS09 Dgr |
H350 H410 |
|||
| 607-627-00-4 | [(4S,5S)-4-benzyl-2-oxo-5-oxazolidinyl]methyl 4-nitrobenzenesulfonate | 416-360-0 | 162221-28-5 | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 607-628-00-X | 4-oxo-4-(p-tolyl)butyric acid adduct with 4-ethylmorpholine | 419-240-6 | 171054-89-0 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-629-00-5 | [[2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphinyl] acetic acid | 419-270-1 | 123599-82-6 | Eye Irrit. 2 | H319 |
GHS07 Wng |
H319 | |||
| 607-630-00-0 | acrylic acid, 3-(trimethoxysilyl)propyl ester | 419-560-6 | 4369-14-6 |
Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 3 |
H332 H314 H317 H412 |
GHS05 GHS07 Dgr |
H332 H314 H317 H412 |
|||
| 607-631-00-6 |
reaction mass of: 2-(2-((oxo(phenyl)acetyl)oxy)ethoxy)ethyl oxo(phenyl)acetate; (2-(2-hydroxyethoxy)ethyl) oxo(phenyl)acetate |
442-300-8 | — | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 607-632-00-1 | N-[3-(2,4-di-(1,1-dimethyl-propyl)phenoxy)-propyl]-1-hydroxy-5-(2-methylpropyl-oxycarbonylamino)-naphthamide | 420-210-1 | 111244-14-5 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-633-00-7 | trisodium 5-{[4-chloro-6-(1-naphthylamino)-1,3,5-triazin-2-yl]amino}-4-hydroxy-3-[(E)-(4-methoxy-2-sulfonatophenyl)diazenyl]-2,7-naphthalenedisulfonate | 440-480-2 | 341026-59-3 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|||
| 607-634-00-2 |
(S)-(–)-2-acetoxypropionylchloride; (1S)-2-chloro-1-methyl-2-oxoethyl acetate |
420-610-4 | 36394-75-9 |
Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 |
H302 H314 H317 |
GHS05 GHS07 Dgr |
H302 H314 H317 |
|||
| 607-635-00-8 | trisodium N-(3-propionato)-l-aspartate | 422-090-4 | 172737-80-3 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-636-00-3 | 1-bromo-2-methylpropyl propionate | 422-900-6 | 158894-67-8 |
Flam. Liq. 3 Carc. 2 Skin Corr. 1B Skin Sens. 1 |
H226 H351 H314 H317 |
GHS02 GHS05 GHS08 GHS07 Dgr |
H226 H351 H314 H317 |
|||
| 607-637-00-9 | disodium 8-amino-5-{4-[2-(sulfonatoethoxy)sulfonyl]phenylazo}naphthalene-2-sulfonate | 423-730-5 | 250688-43-8 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-638-00-4 | 2-hydroxybenzoic acid 2-butyloctyl ester | 431-090-3 | 190085-41-7 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-639-00-X | 2-(2-oxo-5-(1,1,3,3-tetramethylbutyl)-2,3-dihydro-1-benzofuran-3-yl)-4-(1,1,3,3-tetramethylbutyl)phenyl acetate | 431-770-1 | 216698-07-6 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-641-00-0 |
2-(formylamino)-3-thiophenecarboxylic acid; 2-formamido-3-thiophenecarboxylic acid |
431-930-9 | 43028-69-9 |
Acute Tox. 4 * Skin Sens. 1 |
H302 H317 |
GHS07 Wng |
H302 H317 |
|||
| 607-642-00-6 | 3,6,9-trithiaundecamethylene-1,11-dimethacrylate | 432-210-7 | 141631-22-3 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 607-643-00-1 | dimethyl (2S)-2-hydroxysuccinate | 432-310-0 | 617-55-0 |
Flam. Liq. 3 Eye Dam. 1 Skin Sens. 1 |
H226 H318 H317 |
GHS02 GHS05 GHS07 Dgr |
H226 H318 H317 |
|||
| 607-644-00-7 | methyl 2,2-dimethyl-6-methylenecyclohexanecarboxylate | 432-350-9 | 81752-87-6 | Skin Irrit. 2 | H315 |
GHS07 Wng |
H315 | |||
| 607-645-00-2 | tetrasodium 2-(4-fluoro-6-(methyl-(2-(sulfatoethylsulfonyl)ethyl)amino)-1,3,5-triazin-2-ylamino)-5-hydroxy-6-(4-methyl-2-sulfonatophenylazo)naphthalene-1,7-disulfonate | 432-550-6 | 243858-01-7 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-646-00-8 |
d-erythro-hexanoic acid 2,4-dideoxy-3,5-O-(1-methylethylidene)-1,1-dimethylethylester; tert-butyl 2-[(4R,6S)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetate |
432-960-5 | 124655-09-0 | Acute Tox. 4 * | H302 |
GHS07 Wng |
H302 | |||
| 607-647-00-3 | 5-acetoxy-2-(R,S)butyryloxymethyl-1,3-oxathiolane | 433-530-1 | 143446-73-5 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 |
H302 H317 H400 |
GHS07 GHS09 Wng |
H302 H317 H400 |
|||
| 607-649-00-4 | [3-(chlorocarbonyl)-2-methylphenyl]acetate | 433-690-0 | 167678-46-8 |
Skin Corr. 1A Skin Sens. 1 |
H314 H317 |
GHS05 GHS07 Dgr |
H314 H317 |
|||
| 607-650-00-X | 2-methyl-1,5-pentanediamine-1,3-benzenedicarboxylate | 433-910-5 | 145153-52-2 | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 607-651-00-5 | sodium 2-(nonanoyloxy)benzenesulfonate | 434-360-9 | 91125-43-8 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|||
| 607-652-00-0 | ethyl N2-dodecanoyl-l-argininate hydrochloride | 434-630-6 | 60372-77-2 |
Eye Dam. 1 Aquatic Acute 1 |
H318 H400 |
GHS05 GHS09 Dgr |
H318 H400 |
|||
| 607-653-00-6 | tetrakis(bis(2-hydroxyethyl)methylammonium) 3-(4-(7-acetylamino-1-hydroxy-3-sulfonatonaphthalen-2-ylazo)-5-methoxy-2-sulfonatophenylazo)-7-(4-amino-3-sulfonatophenylamino)-4-hydroxynaphthalene-2-sulfonate | 434-840-8 | 225786-91-4 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 607-654-00-1 | (S)-3-hydroxy-γ-butyrolactone | 434-990-4 | 7331-52-4 | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 607-655-00-7 | ethyl 6,8-dichlorooctanoate | 435-080-1 | 1070-64-0 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|||
| 607-656-00-2 | sodium salt of 4-amino-3,6-bis[[5-[[4-chloro-6-[(2-methyl-4-sulfophenyl)amino]-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]azo]-5-hydroxy-2,7-naphthalenedisulfonic acid | 435-350-7 | 141250-43-3 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|||
| 607-657-00-8 | pentasodium 7-(4-(4-(3-(2-sulfatoethanesulfonyl)phenylamino)-6-(4-(2-sulfatoethanesulfonyl)phenylamino)-1,3,5-triazin-2-ylamino)-2-ureidophenylazo)naphthalene-1,3,6-trisulfonate | 436-920-8 | 172399-10-9 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-658-00-3 | 3,10-diamino-6,13-dichloro-2-((6-(((4-(1,1-dimethylethyl)phenyl)sulfonyl)amino)-2-naphthalenyl)sulfonyl)-4,11-triphenodioxazinedisulfonic acid, lithium potassium sodium salt | 440-770-9 | 371921-63-0 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|||
| 607-659-00-9 | pentasodium N-[5-[[4-[[3-[(aminocarbonyl)amino]-4-[(3,6,8-trisulfonatonaphthalen-2-yl)azo]phenyl]amino]-6-chloro-1,3,5-triazin-2-yl]amino]-2-sulfonato-4-[[4-[[-2-(oxysulfonato)ethyl] sulfonyl]phenyl]azo]phenyl]-3-aminopropanoic acid | 442-030-0 | 321912-47-4 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-660-00-4 | 2-{4-[4-[4-fluoro-6-(2-(2-vinylsulfonylethoxy)ethylamino)-1,3,5-triazin-2-ylamino]phenylazo]phenylazo}naphthalene-4,6,8-trisulfonate, trisodium salt | 442-230-8 | 321679-52-1 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 607-661-00-X | 1,1-dimethylethyl 4'-(bromomethyl)biphenyl-2-carboxylate | 442-850-9 | 114772-40-6 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 607-662-00-5 | methyl 2-(acetylamino)-3-chloropropionate | 442-860-3 | 87333-22-0 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|||
| 607-663-00-0 | bis(2-ethylhexyl) naphthalene-2,6-dicarboxylate | 442-980-6 | 127474-91-3 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-664-00-6 | methyl 2-chlorosulfonyl-4-(methanesulfonylaminomethyl) benzoate | 443-120-2 | 393509-79-0 |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|||
| 607-665-00-1 | trans-methyl-2-ethyl-but-2-enoate | 443-150-6 | 101226-85-1 | Flam. Liq. 3 | H226 |
GHS02 Wng |
H226 | |||
| 607-666-00-7 | (2S)-5-(benzyloxy)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-5-oxopentanoic acid | 443-560-5 | 88784-33-2 | Eye Irrit. 2 | H319 |
GHS07 Wng |
H319 | |||
| 607-667-00-2 | chloro-1-ethylcyclohexyl carbonate | 444-950-8 | 99464-83-2 |
Muta. 2 Skin Sens. 1 |
H341 H317 |
GHS08 GHS07 Wng |
H341 H317 |
|||
| 607-668-00-8 | trans-2-isopropyl-5-carboxy-1,3-dioxane | 445-770-2 | 42031-28-7 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|||
| 607-669-00-3 | methyl (9-acetoxy-3,8,10-triethyl-7,8,10-trimethyl-1,5-dioxa-9-aza-spiro[5.5]undec-3-yl)octadecanoate | 445-990-9 | 376588-17-9 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 607-670-00-9 |
dibutyl-3-(4-(5-ammonio-2-butyl)benzofuran-3-yl)carbonyl)phenoxy)propyl ammonium oxalate; (5-amino-2-butylbenzofuran-3-yl) [4-(3-dibutylaminopropoxy)phenyl]methanone, dioxalate |
448-700-9 | 500791-70-8 |
STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H373** H318 H317 H400 H410 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H373** H318 H317 H410 |
M=10 | ||
| 607-671-00-4 | diethyl 1,4-cyclohexanedicarboxylate | 417-310-0 | 72903-27-6 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 607-672-00-X |
reaction mass of: 2-hydroxy-3-(methacryloyloxy)propyl (2-benzoyl)benzoate; 1-hydroxymethyl-2-(methacryloyloxy)ethyl (2-benzoyl)benzoate; x-hydroxy-y-(methacryloyloxy)propyl(or -ethyl) (2-benzoyl)benzoate |
419-000-0 | — |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|||
| 607-673-00-5 | 1-ethyl-5,6,7,8-tetrahydroquinolinium tosylate | 419-570-0 | — |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|||
| 607-675-00-6 |
reaction mass of: cis-9-octadecenedioic acid; cis-9-cis-12-octadecadienedioic acid; hexadecanedioic acid; octadecanedioic acid |
422-260-8 | — |
Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H400 H410 |
GHS05 GHS09 Dgr |
H318 H410 |
|||
| 607-676-00-1 |
reaction mass of: 2-methylnonanedioic acid; 2,4-dimethyl-4-methoxycarbonylundecanedioic acid; 2,4,6-trimethyl-4,6-dimethoxycarbonyltridecanedioic acid; 8,9-dimethyl-8,9-dimethoxycarbonylhexadecanedioic acid |
423-670-1 | — |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|||
| 607-677-00-7 | 2,5-dioxopyrrolidin-1-yl N-{[methyl[[2-(1-methylethyl)-4-thiazolyl]methyl]amino]carbonyl}-l-valinate | 424-660-8 | — |
STOT RE 2 * Eye Dam. 1 Skin Sens. 1 |
H373** H318 H317 |
GHS05 GHS08 GHS07 Dgr |
H373** H318 H317 |
|||
| 607-678-00-2 |
reaction mass of: ethyl (2R,3R)-3-isopropylbicyclo[2.2.1]hept-5-ene-2-carboxylate; ethyl (2S,3S)-3-isopropylbicyclo[2.2.1]hept-5-ene-2-carboxylate |
427-090-8 | — |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|||
| 607-679-00-8 |
reaction mass of: 3-{5-[3-(4-{1,6-dihydro-2-hydroxy-4-methyl-1-[3-(methylammonio)propyl]-6-oxo-3-pyridylazo}benzamido)phenylazo]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl}propyl(methyl)ammonium di(acetate); 3-{5-[4-(3-{1,6-dihydro-2-hydroxy-4-methyl-1-[3-(methylammonio)propyl]-6-oxo-3-pyridylazo}benzamido]phenylazo]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl}propyl(dimethyl)ammonium di(acetate); 3-{5-[3-(4-{1-[3-(dimethylammonio)propyl]-1,6-dihydro-2-hydroxy-4-methyl-6-oxo-3-pyridylazo}benzamido)phenylazo]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl}propyl(dimethyl)ammonium di(acetate) |
431-440-5 | — |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|||
| 607-680-00-3 | tert-butyl(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4S,6S)-2,2-dimethyl[1,3]dioxan-4-yl)acetate | 432-810-9 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-681-00-9 |
reaction mass of: 9-nonyl-10-octyl-19-carbonyloxyhexadecylnonadecanoic acid; 9-nonyl-10-octyl-19-carbonyloxyoctadecylnonadecanoic acid; dihexadecyl 9-nonyl-10-octylnonadecandioate; 1-octadecyl,19-hexadecyl 9-nonyl-10-octylnonadecandioate; dioctadecyl 9-nonyl-10-octylnonadecandioate |
432-910-2 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-682-00-4 | complex reaction mass of Chinese gum rosin post reacted with acrylic acid | 434-230-1 | 144413-22-9 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-683-00-X |
reaction mass of: methyl 3-((1E)-2-methylprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate; methyl 3-((1Z)-2-methylprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate (20:80) |
435-450-0 | — |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|||
| 607-684-00-5 | alkenes, C12-14, hydroformylation products, distn. residues, C-(hydrogen sulfobutanedioates), disodium salts | 435-660-2 | 243662-67-1 |
Skin Irrit. 2 Skin Sens. 1 |
H315 H317 |
GHS07 Wng |
H315 H317 |
|||
| 607-685-00-0 | ammonium 2-cocoyloxyethanesulfonate | 441-050-7 | — |
Skin Irrit. 2 Eye Dam. 1 |
H315 H318 |
GHS05 Dgr |
H315 H318 |
|||
| 607-686-00-6 | 6,6'-bis(diazo-5,5',6,6'-tetrahydro-5,5'-dioxo)[methylene-bis(5-(6-diazo-5,6-dihydro-5-oxo-1-naphthylsulphonyloxy)-6-methyl-2-phenylene]di(naphthalene-1-sulfonate) | 441-550-5 | — |
Self-react. C **** Carc. 2 |
H242 H351 |
GHS02 GHS08 Dgr |
H242 H351 |
|||
| 607-687-00-1 |
reaction mass of: 2-{3,6-bis-[(2-ethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (2-10 %); 2-{3,6-bis-[(2,3-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (2-10 %); 2-{3,6-bis-[(2,4-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (2-10 %); 2-{3,6-bis-[(2,5-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (2-10 %); 2-{3-[(2,3-dimethylphenyl)-methylamino]-6-[(2-ethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (7-20 %); 2-{3-[(2,4-dimethylphenyl)-methylamino]-6-[(2-ethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (7-20 %); 2-{3-[(2,5-dimethylphenyl)-methylamino]-6-[(2-ethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (7-20 %); 2-{3-[(2,3-dimethylphenyl)-methylamino]-6-[(2,4-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (7-20 %); 2-{3-[(2,3-dimethylphenyl)-methylamino]-6-[(2,5-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (7-20 %); 2-{3-[(2,4-dimethylphenyl)-methylamino]-6-[(2,5-dimethylphenyl)-methylamino]-xanthylium-9-yl}-benzenesulfonate (7-20 %) |
442-800-6 | — |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|||
| 607-688-00-7 | (R)-1-cyclohexa-1,4-dienyl-1-methoxycarbonyl-methylammoniumchloride | 444-320-2 | — | Acute Tox. 4 * | H302 |
GHS07 Wng |
H302 | |||
| 607-689-00-2 |
reaction mass of: methyl 1,4-dimethylcyclohexanecarboxylate ( „para-isomer” including cis- and trans- isomers); methyl 1,3-dimethylcyclohexanecarboxylate ( „meta-isomer” including cis- and trans-isomers) |
444-920-4 | — | Aquatic Chronic 3 | H412 | — | H412 | |||
| 607-690-00-8 | dimethyl[2S,2S']-6,6,6'6'-tetramethoxy-2,2'-[N,N'-bis(trifluoracetyl)-S,S'-bi(L-homocysteinyl) diimino]dihexanoate | 432-860-1 | 255387-46-3 | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 607-691-00-3 | magnesium salts, fatty acids, C16-18 and C18 unsaturated, branched and linear | 448-690-6 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-692-00-9 | zinc salts, fatty acids, C16-18 and C18 unsaturated, branched and linear | 446-470-4 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-693-00-4 | hexyl 2-(1-(diethylaminohydroxyphenyl)methanoyl)benzoate | 443-860-6 | 302776-68-7 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 607-694-00-X | ethyl 5,5-diphenyl-2-isoxazoline-3-carboxylate | 443-870-0 | 163520-33-0 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|||
| 608-020-00-7 | diphenoxymethylenecyanamide | 427-300-8 | 79463-77-7 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|||
| 608-032-00-2 |
acetamiprid (ISO); (E)-N1-[(6-chloro-3-pyridyl)methyl]-N2-cyano-N1-methylacetamidine |
— | 135410-20-7 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|||
| 608-042-00-7 | (S)-2,2-diphenyl-2-(3-pyrrolidinyl)acetonitrile hydrobromide | 421-810-4 | 194602-27-2 |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H302 H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H317 H411 |
|||
| 608-044-00-8 | 2-cyclohexylidene-2-phenylacetonitrile | 423-740-1 | 10461-98-0 |
Acute Tox. 4 * Aquatic Chronic 2 |
H302 H411 |
GHS07 GHS09 Wng |
H302 H411 |
|||
| 608-046-00-9 | 5-(4-chloro-2-nitro-phenylazo)-1,2-dihydro-6-hydroxy-1,4-dimethyl-2-oxo-pyridine-3-carbonitrile | 425-310-7 | 77889-90-8 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 608-047-00-4 | 2-piperidin-1-yl-benzonitrile | 427-330-1 | 72752-52-4 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 608-048-00-X | 1-(3-cyclopentyloxy-4-methoxyphenyl)-4-oxo-cyclohexanecarbonitrile | 427-450-4 | 152630-47-2 |
Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H373** H317 H411 |
GHS08 GHS07 GHS09 Wng |
H302 H373** H317 H411 |
|||
| 608-049-00-5 | 2-(4-(4-(butyl-(1-methylhexyl)amino)phenyl)-3-cyano-5-oxo-1,5-dihydropyrrol-2-ylidene)propandinitrile | 429-180-2 | 157362-53-3 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|||
| 608-050-00-0 |
reaction mass of: 5-(2-cyano-4-nitrophenylazo)-2-(2-(2-hydroxyethoxy)ethylamino)-4-methyl-6-phenylaminonicotinonitrile; 5-(2-cyano-4-nitrophenylazo)-6-(2-(2-hydroxyethoxy)ethylamino)-4-methyl-2-phenylaminonicotinonitrile |
429-760-5 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 608-051-00-6 | (R)-4-(4-dimethylamino-1-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitrile | 430-760-2 | 219861-18-4 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H317 H411 |
GHS07 GHS09 Wng |
H302 H317 H411 |
|||
| 608-052-00-1 | (S)-4-(4-dimethylamino-1-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitrile | 430-770-7 | 128173-52-4 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H317 H411 |
GHS07 GHS09 Wng |
H302 H317 H411 |
|||
| 608-053-00-7 | (R,S)-4-(4-dimethylamino-1-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitrile | 430-780-1 | 103146-25-4 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H317 H411 |
GHS07 GHS09 Wng |
H302 H317 H411 |
|||
| 608-054-00-2 | (R,S)-4-(4-dimethylamino-1-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitrile hemisulfate | 430-790-6 | — |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H302 H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H317 H411 |
|||
| 608-055-00-8 |
fipronil (ISO); 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile |
— | 120068-37-3 |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H331 H311 H301 H372** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H331 H311 H301 H372** H410 |
M=10 | ||
| 608-056-00-3 | N-methyl-N-cyanomethylmorpholiniummethylsulfate | 429-340-1 | — |
Acute Tox. 4 * Eye Dam. 1 |
H302 H318 |
GHS05 GHS07 Dgr |
H302 H318 |
|||
| 608-057-00-9 | 4-cyanomethyl-4-methylmorpholin-4-iumhydrogene sulfate | 431-200-1 | 208538-34-5 |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 |
H302 H318 H317 |
GHS05 GHS07 Dgr |
H302 H318 H317 |
|||
| 608-059-00-X | 5-amino-1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-1H-pyrazole-3-carbonitrile | 421-240-6 | 120068-79-3 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 608-060-00-5 | 5-methyl-2-[(2-nitrophenyl)amino]-3-thiophenecarbonitrile | 421-300-1 | 138564-59-7 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 608-062-00-6 | 2-fluoro-4-hydroxybenzonitrile | 422-810-7 | 82380-18-5 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|||
| 608-063-00-1 | (S)-α-hydroxy-3-phenoxy-benzeneacetonitrile | 441-070-6 | 61826-76-4 |
Acute Tox. 3 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H318 H317 H400 H410 |
GHS06 GHS05 GHS09 Dgr |
H301 H318 H317 H410 |
|||
| 608-064-00-7 | cyanomethyltrimethylammoniummethylsulfate | 433-720-2 | — | Aquatic Chronic 3 | H412 | — | H412 | |||
| 609-069-00-7 |
musk ketone; 3,5-dinitro-2,6-dimethyl-4-tert-butylacetophenone; 4'-tert-butyl-2',6'-dimethyl-3',5'-dinitroacetophenone |
201-328-9 | 81-14-1 |
Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H400 H410 |
GHS08 GHS09 Wng |
H351 H410 |
|||
| 609-072-00-3 | 4-mesyl-2-nitrotoluene | 430-550-0 | 1671-49-4 |
Repr. 2 Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 |
H361f*** H302 H317 H412 |
GHS08 GHS07 Dgr |
H361f*** H302 H317 H412 |
|||
| 609-073-00-9 | lithium potassium sodium N,N''-bis{6-[7-[4-(4-chloro-1,3,5-triazin-2-yl)amino-4-(2-ureidophenylazo)]naphthalene-1,3,6-trisulfonato]}-N'-(2-aminoethyl)piperazine | 427-850-9 | — | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 611-050-00-3 |
reaction mass of: pentasodium 7-amino-3-[[4-[[4-[[4-[[4-[(6-amino-1-hydroxy-3-sulfonato-2-naphthyl)azo]-7-sulfonato-1-naphthyl]azo]phenyl]amino]-3-sulfonatophenyl]azo]-6-sulfonato-1-naphthyl]azo]-4-hydroxynaphthalen-2-sulfonate; pentasodium 7-amino-8-[4-[4-[4-[4-(2-amino-5-hydroxy-7-sulfonato-naphthalen-1-ylazo)-7-sulfonatonaphthalen-1-ylazo]-phenylamino]-3-sulfonato-phenylazo]-6-sulfonato-naphthalen-1-ylazo]-4-hydroxy-naphthalene-2-sulfonate; pentasodium 7-amino-8-[4-[4-[4-[4-(6-amino-1-hydroxy-3-sulfonato-naphthalen-1-ylazo)-7-sulfonatonaphthalen-1-ylazo]-phenylamino]-3-sulfonato-phenylazo]-6-sulfonato-naphthalen-1-ylazo]-4-hydroxy-naphthalene-2-sulfonate; tetrasodium 7-amino-4-hydroxy-3-[4-[4-[4-(4-hydroxy-7-sulfonato-naphthalen-1-ylazo)-2-sulfonato-phenylamino]phenylazo]-6-sulfonato-naphthalen-1-ylazo]naphthalene-2-sulfonate; tetrasodium 7-amino-4-hydroxy-3-[4-[4-[4-(4-amino-7-sulfonato-naphthalen-1-ylazo)-2-sulfonato-phenylamino]phenylazo]-6-sulfonato-naphthalen-1-ylazo]naphthalene-2-sulfonate |
415-350-3 | — |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|||
| 611-102-00-5 |
reaction product of: C.I. Leuco Sulfur Black 1 and reaction mass of: disodium-4-{4-[8-amino-1-hydroxy-7-(4-sulfamoylphenylazo)-3,6-disulfonato-2-naphthylazo]phenylsulfonylamino}benzendiazoniumchlorid; disodium-4-{4-[2,6-dihydroxy-3-(8-hydroxy-3,6-disulfonato-1-naphthylazo)phenylazo]phenylsulfonylamino}benzen-diazoniumchlorid |
424-500-7 | — | Aquatic Chronic 3 | H412 | — | H412 | |||
| 611-139-00-7 | reaction product of: C.I. Leuco Sulfur Black 1 with (3-chloro-2-hydroxypropyl)trimethylammonium chloride | 424-510-1 | — |
Eye Dam. 1 Aquatic Chronic 2 |
H318 H411 |
GHS05 GHS09 Dgr |
H318 H411 |
|||
| 611-141-00-8 | 5-(4-[4-[4-(3,5-dicarboxy-phenyl-azo)phenylamino]-6-morpholin-4-yl-1,3,5-triazin-2-ylamino]phenylazo)isophthalic acid, mixed monosodium and diammonium salt | 414-410-6 | — |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|||
| 611-142-00-3 |
product-by-process definition polyazodyestuff obtained by coupling 4-[4-(1-amino-8-hydroxy-3,6-disulfo-2-naphthylazo)phenylsulfonylamino]benzenediazonium with reaction mass of 4-carboxybenzenediazonium and diphenylamine-3-sulfo-4,4'-bisdiazonium, and further coupling of the obtained compounds with reaction mass of naphth-2-ol and 3-aminophenol, sodium salts; sodium chloride |
425-740-5 | — |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|||
| 611-143-00-9 |
reaction mass of: trisodium 2-(2-[α-(2-carboxylato-κ-O-4-sulfonatophenylazo)benzylidene]hydrazino-κ-N')-6-(2,6-difluoropyrimidin-4-ylamino)-4-sulfonatophenolatocuprate (II); trisodium 2-(2-[α-(2-carboxylato-κ-O-4-sulfonatophenylazo)benzylidene]hydrazino-κ-N')-6-(4,6-difluoropyrimidin-2-ylamino)-4-sulfonatophenolatocuprate (II) |
428-260-4 | — | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 611-144-00-4 |
reaction mass of: 7-amino-3,8-bis-[4-(2-sulfoxyethylsulfonyl)phenylazo]-4-hydroxynaphthalene-2-sulfonic acid, Na/K salt; 7-amino-3-[4-(2-sulfoxyethylsulfonyl)phenylazo]-4-hydroxy-8-[4-(2-sulfoxyethylsulfonyl)-2-sulfophenylazo]naphthalene-2-sulfonic acid, Na/K salt; 7-amino-8-[4-(2-sulfoxyethylsulfonyl)-phenylazo]-4-hydroxy-3-[4-(2-sulfoxyethylsulfonyl)-2-sulfophenylazo]naphthalene-2-sulfonic acid, Na/K salt; 7-amino-3,8-bis-[4-(2-sulfoxyethylsulfonyl)-2-sulfophenylazo]-4-hydroxynaphthalene-2-sulfonic acid, Na/K salt |
429-070-4 | 214362-06-8 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 611-145-00-X |
reaction mass of: tetrasodium 3-(1,5-disulfonatonaphthalene-2-ylazo)-4-hydroxy-7-{4-chloro-6-[4-(2-sulfoxyethylsulfonyl)phenylamino]-1,3,5-triazine-2-ylamino}naphthalene-2-sulfonate; 3-(2,5-disulfophenylazo)-4-hydroxy-7-{4-chloro-6-[4-(2-sulfoxyethylsulfonyl)phenylamino]-1,3,5-triazine-2-ylamino}naphthalene-2-sulfonic acid, sodium salt |
429-440-5 | — | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 611-146-00-5 |
reaction mass of: pentasodium 3-(4-(4-(7-(2,4-diamino-5-sulfonato-3-(4-sulfonatophenylazo)phenylazo)-1-hydroxy-3-sulfonatonaphthalen-2-ylazo)-2-sulfonatophenylamino)phenylazo)-4-hydroxy-6-(2-oxo-1-phenylcarbamoylpropylazo)naphthalene-2-sulfonate; pentasodium 6-((2,4-diamino-5-sulfonatophenyl)azo)-3-((4-((4-((7-((2,4-diamino-5-sulfonatophenyl)azo)-1-hydroxy-3-sulfonatonaphthalen-2-yl)azo)phenyl)amino)-2-sulfonatophenyl)azo)-4-hydroxynaphthalene-2-sulfonate; pentasodium 6-((2,4-diamino-5-sulfonato-3-((4-sulfonatophenyl)azo)phenyl)azo)-3-((4-((4-((1,7-dihydroxy-3-sulfonatonaphthalen-2-yl)azo)-2-sulfonatophenyl)amino)phenyl)azo)-4-hydroxynaphthalene-2-sulfonate; hexasodium 6-((2,4-diamino-5-sulfonatophenyl)azo)-3-((4-((4-((7-((2,4-diamino-5-sulfonato-3-((4-sulfonatophenyl)azo)phenyl)azo)-1-hydroxy-3-sulfonatonaphthalen-2-yl)azo)-2-sulfonatophenyl)amino)phenyl)azo)-4-hydroxynaphthalene-2-sulfonate |
430-070-1 | — | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 611-147-00-0 | sodium, potassium, lithium 5-amino-3,6-bis(5-(4-chloro-6-(methyl-(2-methylaminoacetyl)amino)-1,3,5-triazin-2-ylamino)-2-sulfonatophenylazo)-4-hydroxynaphthalene-2,7-disulfonate | 430-090-0 | 205764-96-1 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|||
| 611-148-00-6 |
reaction mass of: 2-(3-(2,6-dichloro-4-nitrophenylazo)carbazol-9-yl)ethanol; 2-(2-(3-(2,6-dichloro-4-nitro-phenylazo)-carbazol-9-yl)-ethoxy)ethanol; 3-(2,6-dichloro-4-nitrophenylazo)carbazol |
429-590-1 | — |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|||
| 611-149-00-1 | 2-(2-chloroacetoxy)ethyl 3-((4-(2,5-dichloro-4-fluorosulfonylphenylazo)-3-methylphenyl)ethylamino)propionate | 427-570-7 | 193486-83-8 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 611-150-00-7 | tetralithium 2-[6-[7-[2-(carboxylato)phenylazo]-8-hydroxy-3,6-disulfonato-1-naphthylamino]-4-hydroxy-1,3,5-triazine-2-ylamino]benzoate | 440-460-3 | — |
Eye Irrit. 2 Aquatic Chronic 3 |
H319 H412 |
GHS07 Wng |
H319 H412 |
|||
| 611-151-00-2 |
chrysoidine; 4-(phenylazo)benzene-1,3-diamine |
207-803-7 | 495-54-5 |
Muta. 2 Acute Tox. 4 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H341 H302 H315 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H341 H302 H315 H410 |
|||
| 611-152-00-8 |
chrysoidine monohydrochloride; 4-phenylazophenylene-1,3-diamine monohydrochloride; [1] chrysoidine monoacetate; 4-(phenylazo)benzene-1,3-diamine monoacetate; [2] chrysoidine acetate; 4-(phenylazo)benzene-1,3-diamine acetate; [3] chrysoidine-p-dodecylbenzenesulfonate; dodecylbenzenesulfonic acid, compound with 4-(phenylazo)benzene-1,3-diamine (1:1); [4] chrysoidine dihydrochloride; 4-(phenylazo)benzene-1,3-diamine dihydrochloride; [5] chrysoidine sulfate; bis[4-(phenylazo)benzene-1,3-diamine] sulfate [6] |
208-545-8 [1] 278-290-5 [2] 279-116-0 [3] 264-409-8 [4] 281-549-5 [5] 282-432-1 [6] |
532-82-1 [1] 75660-25-2 [2] 79234-33-6 [3] 63681-54-9 [4] 83968-67-6 [5] 84196-22-5 [6] |
Muta. 2 Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H341 H302 H315 H318 H400 H410 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H341 H302 H315 H318 H410 |
|||
| 611-153-00-3 |
chrysoidine C10-14-alkyl derivatives; benzenesulfonic acid, mono-C10-14-alkyl derivatives, compounds with 4-(phenylazo)-1,3-benzenediamine; [1] chrysoidine compound with dibutylnaphthalene sulfonic acid; dibutylnaphthalenesulfonic acid, compound with 4-(phenylazo)benzene-1,3-diamine (1:1) [2] |
286-946-7 [1] 304-236-8 [2] |
85407-90-5 [1] 94247-67-3 [2] |
Muta. 2 Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 |
H341 H302 H315 H318 |
GHS05 GHS08 GHS07 Dgr |
H341 H302 H315 H318 |
|||
| 611-154-00-9 | trisodium 5-benzamido-4-hydroxy-3-(4-methyl-2-sulfonatophenylazo)naphthalene-2,7-disulfonate | 403-670-6 | 92408-46-3 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 611-155-00-4 | 4,4'-oxybis(benzenesulfonylazide) | 431-850-4 | 7456-68-0 |
Expl. 1.1**** STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H201 H373** H400 H410 |
GHS01 GHS08 GHS09 Dgr |
H201 H373** H410 |
|||
| 611-156-00-X | triammonium 4-[4-[7-(4-carboxylatoanilino)-1-hydroxy-3-sulfonato-2-naphthylazo]-2,5-dimethoxyphenylazo]benzoate | 432-270-4 | 221354-37-6 |
Repr. 2 STOT RE 2 * Aquatic Chronic 2 |
H361f*** H373** H411 |
GHS08 GHS09 Wng |
H361f*** H373** H411 |
|||
| 611-157-00-5 |
benzenesulfonic acid, 3,3'-(methylenebis((dihydroxyphenylene)azo))bis-, potassium sodium salt; potassium sodium 3-[(E)-(6-{3,4-dihydroxy-2-[(Z)-(3-sulfonatophenyl)diazenyl]benzyl}-2,3-dihydroxyphenyl)diazenyl]benzenesulfonate |
432-590-4 | 243869-48-9 |
Eye Irrit. 2 Aquatic Chronic 3 |
H319 H412 |
GHS07 Wng |
H319 H412 |
|||
| 611-158-00-0 | reaction product of: 2,3,4,2',3',4'-hexahydroxy-5,5'-diacethyl-diphenylmethane and 6-diazo-5,6-dihydro-5-oxo-1-naphthalenesulfonylchloride and 3-diazo-3,4-dihydro-6-methoxy-4-oxo-1-naphthalenesulfonylchloride | 421-520-8 | — |
**** Aquatic Chronic 4 |
**** H413 |
**** |
**** H413 |
|||
| 611-159-00-6 | disodium 4-amino-6-((4-((4-(2,4-diaminophenyl)azo)phenylsulfamoyl)phenyl)azo)-5-hydroxy-3-((4-nitrophenyl)azo)naphthalene-2,7-disulfonate | 421-880-6 | — |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|||
| 611-160-00-1 |
reaction mass of: 1,1,1-tris(phenyl-4'-(3''-diazo-3'',4''-dihydro-4''-oxo-naphthalene-1''-sulfonato)ethane; 1,1,1-tris(phenyl-4'-(6''-diazo-5'',6''-dihydro-5''-oxo-naphthalene-1''-sulfonato)ethane; reaction product of 1,1,1-tris(p-hydroxyphenyl)ethane with 6-diazo-5,6-dihydro-5-oxo-1-naphthylsulfonylchloride and 3-diazo-3,4-dihydro-4-oxo-1-naphthylsulfonylchloride (2:1); reaction product of 1,1,1-tris(p-hydroxyphenyl)ethane with 6-diazo-5,6-dihydro-5-oxo-1-naphthylsulfonylchloride and 3-diazo-3,4-dihydro-4-oxo-1-naphthylsulfonylchloride (1:2) |
422-760-6 | — |
**** Aquatic Chronic 4 |
**** H413 |
**** |
**** H413 |
|||
| 611-161-00-7 | trisodium [1,2'-(2-(8-amino-3,5-disulfonatonaphthalene)azo)-(4'-nitrobenzene)diolato-O,O,N][(Z)-2,2-((phenylcarbamoylprop-1'-enyl)azo)-5-sulfamoylbenzene)diolato-O,O,N]chromate(III) | 423-100-1 | — | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 611-162-00-2 | 2,4-bis(((2-(dimethylammonio)ethyloxy)carbonyl)phen-2-ylazo)benzene-1,3-diolbis(methanesulfonate) | 429-600-4 | — |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|||
| 611-163-00-8 | 2,4-bis(((2-(dimethylammonio)ethyloxy)carbonyl)phen-2-ylazo)benzene-1,3-diol sulfate | 429-610-9 | — |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 2 |
H302 H318 H411 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H411 |
|||
| 611-164-00-3 |
reaction mass of: 2,2'-dimethyl-2,2'-azobutanenitrile; 2-methylpentanenitrile-2-azo-2'-(2'-methylpropanenitrile); 2,2'-dimethyl-2,2'-azoheptanenitrile; 2-methylheptanenitrile-2-azo-2'-(2'-methylpropanenitrile); 2-methylheptanenitrile-2-azo-2'-(2'-methylbutanenitrile) |
429-710-2 | — |
Self React D Acute Tox. 4 * Aquatic Chronic 2 |
H242 H302 H411 |
GHS02 GHS07 GHS09 Dgr |
H242 H302 H411 |
|||
| 611-165-00-9 |
reaction mass of: tetrasodium 4-amino-6-(5-(2,6-difluoropyrimidin-4-ylamino)-2-sulfonatophenylazo)-5-hydroxy-3-(4-(sulfatoethylsulfonyl)phenylazo)naphthalene-2,7-disulfonate; tetrasodium 4-amino-6-(5-(4,6-difluoropyrimidin-2-ylamino)-2-sulfonatophenylazo)-5-hydroxy-3-(4-(2-sulfatoethylsulfonyl)phenylazo)naphthalene-2,7-disulfonate |
431-830-5 | — | Aquatic Chronic 3 | H412 | — | H412 | |||
| 611-166-00-4 |
reaction mass of: pentasodium 4-amino-5-hydroxy-3-{(E)-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}-6-{(E)-2-sulfonato-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}naphthalene-2,7-disulfonate; tetrasodium 4-amino-5-hydroxy-3-{(E)-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}-6-[(E)-2-sulfonato-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; tetrasodium 4-amino-5-hydroxy-6-{(E)-2-sulfonato-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}-3-[(E)-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate |
432-100-9 | — |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|||
| 611-167-00-X | sodium bis[tris(2-hydroxyethyl)ammonium][6-anilino-4'-(4,8-disulfonato-2-naphthylazo)-5'-methyl-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato]cuprate(II) | 435-240-9 | — | Aquatic Chronic 3 | H412 | — | H412 | |||
| 611-168-00-5 |
reaction mass of: 3-[[4-chloro-6-[[7-[(1,5-disulfo-2-naphthalenyl)azo]-8-hydroxy-3,6-disulfo-1-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]-5-[[4-chloro-6-[[8-hydroxy-3,6-disulfo-7-[(2-sulfophenyl)azo]-1-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]benzoic acid; 3,5-bis[[4-chloro-6-[[7-[(1,5-disulfo-2-naphthalenyl)azo]-8-hydroxy-3,6-disulfo-1-naphthalenyl]amino]-1,3,5-triazin-2-yl]amino]benzoic acid |
435-440-6 | — | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 611-169-00-0 | sodium 5-(2-carboxyphenylazo)-6-hydroxynaphthalene-2-sulfonate | 435-800-2 | — | Aquatic Chronic 3 | H412 | — | H412 | |||
| 611-170-00-6 |
reaction mass of: trisodium 2-((1-(2-hydroxy-κ-O-5-(2-sulfonatoethansulfonyl)phenylazo-κ-N2)-1-phenylmethyl)azo-κ-N1)-4-sulfonatobenzoate(5-)-κ-O)cuprate(II); disodium 2-((1-(5-ethenesulfonyl-2-hydroxy-κ-O-phenylazo-κ-N2)-1-phenylmethyl)azo-κ-N1)-4-sulfonatobenzoate-κ-O-(5-))cuprate(II) |
435-880-9 | — | Aquatic Chronic 3 | H412 | — | H412 | |||
| 611-171-00-1 |
reaction mass of: trisodium 3-(5-(2,6-difluoropyrimidin-4-ylamino)-2-sulfonatophenylazo)-5-(4-fluoro-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxy-2,7-naphthalenedisulfonate; trisodium 3-(5-(4,6-difluoropyrimidin-2-ylamino)-2-sulfonatophenylazo)-5-(4-fluoro-6-morpholin-4-yl-1,3,5-triazin-2-ylamino)-4-hydroxy-2,7-naphthalenedisulfonate |
436-890-6 | — |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|||
| 611-172-00-7 |
reaction mass of: triammonium 6-amino-3-((2,5-diethoxy-4-(3-phosphonophenyl)azo)phenyl)azo-4-hydroxy-2-naphthalenesulfonate; diammonium 3-((4-((7-amino-1-hydroxy-3-sulfo-naphthalen-2-yl)azo)-2,5-diethoxyphenyl)azo)benzoate |
438-310-7 | — |
Self-react. C**** Repr. 2 Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 3 |
H242 H361f*** H302 H373** H412 |
GHS02 GHS08 GHS07 Dgr |
H242 H361f*** H302 H373** H412 |
|||
| 611-173-00-2 |
reaction mass of: 3-[3-carbamoyl-5-(5-{4-chloro-6-[4-(2-sulfonatooxyethylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl]propanoic acid, trisodium salt; 3-[3-carbamoyl-5-(5-{4-chloro-6-[4-(vinylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-pyridyl]propanoic acid, disodium salt |
440-510-4 | — |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|||
| 611-174-00-8 |
reaction mass of: 3-[5-(4-ethenesulfonylbutyrylamino)-2-sulfophenylazo]-5-{4-chloro-[6-(4-(3-amino-5-hydroxy-2,7-disulfonaphthalene-4-ylazo)-3-sulfophenylamino]-1,3,5-triazin-2-ylamino}-4-hydroxynaphthalene-2,7-disulfonic acid, sodium salt; 3-[5-(4-(2-chloroethanesulfonyl)butyrylamino)-2-sulfophenylazo]-5-{4-chloro-[6-(4-(3-amino-5-hydroxy-2,7-disulfonaphthalene-4-ylazo)-3-sulfophenylamino]-1,3,5-triazin-2-ylamino}-4-hydroxynaphthalene-2,7-disulfonic acid, sodium salt |
442-290-5 | 457624-86-1 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 611-175-00-3 |
reaction mass of: trisodium 5-{4-chloro-6-[N-ethyl-(3-(2-sulfonatooxy)ethylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-[4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; trisodium 5-{4-chloro-6-[N-ethyl-3-(vinylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-[4-(2-(sulfonatooxy)ethylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; disodium 5-{4-chloro-6-[N-ethyl-3-(vinylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-4-hydroxy-3-[(4-vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; tetrasodium 5-{4-chloro-6-[N-ethyl-3-(2-(sulfonatooxy)ethylsulfonyl)anilino]-1,3,5-triazin-2-ylamino}-3-[4-(2-(sulfonatooxy)ethylsulfonyl)phenylazo]-4-hydroxynaphthalene-2,7-disulfonate |
444-050-5 | — |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|||
| 611-176-00-9 | 2,6-bis(2,3,4-trihydroxybenzyl)-p-cresol ester with 6-diazo-5,6-dihydro-5-oxo-1-naphthalenesulfonate | 444-250-2 | — |
Self-react. C**** Aquatic Chronic 2 |
H242 H411 |
GHS02 GHS09 Dgr |
H242 H411 |
|||
| 611-177-00-4 |
reaction mass of: pentasodium bis[6-anilino-3,5'-disulfonatonaphthalene-2-azobenzene-1,2'-diolato]cobaltate(III); tetrasodium [6-anilino-3,5'-disulfonatonaphthalene-2-azobenzene-1,2'-diolato][6-anilino-5'-sulfamoyl-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato]cobaltate(III); trisodium bis[6-anilino-5'-sulfamoyl-3-sulfonatonaphthalene-2-azobenzene-1,2'-diolato]cobaltate(III) |
444-290-0 | 508202-43-5 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|||
| 611-178-00-X |
reaction mass of: pentasodium 4-amino-5-hydroxy-3-{(E)-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}-6-{(E)-2-sulfonato-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}naphthalene-2,7-disulfonate; tetrasodium 4-amino-5-hydroxy-3-{(E)-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}-6-[(E)-2-sulfonato-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; tetrasodium 4-amino-5-hydroxy-6-[(E)-2-sulfonato-4-[2-(sulfonatooxy)ethylsulfonyl]phenylazo}-3-[(E)-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; trisodium 4-amino-5-hydroxy-3-[(E)-4-(vinylsulfonyl)phenylazo]-6-[(E)-2-sulfonato-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; trisodium 4-amino-5-hydroxy-3-[(2-hydroxyethylsulfonyl)-phenylazo]-6-[(E)-2-sulfonato-4-(vinylsulfonyl)phenylazo]naphthalene-2,7-disulfonate; trisodium 4-amino-5-hydroxy-3-[(E)-4-(vinylsulfonyl)phenylazo]-6-[-2-sulfonato-4-(2-hydroxyethylsulfonyl)phenylazo]naphthalene-2,7-disulfonate |
445-280-9 | — |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|||
| 611-179-00-5 |
reaction mass of: pentasodium 2-[[8-[[4-chloro-6-[[4-(2-sulfonato ethylsulfonyl)]phenyl]amino]-1,3,5-triazin-2-yl]amino-1- hydroxy-3,6-disulfonato-2-naphthalenyl]azo]naphthalene-1,5-disulfonate; 2-[[8-[[4-chloro-6-[[4-[[2-ethenyl]sulfonyl]phenyl]amino]-1,3,5-triazin-2-yl]amino]-1-hydroxy-3,6-disulfonato-2-naphthalenyl]azo]naphthalene-1,5-disulfonate |
450-010-8 | — |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|||
| 611-180-00-0 | iron, complexes with diazotised 4-aminobenzenesulfonamide, diazotised 3-aminobenzenesulfonic acid, diazotised 3-amino-4-hydroxybenzenesulfonamide,diazotised 3-amino-4-hydroxy-N-phenylbenzenesulfonamide, diazotised 5-amino-2-(phenylamino)benzenesulfonic acid and resorcinol, sodium salts | 417-850-7 | — | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 612-057-01-1 |
piperazine; [liquid] |
203-808-3 | 110-85-0 |
Repr. 2 Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1 |
H361fd H314 H334 H317 |
GHS05 GHS08 Dgr |
H361fd H314 H334 H317 |
|||
| 612-122-01-4 | hydroxylamine … % [≤ 55 % in aqueous solution] | 232-259-2 | 7803-49-8 |
Met. Corr. 1 Carc. 2 Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 |
H290 H351 H312 H302 H373** H335 H315 H318 H317 H400 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H290 H351 H312 H302 H373** H335 H315 H318 H317 H400 |
B | ||
| 612-169-00-3 | bis(N-methyl-N-phenylhydrazine)sulfate | 423-170-1 | 618-26-8 |
Flam. Liq. 2 STOT RE 1 Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H225 H372** H302 H318 H317 H400 H410 |
GHS02 GHS05 GHS08 GHS07 GHS09 Dgr |
H225 H372** H302 H318 H317 H410 |
|||
| 612-203-00-7 | C8-10 alkyl dimethyl hydroxyethyl ammoniumchloride (chain < C8: < 3 %, chain = C8: 15 %-70 %, chain = C10: 30 %-85 %, chain > C10: < 3 %) | 417-360-3 | — |
Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 |
H312 H302 H315 |
GHS07 Wng |
H312 H302 H315 |
|||
| 612-208-00-4 | N-methylbenzene-1,2-diammonium hydrogen phosphate | 424-460-0 | — |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H317 H411 |
GHS07 GHS09 Wng |
H302 H317 H411 |
|||
| 612-216-00-8 | 1-amino-1-cyanamino-2,2-dicyanoethylene, sodium salt | 425-870-2 | 19450-38-5 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|||
| 612-219-00-4 | (2-hydroxy-3-(3,4-dimethyl-9-oxo-10-thiaanthracen-2-yloxy)propyl)trimethylammonium chloride | 402-200-7 | — | Aquatic Chronic 3 | H412 | — | H412 | |||
| 612-220-00-X | N-nitro-N-(3-methyl-3,6-dihydro-2H-1,3,5-oxadiazin-4-yl)amine | 431-060-1 | 153719-38-1 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 |
H302 H317 H412 |
GHS07 Wng |
H302 H317 H412 |
|||
| 612-221-00-5 | 2-amino-4-(trifluoromethyl)benzenethiol hydrochloride | 429-560-8 | 4274-38-8 |
Skin Corr. 1B Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 |
H314 H332 H312 H302 H373** H317 H400 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H314 H332 H312 H302 H373** H317 H400 |
|||
| 612-222-00-0 | cis-1-(3-(4-fluorophenoxy)propyl)-3-methoxy-4-piperidinamine | 425-080-8 | 104860-26-6 |
Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H312 H302 H373** H318 H400 H410 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H312 H302 H373** H318 H410 |
|||
| 612-223-00-6 | N-benzyl-N-ethyl-(4-(5-nitro-benzo[c]isothiazol-3-ylazo)phenyl)amine | 425-300-2 | 186450-73-7 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 612-224-00-1 | N2,N4,N6-tris{4-[(1,4-dimethylpentyl)amino]phenyl}-1,3,5-triazine-2,4,6-triamine | 426-150-0 | 121246-28-4 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|||
| 612-225-00-7 | 1,4,7,10-tetraazacyclododecane | 425-450-9 | 294-90-6 |
Skin Corr. 1B Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H314 H312 H302 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H314 H312 H302 H410 |
|||
| 612-226-00-2 | 3-(2'-phenoxyethoxy)propylamine | 427-870-8 | 6903-18-0 |
Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 |
H302 H315 H318 H412 |
GHS05 GHS07 Dgr |
H302 H315 H318 H412 |
|||
| 612-227-00-8 | benzyl-N-(2-(2-methoxyphenoxy)ethyl)amine hydrochloride | 428-290-8 | 120606-08-8 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H318 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H410 |
|||
| 612-228-00-3 |
reaction mass of: N-(3-(trimethoxysilyl)propyl)ethylenediamine; N-benzyl-N-(3-(trimethoxysilyl)propyl)ethylenediamine; N-benzyl-N'-[3-(trimethoxysilyl)propyl]ethylenediamine; N,N'-bis-benzyl-N'-[3-(trimethoxysilyl)propyl]ethylenediamine; N,N,N'-tris-benzyl-N'-[3-(trimethoxysilyl)propyl]ethylenediamine; N,N-bis-benzyl-N'-[3-(trimethoxysilyl)propyl]ethylenediamine |
414-340-6 | — |
Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * STOT SE 2 Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H226 H332 H312 H302 H371 H318 H317 H412 |
GHS02 GHS05 GHS08 GHS07 Dgr |
H226 H332 H312 H302 H371 H318 H317 H412 |
|||
| 612-229-00-9 |
mepanipyrim; 4-methyl-N-phenyl-6-(1-propynyl)-2-pyrimidinamine |
— | 110235-47-7 |
Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H400 H410 |
GHS08 GHS09 Wng |
H351 H410 |
|||
| 612-230-00-4 | N,N-bis(cocoyl-2-oxypropyl)-N,N-dibutylammonium bromide | 431-530-4 | — |
Skin Corr. 1A Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H314 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H314 H317 H410 |
|||
| 612-231-00-X | 3-((C12-18)-acylamino)-N-(2-((2-hydroxyethyl)amino)-2-oxoethyl)-N,N-dimethyl-1-propanaminium chloride | 427-370-1 | 164288-56-6 |
Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H400 H410 |
GHS05 GHS09 Dgr |
H318 H410 |
|||
| 612-232-00-5 |
reaction mass of: triisopropanolamine salt of 1-amino-4-(3-propionamidoanilino)anthraquinone-2-sulfonic acid; triisopropanolamine salt of 1-amino-4-[3,4-dimethyl-5-(2-hydroxyethylaminosulfonyl)anilino]anthraquinone-2-sulfonic acid |
430-410-9 | 186148-38-9 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 612-237-00-2 |
hydroxylammonium hydrogensulfate; hydroxylamine sulfate (1:1); [1] hydroxylamine phosphate; [2] hydroxylamine dihydrogenphosphate; [3] hydroxylamine 4-methylbenzenesulfonate [4] |
233-154-4 [1] 244-077-0 [2] 242-818-2 [3] 258-872-5 [4] |
10046-00-1 [1] 20845-01-6 [2] 19098-16-9 [3] 53933-48-5 [4] |
Expl. 1.1 Carc. 2 Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 |
H201 H351 H312 H302 H373** H319 H315 H317 H400 |
HS01 GHS08 GHS07 GHS09 Dgr |
H201 H351 H312 H302 H373** H319 H315 H317 H400 |
T | ||
| 612-238-00-8 | (3-chloro-2-hydroxypropyl) trimethylammonium chloride … % | 222-048-3 | 3327-22-8 |
Carc. 2 Aquatic Chronic 3 |
H351 H412 |
GHS08 Wng |
H351 H412 |
B | ||
| 612-239-00-3 |
biphenyl-3,3',4,4'-tetrayltetraamine; diaminobenzidine |
202-110-6 | 91-95-2 |
Carc. 1B Muta. 2 |
H350 H341 |
GHS08 Dgr |
H350 H341 |
|||
| 612-240-00-9 |
pyrimethanil (ISO); N-(4,6-dimethylpyrimidin-2-yl)aniline |
— | 53112-28-0 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 612-241-00-4 |
piperazine hydrochloride; [1] piperazine dihydrochloride; [2] piperazine phosphate [3] |
228-042-7 [1] 205-551-2 [2] 217-775-8 [3] |
6094-40-2 [1] 142-64-3 [2] 1951-97-9 [3] |
Repr. 2 Eye Irrit. 2 Skin Irrit. 2 Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 3 |
H361fd H319 H315 H334 H317 H412 |
GHS08 Dgr |
H361fd H319 H315 H334 H317 H412 |
|||
| 612-242-00-X |
cyprodinil (ISO); 4-cyclopropyl-6-methyl-N-phenylpyrimidin-2-amine |
— | 121552-61-2 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
M=10 | ||
| 612-243-00-5 | (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine 2-hydroxy-2-phenylacetate | 420-560-3 | 79617-97-3 |
Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H400 H410 |
GHS05 GHS09 Dgr |
H318 H410 |
M=10 | ||
| 612-244-00-0 | 3-(piperazin-1-yl)-benzo[d]isothiazole hydrochloride | 421-310-6 | 87691-88-1 |
Repr. 2 Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361f*** H302 H319 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H361f*** H302 H319 H317 H410 |
|||
| 612-245-00-6 | 2-ethylphenylhydrazine hydrochloride | 421-460-2 | 19398-06-2 |
Carc. 2 STOT RE 1 Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H372** H302 H318 H317 H400 H410 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H351 H372** H302 H318 H317 H410 |
M=10 | ||
| 612-246-00-1 | (2-chloroethyl)(3-hydroxypropyl)ammonium chloride | 429-740-6 | 40722-80-3 |
Carc. 1B Muta. 1B STOT RE 2 * Skin Sens. 1 Aquatic Chronic 3 |
H350 H340 H373** H317 H412 |
GHS08 GHS07 Dgr |
H350 H340 H373** H317 H412 |
|||
| 612-247-00-7 | N-[3-(1,1-dimethylethyl)-1H-pyrazol-5-yl]-N'-hydroxy-4-nitrobenzenecarboximidamide | 423-530-8 | 152828-23-4 |
STOT RE 1 Acute Tox. 4 * Aquatic Chronic 3 |
H372** H302 H412 |
GHS08 GHS07 Dgr |
H372** H302 H412 |
|||
| 612-248-00-2 | reaction product of diphenylamine, phenothiazine, and alkenes, branched (C8-10, C9-rich) | 439-540-0 | — |
Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 4 |
H315 H317 H413 |
GHS07 Wng |
H315 H317 H413 |
|||
| 612-249-00-8 | 4-[(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1,2-benzenediamine dihydrochloride | 425-030-5 | 159939-85-2 |
Repr. 2 Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 |
H361f*** H302 H314 H317 H411 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H361f*** H302 H314 H317 H411 |
|||
| 612-250-00-3 | chloro-N,N-dimethylformiminium chloride | 425-970-6 | 3724-43-4 |
Repr. 1B Acute Tox. 4 * Skin Corr. 1A |
H360D*** H302 H314 |
GHS05 GHS08 GHS07 Dgr |
H360D*** H302 H314 |
EUH014 | ||
| 612-251-00-9 | cis-1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride | 426-020-3 | 51229-78-8 |
Flam. Sol. 2 Repr. 2 Acute Tox. 4 * Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H228 H361d*** H302 H315 H317 H411 |
GHS02 GHS08 GHS07 GHS09 Wng |
H228 H361d*** H302 H315 H317 H411 |
|||
| 612-252-00-4 |
imidacloprid (ISO); 1-(6-chloropyridin-3-ylmethyl)-N-nitroimidazolidin-2-ylidenamine |
428-040-8 | 138261-41-3 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|||
| 612-253-00-X |
7-methoxy-6-(3-morpholin-4-yl-propoxy)-3H-quinazolin-4-one; [containing < 0,5 % formamide (EC No 200-842-0)] |
429-400-7 | 199327-61-2 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 612-253-01-7 |
7-methoxy-6-(3-morpholin-4-yl-propoxy)-3H-quinazolin-4-one; [containing ≥ 0,5 % formamide (EC No 200-842-0)] |
429-400-7 | 199327-61-2 |
Repr. 1B Aquatic Chronic 3 |
H360D*** H412 |
GHS08 Dgr |
H360D*** H412 |
|||
| 612-254-00-5 | reaction products of diisopropanolamine with formaldehyde (1:4) | 432-440-8 | 220444-73-5 |
Carc. 2 Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 |
H351 H302 H314 H317 H411 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H351 H302 H314 H317 H411 |
|||
| 612-255-00-0 | 1-(3-methoxypropyl)-4-piperidinamine | 431-950-8 | 179474-79-4 |
Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1B Aquatic Chronic 3 |
H312 H302 H314 H412 |
GHS05 GHS07 Dgr |
H312 H302 H314 H412 |
|||
| 612-256-00-6 | benzyl(S)-2-[(2'-cyanobiphenyl-4-ylmethyl)pentanoylamino]-3-methylbutyrate | 427-470-3 | 137864-22-3 |
Acute Tox. 4 * Skin Sens. 1 |
H302 H317 |
GHS07 Wng |
H302 H317 |
|||
| 612-257-00-1 | tripropylammonium dihydrogenphosphate | 433-700-3 | 35687-90-2 | Acute Tox. 4 * | H302 |
GHS07 Wng |
H302 | |||
| 612-259-00-2 | N-ethyl-3-trimethoxysilyl-2-methyl-propanamine | 437-720-3 | 227085-51-0 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 612-261-00-3 | 3,5-dichloro-2-fluoro-4-(1,1,2,3,3,3-hexafluoropropoxy)aniline | 441-190-9 | 121451-05-6 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
M=10 | ||
| 612-265-00-5 | bis(2-hydroxyethyl)-(2-hydroxypropyl)ammonium acetate | 444-360-0 | 191617-13-7 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 612-266-00-0 | 3-chloro-4-(3-fluorobenzyloxy)aniline | 445-590-4 | 202197-26-0 |
Muta. 2 Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H341 H302 H373** H400 H410 |
GHS08 GHS07 GHS09 Wng |
H341 H302 H373** H410 |
|||
| 612-267-00-6 | bis(hydrogenated tallow C16-18-alkyl)hydroxylamine | 418-370-0 | — |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 612-269-00-7 |
reaction mass of: 1-[di(4-octylphenyl)aminomethyl]-5-methyl-1H-benzotriazole; 1-[di(4-octylphenyl)aminomethyl]-4-methyl-1H-benzotriazole; reaction mass of: N-[(5-methyl-1H-benzotriazol-1-yl)methyl]-4-octyl-N-(4-octylphenyl)aniline; N-[(4-methyl-1H-benzotriazol-1-yl)methyl]-4-octyl-N-(4-octylphenyl)aniline |
420-720-2 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 612-270-00-2 | (S)-azetidine-2-carboxylic acid 4-cyanobenzylamide hydrochloride | 433-010-2 | — |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 3 |
H302 H317 H412 |
GHS07 Wng |
H302 H317 H412 |
|||
| 612-271-00-8 |
reaction mass of: ethyl 2-((4-(5,6-dichlorobenzothiazol-2-ylazo)phenyl)ethylamino)benzoate; ethyl 2-((4-(6,7-dichlorobenzothiazol-2-ylazo)phenyl)ethylamino)benzoate |
434-970-5 | 160987-57-5 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 612-272-00-3 | ammonium (η-6-2-(2-(1,2-dicarboxylatoethylamino)ethylamino)butane-1,4-dioato(4-))iron(3+) monohydrate | 435-210-5 | — | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 612-273-00-9 | alkyl(rapeseed oil), bis(2-hydroxyethyl)ammonium fluoride | 435-650-8 | — |
Acute Tox. 4 * Skin Corr. 1A Aquatic Acute 1 Aquatic Chronic 1 |
H302 H314 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H302 H314 H410 |
|||
| 612-274-00-4 | (R,S)-1-[2-amino-1(4-methoxyphenyl)ethyl]cyclohexanol acetate | 445-750-3 | — |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H302 H318 H317 H412 |
GHS05 GHS07 Dgr |
H302 H318 H317 H412 |
|||
| 612-275-00-X | fatty acids, C18-unsatd., dimers, reaction products with 1-piperazineethanamine and tall oil | 447-880-6 | 206565-89-1 |
Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H318 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H315 H318 H317 H410 |
M=10 | ||
| 612-276-00-5 | 1-amino-4-[(4-amino-2-sulfofenyl)amino]-9,10-dihydro-9,10-dioxo-2-anthracenesulfonic acid, disodium salt, reaction products with 2-[[3-[(4,6-dichloro-1,3,5-triazin-2-yl)ethylamino]phenyl]sulfonyl]ethyl hydrogen sulfate, sodium salts | 451-430-4 | 500717-36-2 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|||
| 612-277-00-0 |
reaction mass of: 4-amino-3-(4-ethenesulfonyl-2-sulfonatophenylazo)-5-hydroxy-6-(5-{4-chloro-6-[4-(2-sulfonatooxyethanesulfonyl)phenylamino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)naphthalene-2,7-disulfonate potassium/sodium; 4-amino-5-hydroxy-6-(5-{4-chloro-6-[4-(2-sulfonatooxyethanesulfonyl)phenylamino]-1,3,5-triazin-2-ylamino}-2-sulfonatophenylazo)-3-(2-sulfonato-4-(2-sulfonatooxyethanesulfonyl)phenylazo)naphthalene-2,7-disulfonate potassium/sodium |
451-440-9 | 586372-44-3 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 612-278-00-6 |
ethidium bromide; 3,8-diamino-1-ethyl-6-phenylphenantridinium bromide |
214-984-6 | 1239-45-8 |
Muta. 2 Acute Tox. 2 * Acute Tox. 4 * |
H341 H330 H302 |
GHS06 GHS08 Dgr |
H341 H330 H302 |
|||
| 612-279-00-1 | (R,S)-2-amino-3,3-dimethylbutane amide | 447-860-7 | 144177-62-8 |
Repr. 2 STOT RE 2 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 |
H361f*** H373** H319 H315 H317 |
GHS08 GHS07 Wng |
H361f*** H373** H319 H315 H317 |
|||
| 612-280-00-7 |
3-amino-9-ethyl carbazole; 9-ethylcarbazol-3-ylamine |
205-057-7 | 132-32-1 | Carc. 1B | H350 |
GHS08 Dgr |
H350 | H | ||
| 613-116-01-4 |
tolylfluanid (ISO); dichloro-N-[(dimethylamino)sulphonyl]fluoro-N-(p-tolyl)methanesulphenamide; [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm] |
211-986-9 | 731-27-1 |
Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 |
H319 H335 H315 H317 H400 |
GHS07 GHS09 Wng |
H319 H335 H315 H317 H400 |
M=10 | ||
| 613-161-00-2 | 2,4-diamino-6-hydroxymethylpteridinehydrobromide | 430-620-0 | 76145-91-0 |
STOT RE 2 * Skin Sens. 1 Aquatic Chronic 3 |
H373** H317 H412 |
GHS08 GHS07 Wng |
H373** H317 H412 |
|||
| 613-162-00-8 | (6R-trans)-1-((7-ammonio-2-carboxylato-8-oxo-5-thia-1-azabicyclo-[4.2.0]oct-2-en-3-yl)methyl)pyridinium iodide | 423-260-0 | 100988-63-4 |
Muta. 2 Skin Sens. 1 Aquatic Chronic 2 |
H341 H317 H411 |
GHS08 GHS07 GHS09 Wng |
H341 H317 H411 |
|||
| 613-187-00-4 | 5-(2-amino-5-cyano-6-[2-(2-hydroxyethoxy)ethylamino]-4-methylpyridin-3-ylazo)-3-methyl-2,4-dicarbonitrilethiophene | 410-530-8 | — | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 613-192-00-1 | 3-benzyl-exo-6-nitro-2,4-dioxo-3-aza-cis-bicyclo[3.1.0]hexane | 426-750-2 | 151860-15-0 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|||
| 613-198-00-4 | 2-amino-4-dimethylamino-6-trifluoroethoxy-1,3,5-triazine | 415-500-8 | 145963-84-4 |
Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 3 |
H302 H373** H412 |
GHS08 GHS07 Wng |
H302 H373** H412 |
|||
| 613-229-00-1 | 1-acetyl-4-(3-dodecyl-2,5-dioxo-1-pyrrolidinyl)-2,2,6,6-tetramethylpiperidine | 411-930-5 | 106917-31-1 |
Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H315 H317 H400 H410 |
GHS07 GHS09 Wng |
H315 H317 H410 |
|||
| 613-231-00-2 | 2,6-diamino-3-((pyridine-3-yl)azo)pyridine | 421-430-9 | 28365-08-4 |
Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 2 |
H302 H373** H411 |
GHS08 GHS07 GHS09 Wng |
H302 H373** H411 |
|||
| 613-232-00-8 | 3-(benzo[b]thien-2-yl)-5,6-dihydro-1,4,2-oxathiazine-4-oxide | 431-030-6 | 163269-30-5 |
Acute Tox. 3 * STOT RE 2 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H331 H373** H318 H400 H410 |
GHS06 GHS05 GHS08 GHS09 Dgr |
H331 H373** H318 H410 |
|||
| 613-234-00-9 | imidazo[1,2-b]pyridazin hydrochloride | 431-510-5 | 18087-70-2 |
Acute Tox. 4 * Eye Irrit. 2 |
H302 H319 |
GHS07 Wng |
H302 H319 |
|||
| 613-235-00-4 | 2,3-dihydro-2,2-dimethyl-1H-perimidine | 424-060-6 | 6364-17-6 |
Acute Tox. 4* STOT RE 2 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373** H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H302 H373** H317 H410 |
|||
| 613-236-00-X | 2-chloro-3-trifluoromethylpyridine | 424-520-6 | 65753-47-1 |
Acute Tox. 3 * Acute Tox. 3 * STOT RE 1 Skin Corr. 1B Aquatic Chronic 3 |
H311 H301 H372** H314 H412 |
GHS06 GHS05 GHS08 Dgr |
H311 H301 H372** H314 H412 |
|||
| 613-237-00-5 | 6-tert-butyl-3-(3-dodecylsulfonyl)propyl-7H-1,2,4-triazolo[3.4b][1,3,4]thiadiazine | 424-950-4 | 133949-92-5 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 613-238-00-0 | sodium 2-[[4-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]phenyl]sulfonyl]ethyl sulfate | 430-890-1 | 81992-66-7 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
|||
| 613-239-00-6 | 2-[3-(methylamino)propyl]-1H-benzimidazole | 425-760-4 | 64137-52-6 |
Eye Dam. 1 Aquatic Chronic 3 |
H318 H412 |
GHS05 Dgr |
H318 H412 |
|||
| 613-241-00-7 | 3-(2H-tetrazol-5-yl)pyridine | 426-810-8 | 3250-74-6 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 613-242-00-2 | reaction products of 3,10-bis((2-aminopropyl)amino)-6,13-dichloro-4,11-triphenodioxazinedisulfonic acid with 2-amino-1,4-benzenedisulfonic acid, 2-((4-aminophenyl)sulfonyl)ethyl hydrogen sulfate and 2,4,6-trifluoro-1,3,5-triazine, sodium salts | 426-860-0 | 191877-09-5 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 613-243-00-8 | 4,4'-(1,6-hexamethylenebis(formylimino))bis(2,2,6,6-tetramethyl-1-oxylpiperidine) | 427-350-0 | 182235-14-9 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 613-244-00-3 | 5,7-dichloro-4-hydroxyquinoline | 427-420-0 | 21873-52-9 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 613-245-00-9 | 2-fluoro-6-trifluoromethylpyridine | 428-100-3 | 94239-04-0 |
Flam. Liq. 3 Acute Tox. 4 * Acute Tox. 4 * Aquatic Chronic 3 |
H226 H332 H302 H412 |
GHS02 GHS07 Wng |
H226 H332 H302 H412 |
|||
| 613-246-00-4 | 2-hydroxymethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine | 428-200-7 | 103577-66-8 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 613-247-00-X | 3-(2-methoxy-4-methoxycarboxybenzyl)-5-nitroindole | 428-910-7 | 107786-36-7 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 613-248-00-5 | 3,4-dimethyl-1H-pyrazole | 429-130-1 | 2820-37-3 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H302 H318 H412 |
GHS05 GHS07 Dgr |
H302 H318 H412 |
|||
| 613-249-00-0 | 1-(2-hydroxyethyl)-1H-pyrazol-4,5-diyldiammoniumsulfate | 429-300-3 | 155601-30-2 |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H318 H317 H411 |
GHS05 GHS07 GHS09 Dgr |
H318 H317 H411 |
|||
| 613-250-00-6 |
reaction mass of: carbonato-bis-N-ethyl-2-isopropyl-1,3-oxazolidine; methyl carbonato-N-ethyl-2-isopropyl-1,3-oxazolidine; 2-isopropyl-N-hydroxyethyl 1,3-oxazolidine |
429-990-6 | — |
Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H318 H317 H412 |
GHS05 GHS07 Dgr |
H318 H317 H412 |
|||
| 613-251-00-1 | (R)-3-[(1-methylpyrrolidin-2-yl)methyl]-5-[2-(phenylsulfonyl)ethenyl]-1H-indole | 430-560-5 | 180637-89-2 |
Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 |
H302 H373** H318 H317 |
GHS05 GHS08 GHS07 Dgr |
H302 H373** H318 H317 |
|||
| 613-253-00-2 |
2,2-dialkyl-4-hydroxymethyl-1,3-dioxolane; reaction products with ethylene oxide (alkyl is C1-12 and the sum to C13, average degree of ethoxylation is 3,5) |
430-580-4 | — |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
EUH019 | ||
| 613-254-00-8 |
forchlorfenuron (ISO); 1-(2-chloro-4-pyridyl)-3-phenylurea |
— | 68157-60-8 |
Carc. 2 Aquatic Chronic 2 |
H351 H411 |
GHS08 GHS09 Wng |
H351 H411 |
|||
| 613-255-00-3 | reaction mass of isomers of: sodium [(2-hydroxyethylsulfamoyl){[2-(2-piperazin-1-ylethylamino)ethylsulfamoyl][2-(4-aminoethylpiperazine-1-yl)ethylsulfamoyl](sulfamoyl)}(sulfonatophthalocyaninato)]copper(II) | 424-270-8 | — | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 613-256-00-9 | 3'5'-anhydro thymidine | 425-810-5 | 38313-48-3 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 613-257-00-4 | 2-phthalimidoethyl N-[4-(2-cyano-4-nitrophenylazo)phenyl]-N-methyl-β-alaninate | 426-400-9 | 170222-39-6 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 613-258-00-X |
reaction mass of: 4-chloro-7-methylbenzotriazole sodium salt; 4-chloro-5-methylbenzotriazole sodium salt; 5-chloro-4-methylbenzotriazole sodium salt |
427-730-6 | 202420-04-0 |
Skin Corr. 1B Aquatic Chronic 3 |
H314 H412 |
GHS05 Dgr |
H314 H412 |
|||
| 613-259-00-5 |
reaction mass of: [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-cis-chrysanthemate; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemate |
428-790-6 | 72963-72-5 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|||
| 613-260-00-0 | (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinolin | 430-730-9 | — |
Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H400 H410 |
GHS05 GHS09 Dgr |
H318 H410 |
|||
| 613-261-00-6 | pyrazole-1-carboxamidine monohydrochloride | 429-520-1 | 4023-02-3 |
Acute Tox. 4 * STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H302 H373** H318 H317 H412 |
GHS05 GHS08 GHS07 Dgr |
H302 H373** H318 H317 H412 |
|||
| 613-262-00-1 | disodium (E)-1,2-bis-(4-(4-methylamino-6-(4-methylcarbamoylphenylamino)-1,3,5-triazin-2-ylamino)phenyl-2-sulfonato)ethene | 427-310-2 | 180850-95-7 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 613-263-00-7 | monosodium 3-cyano-5-fluoro-6-hydroxypyridine-2-olate | 429-570-2 | — | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 613-266-00-3 | 2-chloro-5-chloromethylthiazole | 429-830-5 | 105827-91-6 |
Acute Tox. 3 * Skin Corr. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H311 H314 H302 H317 H411 |
GHS06 GHS05 GHS09 Dgr |
H311 H314 H302 H317 H411 |
|||
| 613-267-00-9 |
thiamethoxam (ISO); 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine |
428-650-4 | 153719-23-4 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
M=10 | ||
| 613-268-00-4 | (4aS-cis-)-6-benzyl-octahydropyrrolo[3.4-b]pyridine | 425-930-8 | 151213-39-7 |
Skin Corr. 1B Acute Tox. 4 * Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 2 |
H314 H332 H302 H373** H411 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H314 H332 H302 H373** H411 |
|||
| 613-269-00-X | 2-thiazolidinylidenecyanamide | 427-720-1 | 26364-65-8 |
Acute Tox. 4* STOT RE 2 * Aquatic Chronic 3 |
H302 H373** H412 |
GHS08 GHS07 Wng |
H302 H373** H412 |
|||
| 613-270-00-5 | 5-amino-N-(2,6-dichloro-3-methylphenyl)-1H-1,2,4-triazole-3-sulfonamide | 428-150-6 | 113171-13-4 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 613-271-00-0 |
tritosulfuron (ISO) (containing ≤ 0,02 % AMTT); 1-[4-methoxy-6-(trifluoromethyl)-1,3,5-triazin-2-yl]-3-[2-(trifluoromethyl)benzenesulfonyl]urea (containing ≤ 0,02 % AMTT) |
— | 142469-14-5 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
M=10 | ||
| 613-272-00-6 |
pyraclostrobin (ISO); methyl N-{2-[1-(4-chlorophenyl)-1H-pyrazol-3-yloxymethyl]phenyl}(N-methoxy)carbamate |
— | — |
Acute Tox. 3 * Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H331 H315 H400 H410 |
GHS06 GHS09 Dgr |
H331 H315 H410 |
M=100 | ||
| 613-273-00-1 | tetrahydro-3-methyl-5-((2-phenylthio)thiazol-5-ylmethyl)-[4H]-1,3,5-oxadiazinan-4-ylidene-N-nitroamine | 427-600-9 | 192439-46-6 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 613-274-00-7 | 2,6-dichloro-1-fluoropyridiniumtetrafluoroborate | 427-400-1 | 140623-89-8 |
Skin Corr. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H314 H302 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H314 H302 H317 H410 |
|||
| 613-275-00-2 | 3-(2-chloroethyl)-6,7,8,9-tetra-hydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one monohydrochloride | 424-530-0 | 93076-03-0 |
Acute Tox. 3 * STOT SE 2 STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H301 H371** H373** H318 H317 H411 |
GHS06 GHS05 GHS08 GHS09 Dgr |
H301 H371 H373** H318 H317 H411 |
|||
| 613-276-00-8 | 1-(2-chlorophenyl)-1,2-dihydro-5H-tetrazol-5-one | 426-110-2 | 98377-35-6 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|||
| 613-277-00-3 | (4-(6-diethylamino-2-methylpyridin-3-yl)imino-4,5-dihydro-3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-one | 427-070-9 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 613-278-00-9 | (3-aminophenyl)pyridin-3-ylmethanone | 428-230-0 | 79568-06-2 |
STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H373** H400 H410 |
GHS08 GHS09 Wng |
H373** H410 |
|||
| 613-279-00-4 | 2-ethyl-2,3-dihydro-2-methyl-1H-perimidine | 424-380-6 | 43057-68-7 |
Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373** H400 H410 |
GHS08 GHS07 GHS09 Wng |
H302 H373** H410 |
|||
| 613-280-00-X |
tetrahydro-1,3-dimethyl-1H-pyrimidin-2-one; dimethyl propyleneurea |
230-625-6 | 7226-23-5 |
Repr. 2 Acute Tox. 4 * Eye Dam. 1 |
H361f*** H302 H318 |
GHS05 GHS08 GHS07 Dgr |
H361f*** H302 H318 |
|||
| 613-281-00-5 | quinoline | 202-051-6 | 91-22-5 |
Carc. 1B Muta. 2 Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Aquatic Chronic 2 |
H350 H341 H312 H302 H319 H315 H411 |
GHS08 GHS07 GHS09 Dgr |
H350 H341 H312 H302 H319 H315 H411 |
|||
| 613-282-00-0 |
triticonazole (ISO); (RS)-(E)-5-(4-chlorobenzylidene)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-methyl)cyclopentanol |
— | 131983-72-7 | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 613-283-00-6 |
ketoconazole; 1-[4-[4-[[(2SR,4RS)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone |
265-667-4 | 65277-42-1 |
Repr. 1B Acute Tox. 3 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H360F*** H301 H373** H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H360F*** H301 H373** H410 |
|||
| 613-284-00-1 |
metconazole (ISO); (1RS,5RS;1RS,5SR)-5-(4-chlorobenzyl)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol |
— | 125116-23-6 |
Repr. 2 Acute Tox. 4 * Aquatic Chronic 2 |
H361d*** H302 H411 |
GHS08 GHS07 GHS09 Wng |
H361d*** H302 H411 |
|||
| 613-285-00-7 |
1-hydroxybenzotriazole, anhydrous; [1] 1-hydroxybenzotriazole, monohydrated [2] |
219-989-7 [1] 219-989-7 [2] |
2592-95-2 [1] 123333-53-9 [2] |
Expl. 1.3 | H203 |
GHS01 Dgr |
H203 | |||
| 613-286-00-2 |
potassium 1-methyl-3-morpholinocarbonyl-4-[3-(1-methyl-3-morpholinocarbonyl-5-oxo-2-pyrazolin-4-ylidene)-1-propenyl]pyrazole-5-olate; [containing < 0,5 % N,N-dimethylformamide (EC No 200-679-5)] |
418-260-2 | 183196-57-8 | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 613-286-01-X |
potassium 1-methyl-3-morpholinocarbonyl-4-[3-(1-methyl-3-morpholinocarbonyl-5-oxo-2-pyrazolin-4-ylidene)-1-propenyl]pyrazole-5-olate; [containing ≥ 0,5 % N,N-dimethylformamide (EC No 200-679-5)] |
418-260-2 | 183196-57-8 |
Repr. 1B Skin Sens. 1 |
H360D*** H317 |
GHS08 GHS07 Dgr |
H360D*** H317 |
|||
| 613-287-00-8 | 1-(3-iodo-4-aminobenzyl)-1H-1,2,4-triazole | 419-540-7 | 160194-26-3 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H317 H411 |
GHS07 GHS09 Wng |
H302 H317 H411 |
|||
| 613-288-00-3 | 1,3-bis(dimethylcarbamoyl)-imidazolium chloride | 420-930-4 | 135756-61-5 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H302 H318 H412 |
GHS05 GHS07 Dgr |
H302 H318 H412 |
|||
| 613-289-00-9 | 3-(4-chloro-2-fluoro-5-methylphenyl)-1-methyl-5-(trifluoromethyl)-1H-pyrazole | 432-020-4 | 142623-48-1 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 613-290-00-4 | 4-hydroxy-7-(2-aminoethyl)-1,3-benzothiazol-2(3H)-one hydrochloride | 432-470-1 | 189012-93-9 |
Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H318 H317 H410 |
|||
| 613-291-00-X | 2,4-dihydro-4-(4-(4-(4-hydroxyphenyl)-1-piperazinyl)phenyl)-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one | 434-820-9 | 106461-41-0 |
STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H373** H400 H410 |
GHS08 GHS09 Wng |
H373** H410 |
|||
| 613-292-00-5 | N,N',N''-tris(2-methyl-2,3-epoxypropyl)-perhydro-2,4,6-oxo-1,3,5-triazine | 435-010-8 | 26157-73-3 |
Muta. 2 Aquatic Chronic 3 |
H341 H412 |
GHS08 Wng |
H341 H412 |
|||
| 613-293-00-0 | 2-(4-tert-butylphenyl)-6-cyano-5-[bis(ethoxycarbonylmethyl)carbamoyloxy]-1H-pyrrolo[1,2-b][1,2,4] triazole-7-carboxylic acid 2,6-di-tert-butyl-4-methylcyclohexylester | 448-050-6 | 444065-11-6 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 613-294-00-6 | 2-hexyldecanoic acid [4-(6-tert-butyl-7-chloro-1H-pyrazolo[1,5-b][1,2,4]triazol-2-yl)phenylcarbamoyl]methylester | 448-260-8 | 379268-96-9 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 613-295-00-1 | 11-amino-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c,f][1,2]thiazepine hydrochloride | 448-720-8 | 363138-44-7 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H302 H318 H412 |
GHS05 GHS07 Dgr |
H302 H318 H412 |
|||
| 613-296-00-7 | pentapotassium 2-(4-(5-[1-(2,5-disulfonatophenyl)-4,5-dihydro-3-methylcarbamoyl-5-oxopyrazol-4-ylidene]-3-methyl-1,3-pentadienyl)-3-methylcarbamoyl-5-oxidopyrazol-1-yl)benzene-1,4-disulfonate | 418-270-7 | — |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|||
| 613-297-00-2 | 5-(2-bromophenyl)-2-tert-butyl-2H-tetrazole | 420-820-6 | — |
Flam. Liq. 3 Acute Tox. 4 * Aquatic Chronic 2 |
H226 H302 H411 |
GHS02 GHS07 GHS09 Wng |
H226 H302 H411 |
|||
| 613-298-00-8 | bis-(6-hydroxy-4-methyl-5-(3-methylimidazolium-1-yl)-3-(4-phenylazo)-1H-pyridin-2-one)ethylene dilactate | 421-560-6 | — |
STOT RE 2 * Eye Dam. 1 Aquatic Chronic 2 |
H373** H318 H411 |
GHS05 GHS08 GHS09 Dgr |
H373** H318 H411 |
|||
| 613-299-00-3 |
main component 1 (isomer 1): 2-{6-fluoro-4-[3-(2,5-disulfo-phenylazo)-4-hydroxy-2-sulfonapht-7-ylamino]-1,3,5-triazin-2-ylamino}-3-{6-fluoro-4-[3-(1,5-disulfonaphth-2-ylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-propane sodium salt; main component 1 (isomer 2): 2-{6-fluoro-4-[3-(2,5-disulfo-phenylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-3-{6-fluoro-4-[3-(2,5-disulfo-phenylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-propane sodium salt; main component 2: 2,3-bis-{6-fluoro-4-[3-(2,5-disulfo-phenylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-propane sodium salt; main component 3: 2,3-bis-{6-fluoro-4-[3-(1,5-disulfonaphth-2-ylazo)-4-hydroxy-2-sulfonaphth-7-ylamino]-1,3,5-triazin-2-ylamino}-propane sodium salt |
422-610-1 | — | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 613-300-00-7 | 1-imidazol-1-yl-octadecan-2-ol | 434-120-3 | — |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 613-301-00-2 | dimethyl-1-{[2-methoxy-5-(2-methyl-butoxycarbonyl)phenylcarbamoyl]-[2-octadecyl-1,1-dioxo-1,2,4-benzothiadiazin-3-yl]methyl} imidazole-4,5-dicarboxylate | 443-910-7 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 613-302-00-8 | disodium 2-(5-carbamoyl-1-ethyl-2-hydroxy-4-methyl-6-oxo-1,6-dihydro-pyridine-3-ylazo)-4-(4-fluoro-6-(4-(2-sulfonyloxy-ethylsulfonyl)-phenylamino)-1,3,5-triazine-2-ylamino)benzene sulfonate | 432-980-4 | 243858-60-8 | Eye Dam. 1 | H318 |
GHS05 Dgr |
H318 | |||
| 613-303-00-3 | 2-(1-methyl-2-(4-phenoxyphenoxy)ethoxy)pyridine | 429-800-1 | 95737-68-1 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 613-304-00-9 | 5,6-dihydroxy-2,3-dihydro-1H-indolium bromide | 421-170-6 | 138937-28-7 |
Acute Tox. 4 * Eye Dam. 1 |
H302 H318 |
GHS05 GHS07 Dgr |
H302 H318 |
|||
| 613-305-00-4 | 2-(2-hydroxy-4-octyloxyphenyl)-2H-benzotriazole | 448-630-9 | 3147-77-1 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 613-306-00-X | (2,5-dioxopyrrolidin-1-yl)-9H-fluoren-9-ylmethyl carbonate | 433-520-5 | 82911-69-1 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Chronic 2 |
H302 H317 H411 |
GHS07 GHS09 Wng |
H302 H317 H411 |
|||
| 613-307-00-5 |
clothianidin (ISO); 3-[(2-chloro-1,3-thiazol-5-yl)methyl]-2-methyl-1-nitroguanidine |
— | 210880-92-5 |
Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
M=10 | ||
| 613-308-00-0 | 2-amino-5-methylthiazole | 423-800-5 | 7305-71-7 |
Acute Tox. 4 * STOT RE 2 * Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373** H400 H410 |
GHS08 GHS07 GHS09 Wng |
H302 H373** H410 |
|||
| 613-309-00-6 | 1-methyl-3-phenyl-1-piperazine | 431-180-2 | 5271-27-2 |
Acute Tox. 4 * Acute Tox. 4 * Skin Irrit. 2 Eye Dam. 1 Aquatic Chronic 3 |
H312 H302 H315 H318 H412 |
GHS05 GHS07 Dgr |
H312 H302 H315 H318 H412 |
|||
| 613-310-00-1 | (-)(3S,4R)-4-(4-fluorophenyl)-3-(3,4-methylenedioxy-phenoxymethyl)-N-benzylpiperidine hydrochloride | 432-360-3 | 105813-13-6 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
|||
| 613-311-00-7 | methyl-5-nitrophenyl-guanidine | 435-500-1 | 152460-07-6 |
Acute Tox. 4 * Eye Irrit. 2 Skin Sens. 1 Aquatic Chronic 3 |
H302 H319 H317 H412 |
GHS07 Wng |
H302 H319 H317 H412 |
|||
| 613-312-00-2 | 2-(4-methyl-2-phenyl-1-piperazinyl)benzenemethanol monohydrochloride | 420-200-5 | — |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H302 H318 H317 H412 |
GHS05 GHS07 Dgr |
H302 H318 H317 H412 |
|||
| 613-313-00-8 | 2-(4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)-1H-isoindole-1,3(2H)-dione | 442-780-9 | 173838-67-0 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 613-314-00-3 |
4-decyloxazolidin-2-one; 4-decyl-1,3-oxazolidin-2-one |
443-770-7 | 7693-82-5 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 613-315-00-9 | tetrapotassium 4-[5-[3-carboxylato-4,5-dihydro-5-oxo-1-(4-sulfonatophenyl)pyrazol-4-ylidene]-3-(piperidinocarbonyl)penta-1,3-dienylidene]-5-hydroxy-1-(4-sulfonatophenyl)pyrazole-3-carboxylate | 430-390-1 | — |
Acute Tox. 4 * Aquatic Chronic 3 |
H332 H412 |
GHS07 Wng |
H332 H412 |
|||
| 613-316-00-4 |
trimethylopropane tri(3-aziridinylpropanoate); (TAZ) |
257-765-0 | 52234-82-9 |
Muta. 2 Eye Dam. 1 Skin Sens. 1 |
H341 H318 H317 |
GHS05 GHS08 GHS07 Dgr |
H341 H318 H317 |
H | ||
| 615-033-00-1 | reaction product of diphenylmethanediisocyanate, octylamine, oleylamine and cyclohexylamine (1:1.58:0.32:0.097) | 430-980-9 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 615-034-00-7 | reaction product of diphenylmethanediisocyanate, octylamine, 4-ethoxyaniline and ethylenediamine (1:0,37:1,53:0,05) | 430-750-8 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 615-035-00-2 | reaction product of diphenylmethanediisocyanate, octylamine and oleylamine (molar ratio 1:1.86:0.14) | 430-930-6 | 122886-55-9 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 615-036-00-8 | reaction product of diphenylmethanediisocyanate, toluenediisocyanate (reaction of isomers: 65 % 2,4- and 35 % 2,6-diisocyanate), octylamine, oleylamine and 4-ethoxyaniline (molar ratio 4:1:7:1:2) | 430-940-0 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 615-037-00-3 | reaction product of diphenylmethanediisocyanate, toluenediisocyanate (reaction mass of isomers: 65 % 2,4- and 35 % 2,6-diisocyanate), octylamine and oleylamine (molar ratio 4:1:9:1) | 430-950-5 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 615-038-00-9 | reaction product of toluenediisocyanate (reaction mass of isomers: 65 % 2,4- and 35 % 2,6-diisocyanate) and aniline (molarratio 1:2) | 430-960-1 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 615-039-00-4 | reaction product of diphenylmethanediisocyanate, toluenediisocyanate (reaction mass of isomers: 65 % 2,4- and 35 % 2,6-diisocyanate), octylamine, oleylamine and 4-ethoxyaniline (molar ratio 3.88:1:6.38:0.47:2.91) | 430-970-4 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 615-044-00-1 | 4-chlorophenylisocyanate | 203-176-9 | 104-12-1 |
Acute Tox. 2 * Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Resp. Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H330 H302 H335 H315 H318 H334 H400 H410 |
GHS06 GHS05 GHS08 GHS09 Dgr |
H330 H302 H335 H315 H318 H334 H410 |
|||
| 615-045-00-7 | 4,4'-methylene bis(3-chloro-2,6-di-ethylphenylisocyanate) | 420-530-1 | — |
Resp. Sens. 1 Skin Sens. 1 Aquatic Chronic 4 |
H334 H317 H413 |
GHS08 Dgr |
H334 H317 H413 |
|||
| 616-107-00-6 |
cinidon ethyl (ISO); ethyl (Z)-2-chloro-3-[2-chloro-5-(cyclohex-1-ene-1,2-dicarboximido)phenyl]acrylate |
— | 142891-20-1 |
Carc. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H317 H410 |
|||
| 616-122-00-8 | methyl-neodecanamide | 414-460-9 | 105726-67-8 | Acute Tox. 4 * | H302 |
GHS07 Wng |
H302 | |||
| 616-126-00-X | 1-methyl-4-nitro-3-propyl-1H-pyrazole-5-carboxamide | 423-960-6 | 139756-01-7 |
Acute Tox. 4 * STOT RE 2 * Aquatic Chronic 3 |
H302 H373** H412 |
GHS08 GHS07 Wng |
H302 H373** H412 |
|||
| 616-131-00-7 | 1-aminocyclopentanecarboxamide | 422-950-9 | 17193-28-1 |
STOT RE 1 Acute Tox. 4 * Eye Dam. 1 |
H372** H302 H318 |
GHS05 GHS08 GHS07 Dgr |
H372** H302 H318 |
|||
| 616-136-00-4 | reaction product of cocoalkyldiethanolamides and cocoalkylmonoglycerides and molybdenumtrioxide (1.75-2.2: 0.75-1.0:0.1-1.1) | 430-380-7 | — | Aquatic Chronic 2 | H411 | GHS09 | H411 | |||
| 616-137-00-X | 4-dichloroacetyl-1-oxa-4-azaspiro[4,5]decane | 401-130-4 | 71526-07-3 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|||
| 616-138-00-5 | benzoic acid, N-tert-butyl-N'-(4-chlorobenzoyl)hydrazide | 431-600-4 | 112226-61-6 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|||
| 616-139-00-0 | (3S,4aS,8aS)-N-tert-butyldecahydro-3-isoquinolinecarboxamide | 420-380-5 | 136465-81-1 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Chronic 3 |
H302 H318 H412 |
GHS05 GHS07 Dgr |
H302 H318 H412 |
|||
| 616-140-00-6 | N,N''-(methylenedi-4,1-phenylene)bis[N'-(4-methylphenyl)urea] | 429-380-1 | 133336-92-2 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 616-141-00-1 |
zoxamide (ISO); (RS)-3,5-dichloro-N-(3-chloro-1-ethyl-1-methyl-2-oxopropyl)-p-toluamide |
— | 156052-68-5 |
Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H317 H400 H410 |
GHS07 GHS09 Wng |
H317 H410 |
M=10 | ||
| 616-144-00-8 | 3,4-dichloro-N-[5-chloro-4-[2-[4-dodecyloxyphenylsulfonyl]butyramido]-2-hydroxyphenyl]benzamide | 431-130-1 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 616-145-00-3 |
pethoxamide (ISO); 2-chloro-N-(2-ethoxyethyl)-N-(2-methyl-1-phenylprop-1-enyl)acetamide |
— | 106700-29-2 |
Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H317 H400 H410 |
GHS07 GHS09 Wng |
H302 H317 H410 |
M=100 | ||
| 616-146-00-9 | N-(2-methoxy-5-octadecanoylaminophenyl)-2-(3-benzyl-2,5-dioxoimidazolidin-1-yl)-4,4-dimethyl-3-oxopentanoic acidamide | 431-330-7 | 142776-95-2 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 616-147-00-4 | 1-methyl-4-(2-methyl-2H-tetrazol-5-yl)-1H-pyrazole-5-sulfonamide | 424-160-1 | 139481-22-4 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|||
| 616-148-00-X | N-[6,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6-oxo-1H-purin-2-yl]acetamide | 424-550-1 | 84245-12-5 |
Carc. 1B Muta. 1B Repr. 1B |
H350 H340 H360FD |
GHS08 Dgr |
H350 H340 H360FD |
|||
| 616-150-00-0 | (2R,3S)-N-(3-amino-2-hydroxy-4-phenylbutyl)-N-isobutyl-4-nitrobenzenesulfonamide hydrochloride | 425-260-6 | — |
STOT RE 2 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 2 |
H373** H318 H317 H411 |
GHS05 GHS08 GHS07 GHS09 Dgr |
H373** H318 H317 H411 |
|||
| 616-151-00-6 | N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide | 425-650-6 | 171887-03-9 |
Acute Tox. 4 * Eye Dam. 1 Skin Sens. 1 Aquatic Chronic 3 |
H302 H318 H317 H412 |
GHS05 GHS07 Dgr |
H302 H318 H317 H412 |
|||
| 616-152-00-1 | 4-(4-fluorophenyl)-2-(2-methyl-1-oxopropyl)-4-oxo-3,N-diphenylbutanamide | 425-850-3 | 125971-96-2 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 616-153-00-7 | 4-methyl-3-oxo-N-phenyl-2-(phenylmethylene)pentanamide | 425-860-8 | 125971-57-5 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|||
| 616-154-00-2 | 3,4-dichloro-N-[5-chloro-4-[2-[4-(hexadecyloxy)phenylsulfonyl]butyramido]-2-hydroxyphenyl]benzamide | 431-110-0 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 616-155-00-8 | N,N,N',N'-tetracyclohexyl-1,3-benzenedicarboxamide | 431-040-0 | 104560-40-9 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 616-156-00-3 | 6-(2-chloro-6-cyano-4-nitrophenylazo)-4-methoxy-3-[N-(methoxycarbonylmethyl)-N-(1-methoxycarbonylethyl)amino]acetanilide | 430-500-8 | 204277-61-2 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 616-157-00-9 | 3-amino-4-hydroxy-N-(3-isopropoxypropyl)benzenesulfonamide hydrochloride | 427-780-9 | 114565-70-7 |
Acute Tox. 4 * Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic |
H302 H318 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H302 H318 H410 |
|||
| 616-158-00-4 | N-[4-cyano-3-trifluoromethylphenyl]methacrylamide | 427-880-2 | 90357-53-2 |
STOT RE 2 * Aquatic Chronic 2 |
H373** H411 |
GHS08 GHS09 Wng |
H373** H411 |
|||
| 616-160-00-5 | 2,2'-azobis[N-(2-hydroxyethyl)-2-methylpropionamide] | 429-090-3 | 61551-69-7 |
Skin Sens. 1 Aquatic Chronic 3 |
H317 H412 |
GHS07 Wng |
H317 H412 |
|||
| 616-161-00-0 | 2,4-dichloro-5-hydroxyacetanilide | 429-110-0 | 67669-19-6 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 616-162-00-6 | isostearic acid monoisopropanolamide | 431-540-9 | — |
Skin Irrit. 2 Aquatic Chronic 2 |
H315 H411 |
GHS07 GHS09 Wng |
H315 H411 |
|||
| 616-163-00-1 | 4,4'-methylenebis[N-(4-chlorophenyl)-3-hydroxynaphthalene-2-carboxamide] | 430-350-3 | 192463-88-0 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 616-164-00-7 |
dimoxystrobin (ISO); (E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide |
— | 149961-52-4 |
Carc. 2 Repr. 2 Acute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1 |
H351 H361d*** H332 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H361d*** H332 H410 |
M=10 | ||
| 616-165-00-2 |
beflubutamid (ISO); (RS)-N-benzyl-2-(α,α,α,4-tetrafluoro-m-tolyoxy)butyramide |
— | 113614-08-7 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | M=100 | ||
| 616-166-00-8 |
cyazofamid (ISO); 4-chloro-2-cyano-N,N-dimethyl-5-p-tolylimidazole-1-sulfonamide |
— | 120116-88-3 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | M=10 | ||
| 616-167-00-3 | N,N-dibutyl-(2,5-dihydro-5-thioxo-1H-tetrazol-1-yl)acetamide | 418-290-6 | 168612-06-4 |
Eye Irrit. 2 Skin Sens. 1 |
H319 H317 |
GHS07 Wng |
H319 H317 |
|||
| 616-168-00-9 | 1-dimethylcarbamoyl-4-(2-sulfonatoethyl)pyridinium | 418-440-0 | 136997-71-2 | Skin Sens. 1 | H317 |
GHS07 Wng |
H317 | |||
| 616-169-00-4 | 4-[4-(2,2-dimethyl-propanamido)]phenylazo-3-(2-chloro-5-(2-(3-pentadecylphenoxy)butylamido)anilino)-1-(2,4,6-trichlorophenyl)-2-pyrazoline-5-one | 420-220-4 | 92771-56-7 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 616-170-00-X | (2R)-2-amino-2-phenylacetamide | 420-370-0 | 6485-67-2 |
Eye Irrit. 2 Skin Sens. 1 |
H319 H317 |
GHS07 Wng |
H319 H317 |
|||
| 616-171-00-5 | 2-(para-chlorophenyl)glycineamide | 420-830-0 | 102333-75-5 |
Eye Dam. 1 Skin Sens. 1 |
H318 H317 |
GHS05 GHS07 Dgr |
H318 H317 |
|||
| 616-172-00-0 |
N-(2,2,6,6-tetramethyl-1-oxylpiperidin-4-yl)acetamide; (4-acetamido-2,2,6,6-tetramethyl-1-piperidinyl)oxidanyl |
423-840-3 | 14691-89-5 | Acute Tox. 4 * | H302 |
GHS07 Wng |
H302 | |||
| 616-174-00-1 | 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride | 424-560-4 | 151257-01-1 |
Acute Tox. 4 * Eye Irrit. 2 |
H302 H319 |
GHS07 Wng |
H302 H319 |
|||
| 616-175-00-7 | 2-(2-hexyldecyloxy)benzamide | 431-230-3 | 202483-62-3 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 616-176-00-2 | 3-N,N-bis(methoxyethyl)aminoacetanilide | 432-530-7 | 24294-01-7 |
Acute Tox. 4 * Aquatic Chronic 3 |
H302 H412 |
GHS07 Wng |
H302 H412 |
|||
| 616-177-00-8 |
(3-(4-(2-(butyl-(4-methylphenylsulfonyl)amino)phenylthio)-5-oxo-1-(2,4,6-trichlorophenyl)-4,5-dihydro-1H-pyrazole-3-ylamino)-4-chlorophenyl)tetradecanamide; N-[3-({4-[(2-{butyl[(4-methylphenyl)sulfonyl]amino}phenyl)thio]-5-oxo-1-(2,4,6-trichlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl}amino)-4-chlorophenyl]tetradecanamide |
432-970-1 | 217324-98-6 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 616-178-00-3 | N-(5-(bis(2-methoxyethyl)amino)-2-((2-cyano-4,6-dinitrophenyl)-azo)phenyl)acetamide | 434-500-9 | 52583-35-4 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 616-179-00-9 | 2-chloro-N-(4-methylphenyl)acetamide | 435-170-9 | 16634-82-5 |
Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H317 H400 H410 |
GHS05 GHS07 GHS09 Dgr |
H318 H317 H410 |
|||
| 616-180-00-4 | N,N-(dimethylamino)thioacetamide hydrochloride | 435-470-1 | 27366-72-9 |
Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H360D*** H400 H410 |
GHS08 GHS09 Dgr |
H360D*** H410 |
|||
| 616-181-00-X | 4'-methyldodecane-1-sulfonanilide | 435-490-9 | 17417-32-2 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 616-182-00-5 | N'-(1,3-dimethylbutylidene)-3-hydroxy-2-naphthohydrazide | 435-860-1 | 214417-91-1 |
Skin Sens. 1 Aquatic Chronic 2 |
H317 H411 |
GHS07 GHS09 Wng |
H317 H411 |
|||
| 616-183-00-0 | N-dodecyl-4-methoxybenzamide | 442-340-6 | 1854-15-5 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 616-184-00-6 | 3-methyl-N-(5,8,13,14-tetrahydro-5,8,14-trioxonaphth[2,3-c]acridin-6-yl)benzamide | 442-560-2 | 105043-55-8 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 616-186-00-7 | N,N'-(2-chloro-1,4-phenylene)bis(3-oxobutaneamide) | 443-010-4 | 53641-10-4 | Aquatic Chronic 3 | H412 | — | H412 | |||
| 616-188-00-8 | 2-(5,5-dimethyl-2,4-dioxooxazolidin-3-yl)-4,4-dimethyl-3-oxo-N-(2-methoxy-5-octadecanoylaminophenyl)pentanoic acid amide | 443-980-9 | 221215-20-9 |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 616-189-00-3 | N-[5-(bis-(2-methoxy-ethyl)-amino]-2-(6-bromo-2-methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylazo)-phenyl]acetamide | 444-780-4 | 452962-97-9 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 616-190-00-9 | N-decyl-4-nitrobenzamide | 445-880-0 | 64026-19-3 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 616-191-00-4 | 2-ethyl-N-methyl-N-(3-methylphenyl)butanamide | 446-190-2 | 406488-30-0 |
Acute Tox. 4 * Eye Irrit. 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Chronic 2 |
H302 H319 H315 H317 H411 |
GHS07 GHS09 Wng |
H302 H319 H315 H317 H411 |
|||
| 616-192-00-X | 2-[2-(3-butoxypropyl)-1,1-dioxo-1,2,4-benzothiadiazin-3-yl]-5'-tert-butyl-2-(5,5-dimethyl-2,4-dioxo-1,3-oxazolidin-3-yl)-2'-[(2-ethylhexyl)thio]acetanilide | 448-060-0 | 727678-39-9 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 616-193-00-5 | N-[2-(2-butyl-4,6-dicyano-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylazo)-5-diethylamino-phenyl]acetamide | 449-940-7 | 368450-39-9 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 616-194-00-0 | 2,2-diethoxy-N,N-dimethylacetamide | 449-950-1 | 34640-92-1 | Eye Irrit. 2 | H319 |
GHS07 Wng |
H319 | |||
| 616-196-00-1 | disodium salt of 1-hydroxy-4-(β-(4-(1-hydroxy-3,6-disulfo-8-acetylamino-2-naphthylazo)phenoxy)ethoxy)-N-dodecyl-2-naphthamide | 419-990-4 | — |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 | |||
| 616-197-00-7 |
reaction mass of: potassium N-[3-(dimethyloxidoamino)propyl]-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane sulfonamidate; N-[3-(dimethyloxidoamino)propyl]-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane sulfonamide |
422-500-1 | — | STOT RE 2 * | H373** |
GHS08 Wng |
H373** | |||
| 616-198-00-2 | 1,3-bis[12-hydroxy-octadecamide-N-methylene]-benzene | 423-300-7 | — |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 616-200-00-1 |
reaction mass of: N,N'-ethane-1,2-diylbis(hexanamide); 12-hydroxy-N-[2-[(1-oxyhexyl)amino]ethyl]octadecanamide; N,N'-ethane-1,2-diylbis(12-hydroxyoctadecanamide) |
432-430-3 | — |
Skin Sens. 1 Aquatic Chronic 4 |
H317 H413 |
GHS07 Wng |
H317 H413 |
|||
| 616-201-00-7 | 12-hydroxyoctadecanoic acid, reaction products with 1,3-benzenedimethanamine and hexamethylenediamine | 432-840-2 | 220926-97-6 |
Acute Tox. 4 * Aquatic Chronic 4 |
H332 H413 |
GHS07 Wng |
H332 H413 |
|||
| 616-202-00-2 |
reaction mass of: 2,2'-[(3,3'-dichloro[1,1'-biphenyl]-4,4'-diyl)bis(azo)]bis[N-(2,4-dimethylphenyl)]-3-oxo-butanamide; 2-[[3,3'-dichloro-4'-[[1[[(2,4-dimethylphenyl)amino]carbonyl]-2-oxopropyl]azo][1,1'-biphenyl]-4-yl]azo]-N-(2-methylphenyl)-3-oxo-butanamide; 2-[[3,3'-dichloro-4'-[[1[[(2,4-dimethylphenyl)amino]carbonyl]-2-oxopropyl]azo][1,1'-biphenyl]-4-yl]azo]-N-(2-carboxylphenyl)-3-oxo-butanamide |
434-330-5 | — |
Carc. 2 Skin Sens. 1 Aquatic Chronic 4 |
H351 H317 H413 |
GHS08 GHS07 Wng |
H351 H317 H413 |
|||
| 616-203-00-8 |
reaction mass of: N-[5-[bis-(2-methoxyethyl)amino]-2-(2-butyl-4,6-dicyano-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl-azo)phenyl]acetamide; N-[2-(2-butyl-4,6-dicyano-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylazo)5-diethylaminophenyl]acetamide |
442-280-0 | — | Aquatic Chronic 4 | H413 | — | H413 | |||
| 616-204-00-3 | N,N''-(methylenedi-4,1-phenylene)bis[N'-octylurea] | 451-060-3 | 122886-55-9 | Aquatic Chronic 4 | H413 | — | H413 | |||
| 617-021-00-1 | methylethylketone peroxide trimer | 429-320-2 | — |
Org. Perox. B**** Asp. Tox. 1 Skin Irrit. 2 Skin Sens. 1 |
H241 H304 H315 H317 |
GHS01 GHS02 GHS08 GHS07 Dgr |
H241 H304 H315 H317 |
|||
| 617-022-00-7 |
reaction mass of: 1,2-dimethylpropylidene dihydroperoxide; dimethyl 1,2-benzenedicarboxylate |
442-480-8 | — |
Org. Perox. C Acute Tox. 4 * Skin Corr. 1B Skin Sens. 1 Aquatic Chronic 2 |
H242 H302 H314 H317 H411 |
GHS02 GHS05 GHS07 GHS09 Dgr |
H242 H302 H314 H317 H411 |
|||
| 647-017-00-5 | laccase | 420-150-4 | 80498-15-3 | Resp. Sens. 1 | H334 |
GHS08 Dgr |
H334 | |||
© Europäische Union 1998-2021
Tipp: Verwenden Sie die Pfeiltasten der Tastatur zur Navigation zwischen Normen.